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The Disrupted-In-Schizophrenia 1 (DISC1) gene is one of the most established risk 
genes for psychiatric illness currently being studied, having originally been identified 
as being directly disrupted by a balanced chromosomal translocation that co-
segregates with schizophrenia and other major mental illness a large Scottish family. 
The DISC1 protein is believed to act as a molecular scaffold within the cell, binding 
to a large number of other proteins.  Three of these protein interactors, 
Phosphodiesterase 4B (PDE4B), Nuclear Distribution Factor E (Aspergillus 
nidulans)-homologue 1 (NDE1) and NDE-Like 1 (NDEL1) all have evidence 
implicating them as schizophrenia-related proteins in their own right.  NDE1 and 
NDEL1 are highly similar proteins which are known to play cellular roles including 
microtubule function and mitosis.  Their orthologues have also been shown to be 
important in neurodevelopment within the mouse brain.  To date, most work in the 
literature has investigated NDEL1, with few focusing on NDE1. 
 
In the thesis, I first seek to establish a basic biology for NDE1 by the identification of 
splice variants expressed in the brain, establishing cellular localisation patterns 
within the cell and investigating NDE1 multimerisation.  The relationship between 
NDE1 and NDEL1 is also investigated, with the two being found to form complexes 
together and to have partially over-lapping expression patterns within the cell.  That 
NDE1 and DISC1 directly interact is confirmed.  The relationship between NDE1 
and PDE4B is then investigated, with the two proteins found to complex within the 
cell.  Additionally, it is shown that NDE1 can be phosphorylated by protein kinase A 
(PKA).  This kinase is cAMP dependant, and is thus indirectly regulated by the 
cAMP-degrading action of PDE4B protein.  Attempts to map and analyse the effect 
of this phosphorylation on NDE1 are made. 
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Chapter 1 - Introduction 
 
1.1 Psychiatric illness 
 
1.1.1 The impact of psychiatric illness 
In 2004, a report was published in which the leading causes of disability world-wide 
were analysed (World Health Organisation 2004).  The impact of a disability on the 
global population was measured in terms of “years of life lost”, a measure taking into 
account the prevalence of a condition and also the duration of its effect.  Alcohol-
related disorders, hearing loss, asthma and osteoarthritis all featured prominently in 
the list; however the single largest impact was caused by an illness which is far 
harder to define: depression.  Also featuring prominently in the list were two other 
psychiatric illnesses: schizophrenia (fifth in males, sixth in females) and bipolar 
disorder (seventh in males, eighth in females).  Over an individuals lifetime, their 
risk of suffering from clinically defined schizophrenia or bipolar disorder has been 
demonstrated to be approximately 0.4% and 0.8% respectively (Judd and Akiskal 
2003; Saha et al. 2005).  The lifetime risk of suffering from major depressive 
episodes is significantly higher, ranging from 3% to almost 17% depending on 
nationality (Andrade et al. 2003). 
 
Despite the wide-spread impact of psychiatric illness, progress at treating the 
conditions has been slow.  This is largely because the underlying biology of most 
mental illnesses is still poorly understood.  By attempting to understand these 
conditions at the subcellular level, it is hoped that better preventative and curative 
therapies can be devised. 
 
1.1.2 Schizophrenia, bipolar disorder and major depression 
Due to the lack of any measurable biomarkers with which to clinically define any 
major mental illness, diagnosis is instead performed by psychiatrists according to 
standardised criteria.  The Diagnostic and Statistical Manual of Mental Disorders 
Fourth Edition (commonly known as DSM-IV, published by the American 
Psychiatric Association) is currently the gold standard for such diagnoses and 
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subdivides major mental illness into discrete conditions.  Three of these conditions 
are briefly described below. 
 
Major depressive disorder, also known as unipolar depression, is characterised by the 
sufferer experiencing prolonged depressive episodes.  During that time a sufferer 
may feel unusually withdrawn, apathetic, pessimistic and potentially suicidal.  
Tiredness, appetite loss and insomnia are also common symptoms. 
 
Sufferers of bipolar disorder, like those of major depressive disorder, experience 
depressive episodes, but additionally experience episodes of mania.  During these 
manic episodes, they can feel euphoric, hyperactive and often lose their inhibitions.  
Sometimes this can lead to delusions and dangerous behaviour. 
 
Finally, schizophrenia is typically characterised as consisting of both positive 
symptoms, such as delusion and hallucination, as well as negative symptoms such as 
social withdrawal and depression.  It can also affect the attention and working 
memory of its sufferers. 
 
1.1.3 Causes of psychiatric illness 
Various environmental factors have been suggested to influence the likelihood of a 
person developing major mental illness.  For example, in schizophrenia such risk 
factors include having used cannabis (Semple et al. 2005), having elderly parents 
(Wohl and Gorwood 2007), being born in the winter or spring (Davies et al. 2003), 
living in an urban area (Pedersen and Mortensen 2001), birth complications such as 
oxygen deprivation (Cannon et al. 2002) and being born to a mother who 
experienced famine (Susser et al. 2008) or suffered from influenza (Byrne et al. 
2007) during pregnancy. 
 
However, over the course of the last century, evidence has been mounting to suggest 
that mental illness also has a strong hereditary component.  A traditional approach to 
measuring the effect of genetics on a condition is to compare the monozygotic and 
dizygotic twins of probands with the condition.  Adopted twins can be used, thus 
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discounting shared environmental effects the study.  A meta-analysis of such studies 
investigating schizophrenia in the period 1920-1978 found that for schizophrenia 
probands with a monozygotic twin (n = 106) in 44.3% of cases that twin also had a 
diagnosis of schizophrenia (Gottesman et al. 1987).  By comparison, the same 
happened in 12.1% of dizygotic twins (n = 149).  This strongly implies that there is a 
major genetic component to schizophrenia, as sharing your genetic make-up with a 
schizophrenia sufferer considerably increases your risk of suffering from the same 
condition.  Additionally, when family members of a proband with schizophrenia are 
investigated, it can be seen that the risk of themselves having schizophrenia 
diminishes in more distant relatives (Gottesman et al. 1987), consistent with disease 
being caused, at least in part, by their genetic make-up. 
 
1.1.4 Candidate genes for major mental illness 
While some inherited conditions, such as cystic fibrosis, can be linked to disruption 
of a single gene, no such central gene exists to explain psychiatric illnesses.  Instead, 
these conditions are believed to be polygenic, with a large number of genes believed 
to act together to influence the risk of developing such a condition. 
 
There are two main hypothesises as to how multiple genes can affect a condition like 
schizophrenia.  The first of these is that the condition may be dependent on a number 
of relatively common gene variants, each of which contributes in a small way to the 
illness.  The illness would then arise due to the cumulative effects of possessing 
multiple of these disease risk variants.  Genome-wide association studies have been 
undertaken in order to test for such common variants (O'Donovan et al. 2008) and 
larger studies are planned (Psychiatric GWAS Consortium 2008). Such analyses 
examine haplotypes from throughout the genomes of a population, some of whom 
are affected by a disease of interest and others who act as healthy controls, in order to 
determine if any alleles are associated with the disease state.  This has the advantage 
over traditional approaches such as linkage analysis (discussed in section 1.2.1.3) of 
being able to look at specific gene variants rather than simply identifying 
chromosomal regions which are likely to contain such variants.  Because of the 
number of different haplotypes which need to be examined in each individual, the 
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large number of individuals required to detect disease-linked polymorphisms of 
moderate effect and the computational power needed to analyse all of the data, such 
studies have only recently become technically practical.  A consensus on a list of 
common variants is, however, still far from being achieved.  Notably, one high 
profile analysis detected only a single variant associated with bipolar disorder, 
despite achieving significantly better results with other non-psychiatric conditions 
(Wellcome Trust Case Control Consortium 2007), implying that psychiatric illnesses 
are amongst the most polygenic illnesses known. 
 
The alternative hypothesis is that mental illness is caused by rare variations in one of 
a number of genes, each individually conferring a large risk of developing the 
condition.  An established method of studying such rare variants is through 
cytogenetics (Pickard et al. 2005).  The theory behind this method is that 
chromosomal translocations, where sections of chromosome arms break off and 
reattach in different orientations or on separate chromosomes, will occasionally 
disrupt expression of a gene critical to mental health.  By examining the 
chromosomes of patients with mental illness, such translocations can be identified.  
Genes lying on or near the breakpoints can then be viewed as potential candidate 
genes for mental illness and further analysis, such as by association study, can be 
used to investigate the wider involvement of variations in this gene in mental illness.  
The translocations themselves are often very rare, however, and are thus unlikely to 
be subsequently identified in other populations. 
 
It should be stated however, that the two models are not mutually exclusive, as even 
if a large proportion of mental illness in the population were to be caused by 
common variants of small effect, rare large variants would still be expected to exist 
in at least part of the population, and particularly in families who appear to display a 
high degree of psychiatric illness heritability. 
 
To date, evidence has been published implicating over 130 genes as being potentially 
involved in the pathology of schizophrenia, and over 100 in bipolar disorder (Carter 
2006, 2007).  Attempting to determine which of these genes play the most significant 
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roles in major mental illness is therefore a matter of great urgency, and also of 
considerable controversy, with opinions on the validity of different candidate genes 
varying considerably.  Studying reviews written in the past year, the genes most 
commonly described as being strong candidates for schizophrenia risk factors are 
COMT, DTNBP1, NRG1, DISC1, DAO, DAOA and DRD4 (Burmeister et al. 2008; 
Gallinat et al. 2008; Maier 2008; Sullivan 2008; Tandon et al. 2008).  Of these, this 
thesis will focus on DISC1.  Definitions of these are other abbreviations can be found 
on page xx. 
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1.2 Disrupted-In-Schizophrenia 1 (DISC1) 
 
1.2.1 DISC1 as a candidate gene for psychiatric illness 
 
1.2.1.1 The t(1;11) family 
In 1968 a survey was made of the cytogenetics of boys being admitted to borstals, a 
type of juvenile detention centre, in Scotland.  During the survey, one 18-year old 
boy was found to possess a chromosomal translocation, which they describe as 
involving chromosome 1 and one of chromosomes 6-12.  Further analysis showed 
that this translocation was balanced and present across four generations of his family 
(Jacobs et al. 1970).  At the time no clinical phenotype was described as being 
associated with the translocation, and the details of the family were deposited in a 
cytogenetics registry in Edinburgh. 
 
Twenty years later, a survey of this register was carried out and it was observed that 
many members of the family had been referred to psychiatrists or mental health 
hospitals in the intervening years (St Clair et al. 1990).  Diagnoses within the family 
included schizophrenia, major and minor depression and, in the case of the original 
boy, severe adolescent conduct disorder.  St Clair and colleagues then studied the 
translocation, which they identified as being between chromosomes 1 and 11, and 
found that psychiatric illness was significantly more common in family members 
with the t(1;11) translocation than in those who appeared cytogenetically normal (St 
Clair et al. 1990). 
 
In a follow-up study a decade later, it was seen that 7 of the 37 t(1;11) translocation 
carriers suffered from schizophrenia, a condition found in none of their relatives 
lacking the translocation (Blackwood et al. 2001).  The translocation was shown to 
be linked to schizophrenia with a LOD score of 3.6 (Logarithm of Odds, determined 
by calculating the probability of the linkage occurring by chance, dividing by the 
probability of it by chance not occuirng and taking log 10 of this ratio).  
Additionally, when schizophrenia was grouped together with bipolar disorder and 
major recurrent depression (one and ten cases in the translocation carriers 
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respectively, no cases of either in the non-carriers) this LOD score increased to 7.1.  
This was unprecedented evidence that the t(1;11) translocation was linked to, and 
most probably causative of, psychiatric illness.  
 
1.2.1.2 Identification of genes at the translocation breakpoints 
The simplest scenario as to how such a translocation could cause psychiatric illness 
was that a gene was directly disrupted on chromosome 1 or chromosome 11 at the 
breakpoint and that disruption of this gene was causative of the illness.  A concerted 
effort was therefore made to map the exact location of the chromosome 1 and 11 
breakpoints and to identify potential genes at these locations (Fletcher et al. 1993; 
Evans et al. 1995; Muir et al. 1995; Devon et al. 1997; Millar et al. 1998; Semple et 
al. 2001).  The breakpoints were determined to be at 1q42.1 and 11q14.3. 
 
Analysis of the breakpoint on chromosome 1 revealed that the translocation directly 
disrupted two previously unknown genes (Millar et al. 2000b) which were named 
Disrupted-In-Schizophrenia 1 and 2 (DISC1 and DISC2).  In contrast no transcripts 
were shown at the time to be disrupted at the chromosome 11 breakpoints (Millar et 
al. 2000b), although more recent work has identified a potential gene at this location 
(Zhou et al. 2008). 
 
The DISC1 gene was shown to consist of 13 exons which encode an 854 amino acid 
protein, DISC1 (Millar et al. 2001).  The t(1;11) translocation breakpoint lies within 
intron 8 of this gene.  DISC2 meanwhile lacks any open reading frames (Millar et al. 
2001).  It does however lie anti-sense to DISC1 and so DISC2 transcripts have the 
potential to act as DISC1 regulators, for example by binding DISC1 transcripts and 
blocking translation (Chubb et al. 2008).  In light of the non-coding nature of DISC2, 
however, the vast majority of work since has instead focused on DISC1.  
Additionally, while DISC1 orthologues have been reported in a number of 
organisms, no DISC2 equivalent has yet been detected in any species other than 
human (Taylor et al. 2003). 
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The DISC1 gene has also been shown to form fusion transcripts with another gene, 
Translin-Associated factor X (TRAX) which lies 5’ of it on chromosome 1 (Millar et 
al. 2000a).  It should therefore be considered that the molecular mechanism of 
psychiatric illness in the t(1:11) family could technically be due to altered expression 
of TRAX transcripts.  Levels of TRAX protein where not, however, seen to be 
affected by the translocation in lymphoblastoid cell lines derived from t(1;11) family 
members (Millar et al. 2005b). 
 
There are two major theories as to why disruption of one copy of the DISC1 gene 
may lead to abnormal phenotypes in the t(1;11) family.  The first of these is that the 
cells of translocation carriers cannot produce DISC1 protein from the translocation-
derived chromosome, and that this haploinsufficiency leads to psychiatric illness.  
This certainly seems to be the case when comparing the levels of both DISC1 
transcripts and various DISC1 protein species in lymphoblastoid cells derived from 
the blood of translocation carriers and healthy members of the family (Millar et al. 
2005b).  The alternative theory is that a truncated form of DISC1, sometimes known 
as mutDISC1 and which contains only the N-terminal 597 amino acids of full length 
DISC1, is instead produced by the translocation-derived chromosome (Morris et al. 
2003; Ozeki et al. 2003).  Such a protein has been shown to have a range of 
dominant negative effects when over-expressed in cell lines (Ozeki et al. 2003; 
Kamiya et al. 2005; Pletnikov et al. 2007; Taya et al. 2007) and to cause phenotypes 
associated with psychiatric illness in over-expressing transgenic mice (Hikida et al. 
2007; Pletnikov et al. 2008; Shen et al. 2008a).  To date, however, no sign of such a 
protein has been detected in the t(1;11) lymphoblastoid cell lines (Millar et al. 
2005b). 
 
1.2.1.3 The DISC locus in global psychiatric illness 
The t(1;11) translocation seen in the Scottish family is believed to be unique.  
Numerous studies, however, have been published implicating the DISC1 gene as 
influencing major mental illness in the wider population.  The majority of these have 
focused on attempting to determine one or more common DISC1 variants which 
increase the risk of schizophrenia or other psychiatric illnesses. 
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Two types of study are generally used.  Linkage analyses look at either single large 
families or at sets of families, typically of a common ethnicity.  By investigating the 
inheritance patterns of chromosomal markers it is possible to determine whether one 
or more such marker co-segregates with a phenotype of interest, such as increased 
disposition to a specific illness.  In this way the approximate locations of disease-
causing genes can be mapped.  This technique is well suited to the identification of 
rare variants with a relatively large effect on disease pathology.  Figure 1.2.A 
summarises studies reported to date which display evidence of the DISC locus or the 
chromosomal region surrounding it being linked to major mental illness.  The 
chromosomal region containing the DISC locus has therefore been repeatedly 
demonstrated to be linked to schizophrenia and bipolar disorder, with linkage to 
schizoaffective disorder and major depressive disorder also reported.  
 
Association analyses meanwhile look at large populations, typically of unrelated 
individuals.  One or more specific single nucleotide polymorphisms (SNPs) or 
haplotypes of several SNPs are genotyped in each member of the population.  Such 
analyses are performed in a population of individuals suffering from a particular 
disease and also in a similar population of healthy controls.  By doing this it is 
possible to identify particular genotypes which are more or less common in the 
affected individuals, and therefore likely to contribute to the pathology of that 
disease.  This technique is well suited to detecting common variants of relatively low 
effect on disease pathology.  Figure 1.2.B summaries studies looking for association 
of DISC1 with major mental illness.  Association of DISC1 variants with 
schizophrenia has been reported now in 15 studies, and association with other 
psychiatric illnesses has also been detected.  To date, however, no individual DISC1 
variant has been robustly demonstrated to be consistently associated with 
schizophrenia in more than a few of these studies.  It therefore appears that while 
variation in DISC1 often leads to psychiatric disorder, no individual common variant 
to account for this.  In addition, a number of genome-wide association studies for 
schizophrenia have been performed in recent years and, while no strong risk factors 
for psychiatric illness have yet emerged by this approach, it has been 
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Figure 1.2.A: Summary of studies investigating linkage of chromosomal regions surrounding the DISC locus with 
schizophrenia (SCZ), bipolar disorder (BPD), major depressive disorder (MDD) and schizoaffective disorder (SCZAFF). 10 
 


















Figure 1.2.B: Association studies of SNPs in and around the DISC1 gene with schizophrenia (SCZ), bipolar disorder (BPD), 
major depressive disorder (MDD), schizoaffective disorder (SCZAFF), autism (AUT) and Asperger’s syndrome (AS).  Negative 
results have also been reported (Zhang et al. 2005; Hashimoto et al. 2006; Arai et al. 2007; Kim et al. 2007; Sanders et al. 
2008). 
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observed that there is at least suggestive evidence for DISC1 playing such a role 
(Sullivan 2008). 
 
Two SNPs in DISC1 exons have been reported and further studied.  The first of these 
variations, leucine-607 to phenylalanine (L607F), has been reported to be over-
represented in patients with schizoaffective disorder (Hodgkinson et al. 2004) but not 
schizophrenia (Song et al. 2008).  Carriers of the Phe allele have been shown to have 
reduced grey matter volume in the superior frontal gyrus and anterior cingulate 
gyrus, while schizophrenia patients carrying it suffer from significantly worse 
hallucinations than those homozygous for the Leu allele (Szeszko et al. 2008). 
 
The other common variation, serine-704 to cysteine (S704C), has been reported to be 
associated with schizophrenia (Callicott et al. 2005; Qu et al. 2007; Song et al. 2008) 
as well as major depression (Hashimoto et al. 2006), although negative results have 
also been reported (Kim et al. 2007).  By using MRI to investigate the brains of 
healthy individuals of known DISC1 genotype, the two alleles have been 
demonstrated to affect grey matter volume in the hippocampus (Callicott et al. 2005), 
cingulate cortex (Hashimoto et al. 2006) and parahippocampal gyrus (Di Giorgio et 
al. 2008) and to produce visibly different patterns of brain activation on a functional 
MRI machine during memory-related tests (Callicott et al. 2005; Prata et al. 2008).  
The Cys allele has also been linked to reduced cognitive ability in elderly females 
(Thomson et al. 2005a).  There is also some evidence to suggest that the S704C 
variation affects the phosphorylation potential (Hashimoto et al. 2006) and the 
specific protein interaction affinities of the DISC1 protein (Kamiya et al. 2006; 
Burdick et al. 2008). 
 
Ultra rare variants have also been reported.  One recent study involved the 
genotyping of the DISC1 gene of 288 schizophrenia patients.  SNPs discovered in 
this way were then investigated in a large pool of control alleles.  By this method, 
five rare DISC1 variants were determined, each of which was found in at least one 
schizophrenia patient, but not in any of 10,000 unaffected controls (Song et al. 
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2008).  These mutations were at G14A, R37W, S90L, R418H and T603I.  To date, 
no further work has been reported as to biological implications of these rare variants.   
 
An additional putative pathological rare variant was reported in a trio of American 
siblings each with schizophrenia or schizoaffective disorder (Sachs et al. 2005).  This 
variant consisted of a four base pair deletion near the 3’ end of DISC1 leading to a 
frame shift mutation.  The variant was also present in the trio’s unaffected father.  
The variant was however later discovered in two individuals out of 694 who lacked 
any psychiatric diagnosis (Green et al. 2006), in a study which failed to identify it in 
any of 655 individuals with schizophrenia.   It is therefore uncertain whether or not 
this variant is pathogenic. 
 
Finally, copy number variation of the DISC1 gene has been reported, however there 
is no available evidence to date as to whether or not these are associated with mental 
illness (Redon et al. 2006). 
 
Together, the linkage and association data surrounding the DISC locus very strongly 
implicate it in psychiatric illness globally.  However, the sheer variety of DISC1 
SNPs and haplotypes linked to various major mental illnesses implies that it is 
unlikely that one or more specific DISC1 variants individually account for more than 
a fraction of cases world-wide.  Nevertheless, it is clear that disruption of the DISC1 
gene considerably increases the chance of an individual having major mental illness.  
It is also interesting that DISC1 has been associated with so many clinically distinct 
psychiatric disorders, adding to the growing body evidence suggesting that the 
pathology of the conditions is less distinct than had previously been assumed. 
 
1.2.2 The DISC1 protein 
 
1.2.2.1 Characterisation of the DISC1 protein 
The full length DISC1 protein is generally described as being of approximately 
100kDa in size.  It is however known to exist also as a number of smaller species, 
with a number of distinct Western blot bands having been seen between 70 and  
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Figure 1.2.C: The predicted secondary  structure of DISC1.  Predicted coiled 
coils, nuclear localisation signal and leucine sipper motifs are indicated in 
green, red and blue respectively.  Adapted from (Chubb et al 2008) with 
additional data from (Taylor et al. 2003, Brandon et al 2005). 
 
80kDa (Miyoshi et al. 2003; James et al. 2004; Ogawa et al. 2005; Sawamura et al. 
2005).  Bands of other sizes, including 98kDa (James et al. 2004) and 45kDa (Koike 
et al. 2006) have also been reported.  These are partially accounted for by the 
existence of a number of splice variants including the full length “long” (L) isoform, 
a “long variant” (Lv) isoform which lacks 22 amino acids near the C-terminus 
(Millar et al. 2000b), a “short” (S) isoform consisting of exons 1-9 plus an additional 
exon, and an “extremely short” (Es) isoform consisting on exons 1-3 only (Taylor et 
al. 2003).  In addition, it has been suggested that DISC1 protein may be post-
translationally truncated within the cell (Millar et al. 2005a).  Determination of the 
identity of other isoforms would involve either the use of mass spectroscopy to 
identify the regions of DISC1 present in each of the remaining undefined DISC1 
species, or a thorough analysis of other splice variants and the predicted amino acid 
sizes of their protein products.  The two approaches would be complementary. 
 
The full length DISC1 protein is described as consisting of two parts.  The N-
terminal region is generally referred to as “globular” due to the lack of a predictable 
secondary structure, while the C-terminal region is referred to as coiled (Millar et al. 
2000b).  Estimates of the number of distinct coils in this region vary, but may be 
eight or more (Chubb et al. 2008).  In addition the existence of two leucine zippers 
(Brandon et al. 2005) and a nuclear localisation signal (Taylor et al. 2003) have been 
predicted.  These are shown in figure 1.2.C 
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The DISC1 protein is most commonly described as being found in punctate 
structures, the nature of which remains to be determined, within the cytoplasm 
(Miyoshi et al. 2003; James et al. 2004).  It has also been described as being found at 
a number of other cellular locations, including the mitochondria (James et al. 2004; 
Millar et al. 2005a), the centrosome (Morris et al. 2003) and the nucleus (Sawamura 
et al. 2008).  The exact cellular localisation pattern is dependent on the specificity of 
the anti-DISC1 used, with antibodies raised against N-terminal regions of DISC1 
producing different results to those raised against C-terminal regions.  This probably 
occurs because different antibodies recognise different DISC1 isoforms.  In rat PC12 
neurons, DISC1 has been seen in the cell processes (Ozeki et al. 2003), and in 
neurons from the human brain it has been identified in post-synaptic densities using 
gold-labelling electron microscopy (Kirkpatrick et al. 2006).  Some antibodies also 
detect DISC1 as being associated with microtubules (Brandon et al. 2005) and found 
at the nucleus (James et al. 2004; Ogawa et al. 2005).  Subcellular fractionation 
studies have demonstrated that some DISC1 species display unique patterns of 
localisation, for example the 71kDa isoform is primarily found in the mitochondria-
enriched fraction (Ozeki et al. 2003; James et al. 2004; Sawamura et al. 2005). 
 
1.2.2.2 DISC1 in the brain and neurodevelopment 
In both human adults and foetuses, DISC1 transcripts are expressed in a variety of 
organs, including the brain (Millar et al. 2000b; James et al. 2004).  Within the 
human and rodent brain, DISC1 expression is most commonly described as being at 
the hippocampus within the granular cells of the dentate gyrus (Ma et al. 2002; 
Austin et al. 2004; James et al. 2004; Lipska et al. 2006) and pyramidal cells of the 
CA3 region (Schurov et al. 2004).  In the adult mouse cerebral cortex, Disc1 is found 
primarily in layers II-III, while in the cerebellum it is found at the Purkinje cell layer 
(Ma et al. 2002; Schurov et al. 2004).  Other regions of the mouse brain where Disc1 
expression has been reported include the hypothalamus, olfactory bulb, basolateral 
amygdala and brain stem (Ma et al. 2002; Austin et al. 2004; Schurov et al. 2004).  
The expression pattern of Disc1 within the brain appears to alter over the course of 
development in embryonic mice (Austin et al. 2004; Schurov et al. 2004).  
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Interestingly mice exposed to one of two antipsychotics, olanzapine and risperidone, 
had increased DISC1 in the frontal cortices (Chiba et al. 2006). 
 
DISC1 is known to be found in the cell processes of cultured neurons (Miyoshi et al. 
2003; Morris et al. 2003; Ozeki et al. 2003), and has been seen to localise to the 
synapses of cortical neurons (Kirkpatrick et al. 2006).  This result is reinforced by 
the fact that the “interactome” of DISC1 (its list of protein binding partners) 
resembles that of an essential synaptic protein (Camargo et al. 2007).  Knock-down 
of DISC1 within cultured neurons by RNA interference (RNAi) has been shown 
repeatedly to lead to a reduced rate of neurite outgrowth and a similar effect can be 
caused by over-expressing a DISC1 dominant negative truncation mutant (Ozeki et 
al. 2003; Kamiya et al. 2005; Pletnikov et al. 2007; Shinoda et al. 2007; Taya et al. 
2007).  Interestingly, in adult neurons, DISC1 knockdown appears to accelerate 
dendritic development, in contrast to observations made in the developing brain 
(Duan et al. 2007).  Neurons in the rodent brain which have their Disc1 level reduced 
by RNAi, including those of the dentate gyrus, have been shown to localise in an 
aberrant manner during development (Duan et al. 2007; Faulkner et al. 2008).  That 
DISC1 is seemingly involved in neuronal differentiation and migration is of 
exceptional interest when viewing it as a protein related to major mental illness. 
 
1.2.2.3 Mouse models of DISC1 
In the past few years, a number of mouse models of DISC1-related illness have been 
published.  The reasoning behind developing such mouse models is two-fold.  
Firstly, such models demonstrate that it is possible to induce phenotypes reminiscent 
of major mental illness simply by altering the workings of the Disc1 gene.  Secondly, 
by modelling DISC1-related psychiatric illness, these mice could be useful in gaining 
a better understanding of these conditions and ultimately in the development of novel 
antipsychotics and antidepressants. 
 
The first of these mouse lines came from the serendipitous discovery that all 129 
inbred mice strains are homozygous for a natural 25 base pair deletion in their Disc1 
gene (Clapcote and Roder 2006; Koike et al. 2006).  This is predicted to cause a 
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frame-shift mutation, introducing a premature stop codon (Koike et al. 2006).  
Indeed, it was reported that the full length Disc1 protein was missing from 
129S6/SvEv mice when compared to C57BL/6J mice (Koike et al. 2006), although 
this finding could not be replicated using a number of other anti-Disc1 antibodies 
(Ishizuka et al. 2007).  Nevertheless, when this mutant Disc1 gene was transferred 
onto a C57BL/6J background and further mutations added to prevent transcription 
passed exon 8, mice bearing one or more copies of it were shown to have impaired 
working memory when compared to their wild type littermates (Koike et al. 2006; 
Kvajo et al. 2008).  These mice displayed smaller pre-frontal cortices and displayed a 
variety of neuronal abnormalities, including altered migration, stunted dendrite 
outgrowth and altered short-term plasticity, in specific areas of the brain (Kvajo et al. 
2008).  The presence of this mutation in 129 mouse strains which have previously 
been used to set up embryonic stem cell lines  also means that caution will be needed 
in any work modelling DISC1 function in such cell lines (Clapcote and Roder 2006). 
 
Clapcote et al screened mice which had been subject to ENU-mutagenesis for 
mutations in exon 2 of Disc1 (Clapcote et al. 2007).  They identified two such 
mutations: a glutamine to leucine substitution (Q31L) and a leucine to proline 
substitution (L100P).  Both homozygous and heterozygous mice carrying each 
mutation showed significantly reduced total brain size.  Q31L mice showed 
increased immobility in the forced swim test, reduced social interaction and reduced 
reward responsiveness compared to wild type litter mates.  The L100P mice 
meanwhile had reduced pre-pulse inhibition and latent inhibition compared to wild 
type litter mates.  They also displayed increased locomotive activity and reduced 
working memory.  It was therefore concluded that the Q31L mice have a depressive-
like phenotype, while the L100P mice have a schizophrenia-like phenotype.  
Interestingly both sets of mice showed altered responsiveness to common 
antidepressants and/or antipsychotics (Clapcote et al. 2007). 
 
As an alternative approach, two groups have produced mouse lines which express a 
transgenic mutant form of human DISC1, encoding amino acids 1-597 only, under a 
calcium-calmodulin-dependent kinase II-α promoter (Hikida et al. 2007; Pletnikov et 
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al. 2008).  They suggest that this would reflect the biology of the t(1;11) family, 
based on a dominant negative model.  The mice of Hikida et al expressed this mutant 
DISC1 from birth in the primary neurons of the forebrain (Hikida et al. 2007).  These 
mice showed some signs of unusual hyperactivity and were more immobile in a 
forced swim test, a model of depression, than their wild-type littermates.  There was 
no sign of altered anxiety or social interactions.   Minor alterations in the relative 
sizes of the left and right ventricles of the mutant mice were also reported (Hikida et 
al. 2007).  Pletnikov et al developed a similar system, but using the Tet system to 
provide inducible expression of mutant Disc1 (Pletnikov et al. 2008).  These mice 
had increased lateral ventricular size and decreased neurite complexity in their 
brains.  Male mutant mice also showed evidence of increased activity and 
aggressiveness.  Female mutant mice, meanwhile, were seen to have reduced spatial 
memory (Pletnikov et al. 2008).  
 
Shen et al used a variation on the approaches of Hikida, Pletnikov et al, producing a 
line of mice expressing two copies of mutated mouse disc1 as well as the two wild-
type copies (Shen et al. 2008a).  Additionally, Shen et al made use of the native 
Disc1 promoter in order to express their transgene.  They theorised that this should 
simulate the ratio of the DISC1 genes in the t(1;11) family, although this would also 
lead to increased Disc1 expression, the effect of which is unclear.  Multiple brain 
abnormalities were reported, including enlarged lateral ventricles and a reduced 
cerebral cortex.  Abnormalities and altered localisation of GABAergic neurons in the 
hippocampus and the parvalbumin cells in the prefrontal cortex were also seen.  The 
mice also had decreased latent inhibition, like the mice of Clapcote et al (2007) and 
displayed some altered behavioural characteristics reminiscent of depression, 
including reduced vocalisation and mobility in certain tests (Shen et al. 2008a). 
 
Finally, Li et al also generated a line of mice with inducible expression of a mutant 
form of DISC1 in the primary forebrain neurons (Li et al. 2007).  The DISC1 mutant 
in question consisted of amino acid 671-852, fused to a fragment of an inactive 
oestrogen receptor.  They found that induction of this mutant at postnatal day seven 
(P7) led to spatial working memory defects, depression-like traits and reduced 
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sociability, while induction in adulthood had no effect (Li et al. 2007).  The 
biological reasons for these behaviours was investigated, and it was found that mice 
induced at P7 had reduced dendritic density in the dentate gyrus and reduced 
synaptic transmission in CA1 hippocampal neurons (Li et al. 2007). 
 
1.2.2.4 The DISC1 interactome 
In order to predict proteins that may be able to interact with DISC1 in the cell, a 
number of yeast-two-hybrid screens were carried out (Millar et al. 2003; Morris et al. 
2003; Ozeki et al. 2003; Brandon et al. 2004; Camargo et al. 2007).  In yeast-two-
hybrid screening, plasmids are generated that encode a protein of interest fused to 
part of a transcription factor.  Two such constructs, one referred to as the “bait” the 
other as the “prey”, are used and between them they contain the entire amino acid 
sequence of a transcription factor.  These can then be co-transformed into yeast and 
the expression of a reporter gene used as a measure of whether the proteins have 
interacted, thus allowing the transcription factor to function.  Libraries of prey 
proteins can then be used, allowing for the screening of large numbers of protein 
interactors. 
 
In combination with other techniques, a long list of potential protein interaction 
partners for DISC1 was built up, which are summarised in table 1.2.  It should be 
noted however that yeast-two-hybrid screens investigate protein-protein interactions 
in a very artificial manner and therefore have a high false positive rate (Deane et al. 
2002), meaning that any interaction determined in this way should be confirmed by 
independent techniques.  In order to definitively state that an interaction is genuine, 
you ideally need both an in vivo test, such as co-immunoprecipitation of endogenous 
protein (to prove that the interaction is of biological relevance) and a separate in vitro 
test to confirm that the interaction is direct.  Such confirmations have, to date, only 
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Name Assays References 
14-3-3ε [YWHAE] Y2H, AC, IV, IP (E) (Camargo et al. 2007; Taya et al. 2007) 
14-3-3γ [YHAG] Y2H (Ozeki et al. 2003) 
α-actinin [ACTN family] Y2H, IP (O) (Morris et al. 2003) 
α-tubulin [TUBA family] IV (Brandon et al. 2004) 
AGTPBP1 Y2H (Camargo et al. 2007) 
AKAP9 Y2H (Millar et al. 2003) 
APAP2 Y2H, IP (O) (Morris et al. 2003) 
APLP1 Y2H (Millar et al. 2003) 
ARFGEF2 AC (Taya et al. 2007) 
ARHGEF11 Y2H (Millar et al. 2003) 
ARIH2 Y2H (Camargo et al. 2007) 
ATF4 Y2H, IV, IP (O) 
(Millar et al. 2003; Morris et al. 2003; 
Sawamura et al. 2008) 
ATF5 Y2H, IP (O) (Morris et al. 2003) 
ATF7ip Y2H (Morris et al. 2003) 
Β4-Spectrin [SPTBN4] Y2H, IP (O) (Morris et al. 2003; Ozeki et al. 2003) 
β-tubulin [TUBB. 
TUBB2] 
Y2H (Camargo et al. 2007) 
BBS1 - BBS8 IP (O) (Kamiya et al. 2008) 
BICD Y2H (Camargo et al. 2007) 
C14orf135 Y2H (Camargo et al. 2007) 
C22orf1 Y2H (Camargo et al. 2007) 
C2orf4 Y2H (Camargo et al. 2007) 
CDC5L Y2H (Camargo et al. 2007) 
CDK5RAP3 Y2H (Camargo et al. 2007) 
CEP63 Y2H, IP (O) (Morris et al. 2003) 
CEP170 Y2H (Camargo et al. 2007) 
Citron [STK21] Y2H (Ozeki et al. 2003) 
CLU Y2H (Camargo et al. 2007) 
Collagen type IV 
[COL6A2] 
Y2H (Morris et al. 2003) 
CRNKL1 Y2H (Camargo et al. 2007) 
DBZ / Su48 [ZNF365] Y2H, IP (O+E) (Camargo et al. 2007; Hattori et al. 2007) 
DISC1 (Self-association) IP (O) (Brandon et al. 2005) 
DMD Y2H (Camargo et al. 2007) 
DMT1 Y2H (Millar et al. 2003) 
DNAJC7 Y2H (Camargo et al. 2007) 
DPYSL2 Y2H (Camargo et al. 2007) 
DPYSL3 Y2H (Camargo et al. 2007) 
DST Y2H (Camargo et al. 2007) 
Dynactin [DCTN1] Y2H, IP (O+E) (Ozeki et al. 2003; Kamiya et al. 2005) 
Dynein [DNC1H1, 
DYNC1I family] 
Y2H, AC, IP (E) 
(Kamiya et al. 2005; Camargo et al. 2007; Taya 
et al. 2007) 
eEF2 Y2H (Camargo et al. 2007) 
eIF3 p40 [EIF3S3] Y2H, IV, IP (O+E) (Morris et al. 2003; Ogawa et al. 2005) 
EXOC7 Y2H (Camargo et al. 2007) 
FBXO41 Y2H (Camargo et al. 2007) 
FEZ1 Y2H, IP (O) (Miyoshi et al. 2003) 
FLJ39502 Y2H (Morris et al. 2003) 
FRYL Y2H (Camargo et al. 2007) 
γ-actinin [ACTG1] Y2H (Camargo et al. 2007) 
γ-tubulin [TUBG family] IP (O+E) (Kamiya et al. 2005) 
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GM130 Y2H (Millar et al. 2003) 
GNB1 Y2H (Camargo et al. 2007) 
GPRASP2 Y2H (Camargo et al. 2007) 
GRB2 AC, IV, IP (O) (Shinoda et al. 2007) 
GRIPAP1 (GRASP1) Y2H (Millar et al. 2003) 
HAPIP (Kalirin, DUO) 
[KALRN] 
Y2H (Millar et al. 2003) 
HRC1 Y2H (Morris et al. 2003) 
KCNQ5 Y2H (Ozeki et al. 2003) 
IMMT Y2H (Millar et al. 2003) 
ITSN Y2H (Morris et al. 2003) 
KIAA1377 Y2H (Morris et al. 2003) 
KIF3A Y2H (Camargo et al. 2007) 
KIF3C Y2H (Camargo et al. 2007) 
KIF5A AC, IV, IP (O+E) (Taya et al. 2007) 
KIF5B AC (Taya et al. 2007) 
KIF5C IV (Taya et al. 2007) 
KIFAP3 Y2H (Camargo et al. 2007) 
KLC1 AC (Taya et al. 2007) 
KLC2 AC (Taya et al. 2007) 
LIS1 [PAFAH1B1] 
Y2H, AC, IV, IP 
(O+E) 
(Brandon et al. 2004; Kamiya et al. 2005; 
Camargo et al. 2007; Taya et al. 2007) 
MACF1 Y2H (Camargo et al. 2007) 
MAP1A Y2H, IP (O) (Morris et al. 2003) 
MATR3 Y2H (Camargo et al. 2007) 
MGAT3 Y2H (Millar et al. 2003) 
MGC2599 Y2H (Millar et al. 2003) 
MIP-T3 (TRAF3IP1) Y2H, IP (O) (Morris et al. 2003) 
MN7 Y2H (Camargo et al. 2007) 
Myosin [MYH7] Y2H (Morris et al. 2003) 
MYT1L Y2H (Camargo et al. 2007) 
N-CoR [NCOR1] IP (O) (Sawamura et al. 2008) 
NDE1 Y2H, IP (O) (Millar et al. 2003; Burdick et al. 2008) 
NDEL1 
Y2H, AC, IV, IP 
(O+E) 
(Millar et al. 2003; Morris et al. 2003; Ozeki et 
al. 2003; Brandon et al. 2004; Taya et al. 2007) 
NPHP6 [CEP290] Y2H (Millar et al. 2003) 
NUP160 Y2H (Camargo et al. 2007) 
OLFM1 Y2H (Camargo et al. 2007) 
PACS1 AC (Taya et al. 2007) 
PCM1 IP (O) (Kamiya et al. 2008) 
PDE4A IV (Millar et al. 2005a) 
PDE4B Y2H, IV, IP (O+E) (Millar et al. 2005a; Murdoch et al. 2007) 
PDE4C IP (O) (Millar et al. 2005a) 
PDE4D IV, IP (O) (Millar et al. 2005a; Murdoch et al. 2007) 
Pericentrin-B (Kendrin) 
[PCTN2] 
Y2H, IP (E) (Miyoshi et al. 2005) 
PGK1 Y2H (Camargo et al. 2007) 
PPF1A4 Y2H (Millar et al. 2003) 
PPME1 Y2H (Camargo et al. 2007) 
PPP4R1 Y2H (Camargo et al. 2007) 
RABGAP1 Y2H (Camargo et al. 2007) 
RACK1 AC (Taya et al. 2007) 
RAD21 Y2H (Camargo et al. 2007) 
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RanBPM [RANBP9] Y2H, IP (O) (Morris et al. 2003) 
ROGDI Y2H (Camargo et al. 2007) 
SEC3L1 Y2H (Camargo et al. 2007) 
SH3BP5 Y2H (Camargo et al. 2007) 
SMARCE1 (BAF57) Y2H (Millar et al. 2003) 
SNX3 Y2H (Camargo et al. 2007) 
SPTAN1 Y2H (Millar et al. 2003) 
SYNE1 Y2H, IP (O) (Morris et al. 2003) 
TENC1 Y2H (Millar et al. 2003) 
TFIP11 Y2H (Camargo et al. 2007) 
TIAM2 (STEF) Y2H (Camargo et al. 2007) 
TNKS Y2H (Camargo et al. 2007) 
TNIK Y2H (Camargo et al. 2007) 
TRAF3IP1 Y2H (Camargo et al. 2007) 
TRIO Y2H (Camargo et al. 2007) 
WKL1 Y2H (Millar et al. 2003) 
XPNPEP1 Y2H (Camargo et al. 2007) 
XRN2 Y2H (Camargo et al. 2007) 
ZNF197 Y2H (Camargo et al. 2007) 
 
Table 1.2: A list of published DISC1 interactors.  The assays column lists the 
methods by which an interaction with DISC1 has been demonstrated.  Y2H: 
yeast-two hybrid screen, AC: affinity chromatography, IP: 
immunoprecipitation using over-expressed (O) or endogenous (E) protein, IV: 
in vitro direct binding assay (including binding of in vitro transcribed and 
translated proteins, binding of bacterially produced proteins and use of 
peptide arrays).  For the sake of space, only the first paper to demonstrate a 
specific interaction by each individual technique is listed in the reference 
column, excepting in the case of simultaneous publications.  Rounded 
brackets indicate synonyms while squared brackets indicate gene names 
where these differ from the name of the protein.  Gene families are quoted 
when it is unclear which gene the protein came from or when interactions 
were identified using antibodies that detected multiple forms of the protein. 
 
 
1.2.3 Phosphodiesterase 4B (PDE4B) 
 
1.2.3.1 PDE4B in psychosis 
One protein interactor which has received much attention in the last few years is 
phosphodiesterase 4B (PDE4B).  Having been identified as a DISC1-interactor in a 
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yeast-two-hybrid screen PDE4B drew attention when a proband with schizophrenia 
was identified, who had a balanced t(1;16) translocation, directly disrupting the 
PDE4B gene (Millar et al. 2005b).  The proband had a cousin with schizophrenia 
who also carried the t(1;16) translocation.  It was suggested that PDE4B-deficiency 
could be the cause of the proband’s schizophrenia also on the grounds that the drug 
rolipram, a known PDE4 inhibitor, is known to act as an antidepressant (Wachtel 
1983) and that Drosophila with mutations in their PDE4B orthologue have learning 
and memory defects (Dudai et al. 1976).  That rolipram, a PDE4-inhibitor, has an 
antidepressant activity furthermore suggests that regulation of the overall activity of 
PDE4B, rather than specifically reduction in activity due to lowered levels of the 
protein, may be associated with psychiatric illness.  Since the original report, three 
genetic studies have been published, each providing evidence that different 
haplotypes of the PDE4B gene are associated with an altered risk of schizophrenia in 
the wider population (Pickard et al. 2007; Fatemi et al. 2008; Numata et al. 2008b).  
Additionally several PDE4B SNPs were found to be associated with major 
depression, although these results were not replicatable in a second population 
sample (Numata et al. 2008a).  PDE4B transcript levels were, however, significantly 
over-represented in major depression sufferers compared to controls, and were 
reduced in patients on antidepressants compared to drug naïve ones (Numata et al. 
2008a). 
 
It therefore appears increasingly likely that altered PDE4B function is a risk factor in 
its own right for schizophrenia and potentially wider mental illness.  Interactions of 
the endogenous DISC1 protein with various PDE4B isoforms in the cell have been 
robustly demonstrated (Millar et al. 2005b; Murdoch et al. 2007). 
 
1.2.3.2 The role of phosphodiesterases 
Cyclic adenosine monophosphate (cAMP) is a versatile secondary messenger within 
the cell.  It is generated from adenosine triphosphate (ATP) by adenylyl cyclase.  The 
only method by which the cell can degrade cAMP is through the use of 
phosphodiesterases such as PDE4B.  Long PDE4 isoforms contain two conserved 
regulatory regions, and the protein binds in such a way that these two regions interact 
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with each other.  Phosphorylation of one of these regions by PKA leads to a 
conformational shift, dramatically increasing the phosphodiesterase activity of the 
molecule.  Thus PDE4-activity is PKA dependent.  PKA consists of two catalytic 
subunits as well as two regulatory subunits which bind to the catalytic subunits and 
inhibit their activity.  Binding of cAMP to the regulatory subunits causes them to 
release the catalytic subunits, activating the protein.  Therefore a negative feedback 
mechanism exists to control the level of cellular cAMP, with cAMP activating PKA, 
PKA activating PDE4 and PDE4 degrading cAMP.  This is summarised in figure 
1.2.D. 
 
1.2.3.3 PDE4B and DISC1 
PDE4B has been shown to bind to the DISC1 protein at multiple sites (Millar et al. 
2005b; Murdoch et al. 2007).  Colocalisation of the two proteins has been seen in 
both differentiated and undifferentiated neurons, including at the mitochondria 
(Millar et al. 2005b).  As stated previously, PDE4B is activated by cAMP-stimulated 
PKA phosphorylation.  It is therefore interesting to note that binding of the 71kDa 
DISC1 isoform to PDE4B is weakened when drugs are used to boost cellular cAMP 
levels (Millar et al. 2005b), although a similar result was not seen with full length 
DISC1 (Murdoch et al. 2007).  It therefore appears that DISC1-PDE4B interactions 
are regulated in an isoform-specific and cAMP-dependent manner, and which may 
play an important role in the degradation of cAMP by PDE4B. 
 
PDE4B shows reduced binding affinity for two mutant versions of mouse Disc1, 
Q31L and L100P, which have been shown to cause depression-like and 
schizophrenia-like behaviour (Clapcote et al. 2007).  This is seemingly because the 
two “pathogenic” mutations lie within two separate PDE4B binding sites (Murdoch 
et al. 2007).  Additionally for Q31L mice, the total PDE4B activity in the brain was 
strikingly reduced compared to wild-type litter mates (Clapcote et al. 2007).  
Together this suggests that the DISC1-PDE4B interaction may be a crucial part of 
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Figure 1.2.D: The regulation of cyclic AMP (cAMP).  a) Adenosine 
triphosphate (ATP) is converted into cAMP by adenylyl cyclase.  The inactive 
protein kinase A (PKA) holoenzyme is bound to an A-Kinase Anchoring 
Protein (AKAP).  b) Following adenylyl cyclase activation, the rate of cAMP 
production increases.  One function of the cAMP is to bind to the regulatory 
(R) subunits of PKA, releasing and activating its catalytic (C) subunits.  c) 
PKA can phosphorylate phosphodiesterase 4 (PDE4), causing a 
conformational shift and activating it.  d) PDE4 begins to degrade cAMP to 
adenosine monophosphate (AMP).  e) The reduction in cAMP allows the 
catalytic PKA subunits to rebind to the regulatory subunits, inactivating the 
holoenzyme.  f) With the cellular PKA activity reduced, PDE4 becomes 
dephosphorylated, deactivating it.  The degradation of cAMP is therefore 
reduced and cellular homeostasis is restored.  Note that, while not shown in 
the diagram, PDE4s also bind to AKAPs. 
 
 
1.2.4 Other protein interactors of DISC1 
 
1.2.4.1 ATF4 and 5 
Activating Transcription Factors 4 and 5 (ATF4 and ATF5) have both been 
demonstrated to bind to DISC1 by yeast-two-hybrid analysis (Millar et al. 2003; 
Morris et al. 2003) and confirmed by immunoprecipitation of over-expressed protein 
(Morris et al. 2003; Sawamura et al. 2008).  Both ATF4 and ATF5 are members of 
the CREB family of proteins, and are transcriptional regulators which play a diverse 
array of roles within the cell.  It has been shown that DISC1 expression can repress 
the transcriptional activity of ATF4, potentially through interaction with the 
transcriptional repressor N-CoR (Sawamura et al. 2008).  ATF4 is also known to be 
phosphorylated by PKA (Elefteriou et al. 2005), providing a potential link between 
ATF4 and PDE4B.  
 
The ATF4 gene is located at chromosomal region 22q13, which shows evidence of 
being linked to psychiatric illness (Pulver et al. 1994; Gill et al. 1996; Liang et al. 
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2002; Takahashi et al. 2005; Zheng et al. 2006).  However, the evidence directly 
associating polymorphisms in ATF4 with psychiatric illness to date is limited 
(Kakiuchi et al. 2007; Qu et al. 2008), with at least seven other genes in this region 
having also been reported to show association (Hong et al. 2004; Brennan and 
Condra 2005; Verma et al. 2005a; Verma et al. 2005b; Severinsen et al. 2006a; 
Severinsen et al. 2006b; Silberberg et al. 2008). 
 
1.2.4.2 DBZ/Su48 
Zinc finger protein 365 (ZNF365), was identified in two studies as a DISC1 
interactor (Camargo et al. 2007; Hattori et al. 2007).  This protein, which Hattori et 
al designated DISC1-Binding Zinc finger protein (DBZ) has also been characterised 
elsewhere under the name Su48 (Wang et al. 2006).  DBZ/Su48 is a centrosomal 
protein (Wang et al. 2006) which is known to be expressed primarily in the brain 
(Nagase et al. 1998).  Over-expression of both DBZ/Su48 and DISC1 simultaneously 
in rat PC12 neurons led to diminished neurite outgrowth (Hattori et al. 2007).  The 
same effect was not seen when either was over-expressed individually, implicating 
the DISC1-DBZ/Su48 complex in neuronal development.  There is also some limited 
but intriguing evidence to suggest that the chromosomal region at which it is found, 
10q21.2, may play a role in the pathology of bipolar disorder (Liu et al. 2003; 
Segurado et al. 2003; Marcheco-Teruel et al. 2006; Tastemir et al. 2006). 
 
1.2.4.3 eIF3 p40 
Eukaryotic Initiation Factor 3 (eIF3) is a complex of at least a dozen protein subunits 
that acts as a scaffold for the formation of translation initiation complexes 
(Hinnebusch 2006).  DISC1 was shown to bind to the p40 subunit of eIF3 and over-
expression of DISC1 led to the production of eIF3 positive stress granules (Ogawa et 
al. 2005).  The p40 subunit is encoded by the EIF3S3 gene, which is found at 
chromosome 8q24.  This region shows linkage to bipolar disorder (Cichon et al. 
2001; McInnis et al. 2003; Macgregor et al. 2004; Park et al. 2004) and to 
schizophrenia (Walss-Bass et al. 2006; Kaneko et al. 2007; Aberg et al. 2008), 
although fine mapping has suggested that the mental illness risk locus may lie away 
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Fasciculation and Elongation protein Zeta 1 (FEZ1) is a protein expressed 
exclusively in the brain (Kuroda et al. 1999).  Mice which were homozygous 
negative for Fez1 showed evidence for increased hyperactivity and increased 
sensitivity to psychostimulants, but expressed no obvious cognitive impairments 
(Sakae et al. 2008).  In combination with PKCζ, FEZ1 has been shown to be 
involved in neuronal differentiation (Kuroda et al. 1999), neurite outgrowth (Fujita et 
al. 2007) and the establishing of neuronal polarity (Ikuta et al. 2007), functions 
which may be related to its ability to activate kinesin-related transport along the 
microtubules (Blasius et al. 2007; Fujita et al. 2007). 
 
The DISC1 and FEZ1 proteins have been shown to interact by yeast-two-hybrid 
screening and by co-immunoprecipitation of over-expressed protein (Miyoshi et al. 
2003).  The two proteins have similarities in their developmental expression profiles 
in the brain (Honda et al. 2004) and their interaction appears to be more abundant 
during neuronal differentiation (Miyoshi et al. 2003).  Intriguingly, over-expression 
of the FEZ1-binding domain of DISC1 leads to stunted neurite outgrowth in PC12 
cells, although whether this phenotype is specifically FEZ1-related or not is unclear.  
The FEZ1 gene lies close to a translocation breakpoint in a schizophrenia patient, 
however other genes are directly disrupted by the translocation (Pickard et al. 2006).  
Similarly, there are two reported cases of the chromosomal region surrounding 
FEZ1, 11q24.2, being deleted in individuals with bipolar affective disorder (Böhm et 
al. 2006; Reardon et al. 2007).  Two FEZ1 SNPs have been shown to be nominally 
associated with schizophrenia (Yamada et al. 2004), however no significant SNPs 
were detected in two subsequent studies (Hodgkinson et al. 2006; Koga et al. 2007).   
 
1.2.4.5 GRB2 
Growth factor Receptor Bound protein 2 (GRB2) is a multi-purpose adaptor protein 
within the cell (Lowenstein et al. 1992).  DISC1 has been shown to exist in a ternary 
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complex with both GRB2 and the kinesin heavy chain protein KIF5B (Shinoda et al. 
2007).  DISC1 is involved in kinesin-1-related transport of GRB2 and is required for 
GRB2-related cellular functions such as the neutrophilin-2-related axonal elongation 
(Shinoda et al. 2007).  GRB2 is also known to bind to the PDE4D family of proteins 
(Beard et al. 1999) which, like PDE4B have been independently implicated in 
schizophrenia (Tomppo et al. 2006). 
 
There is a limited amount of evidence that 17q25, the chromosomal region where 
GRB2 is found, may be linked schizophrenia (Riley et al. 1997; Logue et al. 2006) 
and bipolar disorder (Ewald et al. 2005).  Interestingly, expression of GRB2 in the 
dentate gyrus has been shown to increase following electro-convulsive therapy, a 
treatment for depression (Newton et al. 2004). 
 
1.2.4.6 Kinesins 
Kinesins are a superfamily of ATP-powered motor protein complexes involved in the 
transport of cargo, such as vesicles, towards the distal ends of microtubules and the 
cell periphery (Hirokawa and Noda 2008).  By various techniques, the kinesin heavy 
chains KIF3A, 3C, 5A, 5B and 5C, along with the kinesin light chains KLC1 and 
KLC2 have all been implicated in DISC1 interaction (Camargo et al. 2007; Taya et 
al. 2007).  DISC1 plays a role in the localisation of kinesin-1 and may act as a cargo 
receptor allowing kinesin-1 to transport proteins including GRB2, NDEL1, LIS1 and 
14-3-3ε (Shinoda et al. 2007; Taya et al. 2007).  The DISC1-interacting proteins 
FEZ1 and MIPT3 have also been implicated in kinesin function (Blasius et al. 2007; 
Fujita et al. 2007; Li et al. 2008).  Together this strongly implicates DISC1 as being 
involved in kinesin-related transport. 
 
1.2.4.7 MAP1A 
Microtubule-Associated Protein 1A (MAP1A) was shown to interact with DISC1 in 
a yeast 2-hybrid screen and by co-immunoprecipitation of over-expressed protein 
(Morris et al. 2003).  MAP1A is a large protein known to bind to and be involved in 
the structural development of both microtubules and the actin cytoskeleton 
(Shiomura and Hirokawa 1987; Pedrotti et al. 1994; Pedrotti and Islam 1994).  It is 
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expressed in the developing brain (Garner et al. 1990) and has been implicated as 
playing roles in neurite outgrowth and dendritic remodelling (Di Giovanni et al. 
2004; Szebenyi et al. 2005).  The MAP1A gene is located at 15q15, a locus which 
shows some, currently limited, evidence of linkage to early onset major depressive 
disorder (Camp et al. 2005), bipolar disorder (Marcheco-Teruel et al. 2006), 
schizophrenia (Moon et al. 2006) and catatonia (Stöber et al. 2000). 
 
1.2.4.8 MIP-T3 
Microtubule Interacting Protein that associates with TRAF3 (MIP-T3) is a 
microtubule-associated protein (Ling and Goeddel 2000) which is suggested to play a 
role in the assembly of kinesin motor complexes (Li et al. 2008).  Yeast-two-hybrid 
screens and co-immunoprecipitation of over-expressed protein have suggested that 
MIP-T3 is also a DISC1 interactor, with the ability to recruit DISC1 to the 
microtubules (Morris et al. 2003).  It is also known as TRAF3-Interacting Protein 1 
(TRAF3IP1).  The MIPT-3/TRAF3IP1 gene is found at chromosomal region 2q37, 
which has been linked to schizophrenia in four studies to date (Paunio et al. 2001; 
Lerer et al. 2003; Wijsman et al. 2003; Klei et al. 2005). 
 
1.2.4.9 PCM1 and BBS4 
Pericentriolar Material 1 (PCM1) is a large protein found proximal to, but not at the 
centrioles (Balczon et al. 1994; Kubo et al. 1999).  It functions as a scaffold protein 
and is involved in the recruitment of various other proteins, including pericentrin-B, 
to the centrosome, a process which is essential for correct microtubule organisation 
(Dammermann and Merdes 2002).  PCM1 is itself recruited to the centrosome by 
Bardet-Biedl Syndrome (BBS) protein 4 (Kim et al. 2004).  By co-
immunoprecipitation, DISC1 has been shown to exist in a complex with PCM-1 and 
each of BBS proteins 1-8 (Kamiya et al. 2008).  DISC1 and BBS4 appear to act co-
operatively to recruit PCM-1 to the centrosome and affect the rate of radial neuron 
migration in mouse embryos (Kamiya et al. 2008).  Two studies have so far reported 
association between the PCM1 gene and schizophrenia (Gurling et al. 2006; Datta et 
al. 2008).  The gene is found at 8p22 in close proximity to NRG1, a prominent 
candidate gene for schizophrenia and bipolar disorder.  This makes it difficult to 
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Pericentrin-B (also known as kendrin) is a large centrosomal protein (Flory et al. 
2000; Li et al. 2001) and is orthologous to a splice variant of the better studied 
mouse protein pericentrin-A (Doxsey et al. 1994; Flory and Davis 2003).  
Pericentrin-A is among the first proteins to be found at de novo generated 
centrosomes (Khodjakov et al. 2002) and appears to act as a molecular scaffold, 
anchoring proteins such as PKA to the centrosome (Diviani et al. 2000).  Pericentrin-
B was shown to bind to the central regions of DISC1, and the two proteins appear to 
colocalise at the centrosomes of SH-SY5Y human neuroblastoma cells (Miyoshi et 
al. 2005).  Disruption of their interaction has been shown to disrupt the formation of 
the microtubule network (Shimizu et al. 2008). 
 
Pericentrin-B is encoded by the PCTN gene, mutations in which have been shown to 
cause specific forms of dwarfism, characterised by a reduction of brain size in 
addition to a reduction in general body size (Griffith et al. 2008; Rauch et al. 2008), 
thus implicating pericentrin-B in neurodevelopment.  Intriguingly, a study of mRNA 
levels in post-mortem brains revealed PCTN2 transcripts (the splice form of PCTN 
encoding pericentrin-B) to be over-represented in the brains of bipolar disorder 
patients compared to controls (Anitha et al. 2007).  In addition, the PCTN gene is 
found at chromosomal region 21q22.3 which has been repeatably linked to bipolar 
disorder in various populations (Straub et al. 1994; Vallada et al. 1996; Smyth et al. 
1997; Detera-Wadleigh et al. 1999; Kwok et al. 1999; Liu et al. 2001; Ewald et al. 
2003; Kaneva et al. 2004).  There are also reported cases of schizophrenia sufferers 
who possess a chromosomal deletion at 21q22. (Demirhan and Tastemir 2003). 
 
1.2.4.11 14-3-3 proteins 
The 14-3-3 proteins are a family of ubiquitously expressed phospho-serine/phosphor-
threonine binding proteins involved in a diverse range of signalling pathways and 
protein interactions within the cell (Dougherty and Morrison 2004).  One of these 
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proteins, 14-3-3ε, has been demonstrated to be a DISC1-interacting protein 
(Camargo et al. 2007; Taya et al. 2007).  DISC1 is required for the correct 
localisation of 14-3-3ε to the distal parts of the axon, possibly by facilitating its 
transport to this location by kinesin-1 (Taya et al. 2007).  14-3-3γ has also been seen 
to bind DISC1 in a yeast-two-hybrid screen (Ozeki et al. 2003). 
 
A recent study provided evidence that a SNP in the YWHAE gene, which encodes 14-
3-3ε, is associated with schizophrenia, as well as demonstrating that Ywhae deficient 
mice display behavioural defects (Ikeda et al. 2008).  The chromosomal region 
containing YWHAE, 17p13, also contains LIS1 and is heavily involved in 
lissencephaly brain malformations (see section 1.3.1).  This region has also been 
linked to schizophrenia in one study (Klei et al. 2005). 
 
1.2.4.12 Other interactors from yeast-two-hybrid screens 
A number of other DISC1 yeast-two-hybrid interactors, for which further study has 
not yet been undertaken, also have the potential to link into mental illness pathways.  
For example, citron forms complexes with NMDA receptors (Furuyashiki et al. 
1999), TIAM2 is known to be involved in the radial migration of neurons (Kawauchi 
et al. 2003) and the NPHP6 gene has been repeatedly shown to be linked to the 
Joubert and Meckel syndromes, both of which include neurological symptoms (Sayer 
et al. 2006; Valente et al. 2006; Baala et al. 2007). 
 
It can therefore be seen that DISC1 appears to play roles in numerous cellular 
pathways, several of which have the potential to be involved in the pathology of 
schizophrenia and other psychiatric conditions.  This work will, however, focus on 
the interactions of DISC1 with two proteins: NDE1 and NDEL1, as well as their 
relationship with a third DISC1-interactor, LIS1. 
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1.3 Nuclear Distribution Factor E homologues (NDE1 and NDEL1) 
 
1.3.1 The LIS1 pathway 
The Lissencephaly 1 gene (LIS1, also known as PAFAH1B1) is so named as it was 
identified as being from a chromosomal region disrupted in sufferers of the brain 
malformation Miller-Dieker lissencephaly (Reiner et al. 1993).  The LIS1 gene has 
since been shown to be mutated in the majority of cases of the related, but less 
severe, syndrome isolated lissencephaly (Guerrini and Marini 2006).  The LIS1 
protein appears to play two major roles in the cell.  The first of these is that it is 
known to be one subunit of the platelet-activating factor acetylhydrolase (PAFAH) 
complex (Hattori et al. 1994).  The second occurs through its interactions with the 
dynein and dynactin protein complexes (Faulkner et al. 2000; Tai et al. 2002).  These 
two functions appear to be separate as LIS1 cannot bind to both the PAFAH and 
dynein complexes simultaneously (Tarricone et al. 2004).  This work will focus on 
the dynein-related activity of LIS1. 
 
The microtubules function as “conveyer belts” along which cargo (proteins or 
vesicles) can be trafficked within the cell.  This microtubule network spreads 
throughout the cell from the microtubule organising centre at the centrosome.  
Trafficking occurs both towards and away from the cell periphery, with separate 
motor proteins being involved in each direction of traffic. Cytoplasmic dynein is a 
motor protein complex involved in retrograde transport along the microtubules 
towards the centrosome, and consists of two heavy chains as well as numerous 
intermediate chains, light intermediate chains and light chains.  In order to function it 
requires a second protein complex, dynactin (Gill et al. 1991).  In addition to 
providing transport of cargo from the cell periphery, this system is involved in a 
number of other cellular functions, such as facilitating the migration of the nucleus 
during neuronal development (Shu et al. 2004). 
 
LIS1 interacts with this motor complex (Sasaki et al. 2000) and may function by 
aiding in the transport of dynein back to the distal ends of the microtubules (Yamada 
et al. 2008).  Use of RNAi to knock down the levels of either LIS1 or dynein proteins 
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have been shown to impair nuclear movement (Shu et al. 2004).  Possibly as a result 
of this, neurons lacking LIS1 have been shown to have impaired migration (Shu et al. 
2004; Toyo-Oka et al. 2005).  In combination with the fact that LIS1 is known to be 
a DISC1-interacting protein (Brandon et al. 2004), it would appear that this pathway 
may be of significant interest in studying major mental illness. 
 
1.3.2 Identification of nudE homologues 
The LIS1-dynein-dynactin pathway has been seen to be strongly conserved even in 
ancient organisms such as Aspergillus nidulans, Neurospora crassa and 
Saccharomyces cerevisae (Xiang et al. 1995a; Geiser et al. 1997; Cockell et al. 
2004).  The homologue of LIS1 in the fungus A. nidulans is one of a series of genes 
which, when mutated, lead to deficiencies in nuclear migration (Xiang et al. 1995a).  
These nuclear distribution genes include homologues of LIS1 (nudF), dynein 
subunits (nudA, nudG and nudI) and dynactin subunits (nudK and nudM) (Xiang et 
al. 1995b; Beckwith et al. 1998; Xiang et al. 1999; Efimov and Morris 2000; Zhang 
et al. 2002; Zhang et al. 2003).  In addition, a gene nudE, encoded a protein, NUDE, 
that binds the LIS1/NUDF protein (Efimov and Morris 2000). 
 
In 2000 and 2001, five studies were published that used yeast-two-hybrid screening 
to predict protein interactors of mammalian LIS1.  Three of these studies showed 
LIS1 to interact with a previously unknown protein that was apparently an 
orthologue of NUDE (Feng et al. 2000; Kitagawa et al. 2000; Sasaki et al. 2000).  
This protein was named Nuclear Distribution factor E (Aspergillus nidulans) 
homologue 1 (NDE1).  In addition, three of the studies reported LIS1 to interact with 
a separate protein, a paralogue of NDE1.  This second protein was named NDE-Like 
1 or NDEL1 (Niethammer et al. 2000; Sasaki et al. 2000; Sweeney et al. 2001).   
 
The NDE1 and NDEL1 proteins have highly similar amino acid sequences (see 
figure 1.3.A).  Conservation is particularly high in the region known to be involved 
in LIS1-binding (Feng et al. 2000; Sweeney et al. 2001) and the two genes may have 
descended from a common ancestral gene, such as nudE in A. nidulans.  The exact 
nomenclature of NDE1 and NDEL1 has varied since their identification.  A complete  
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NDE1            -MEDSGKTFSSEEEEANYWKDLAMTYKQRAENTQEELREFQEGSREYEAELETQLQQIET 
NDEL1           MDGEDIPDFSSLKEETAYWKELSLKYKQSFQEARDELVEFQEGSRELEAELEAQLVQAEQ 
                   :.   *** :**: ***:*::.***  :::::** ******** *****:** * *  
 
NDE1            RNRDLLSENNRLRMELETIKEKFEVQHSEGYRQISALEDDLAQTKAIKDQLQKYIRELEQ 
NDEL1           RNRDLQADNQRLKYEVEALKEKLEHQYAQSYKQVSVLEDDLSQTRAIKEQLHKYVRELEQ 
                ***** ::*:**: *:*::***:* *:::.*:*:*.*****:**:***:**:**:***** 
 
NDE1            ANDDLERAKRATIMSLEDFEQRLNQAIERNAFLESELDEKENLLESVQRLKDEARDLRQE 
NDEL1           ANDDLERAKRATIVSLEDFEQRLNQAIERNAFLESELDEKESLLVSVQRLKDEARDLRQE 
                *************:***************************.** *************** 
 
NDE1            LAVQQKQE---KPRTPMPSSVEAERTDTAVQATGSVPSTPIAHRGPSSSLNTPGSFRRGL 
NDEL1           LAVRERQQEVTRKSAPSSPTLDCEKMDSAVQASLSLPATPVGKGTENTFPSP-----KAI 
                ***:::*:   :  :* ..:::.*: *:****: *:*:**:.:   .:  ..     :.: 
 
NDE1            DDSTGGTPLTPAARISALNIVGDLLRKVGALESKLASCRNLVYDQSPNRTGGPASGRSSK 
NDEL1           PNGFGTSPLTPSARISALNIVGDLLRKVGALESKLAACRNFAKDQASRKSYISGNVNCGV 
                 :. * :****:************************:***:. **:..::  ... ...  
 
NDE1            NRDGGERRPSSTSVPLGDK----GLDTSCRWLSKSTTRSSSSC------- 
NDEL1           LNGNGTKFSRSGHTSFFDKGAVNGFDPAPPPPGLGSSRPSSAPGMLPLSV 
                 ...* : . *  ..: **    *:*.:    . .::*.**:         
 
Figure 1.3.A: Sequence alignment of human NDE1 and NDEL1.  Asterisks (*) 
indicate precisely conserved residues while dots indicate similar residues, 
while dots (.) and colons (:) indicate ascending degrees of similarity  
Alignment performed using FASTA Two-Sequence Comparison (Pearson 
and Lipman 1988) 
 
Gene/Protein Names used in the literature 
NDE1 
Nde1, NudE, NUDE, HOM-TES-87,  
mNudE (Mouse), rNUDE (Rat), MP43 (Xenopus) 
NDEL1 
Ndel1, Nudel, NUDEL, NUDEL-oligopeptidase, EOPA,  
EOPARP (Rabbit), Ndel1a & Ndel1b (Zebrafish) 
NDE1/NDEL1 
nudE (A. nidulans), ro-11 (N. crassa), Ndl1 (S. cerevisae), 
NUD-2 (C. elegans) 
 
Table 1.3: A list of alternate names for NDE1 and/or NDEL1 used in the 
literature.  All names refer to the human genes/proteins unless stated.  
“NDE1/NDEL1” includes genes for which it is not possible to determine 
whether they represent direct orthologues specifically of NDE1 or NDEL1 or 
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list of  the synonyms for the two genes used in the literature is therefore displayed in 
table 1.3. 
 
Following the initial demonstration of an interaction using yeast-two-hybrid 
screening, binding of NDEL1 to LIS1 has been robustly demonstrated by co-
immunoprecipitation of both endogenous and in vitro transcribed and translated 
protein (Niethammer et al. 2000; Sweeney et al. 2000).  The NDE1-LIS1 interaction 
has so far only been seen using protein over-expressed in cells (Feng et al. 2000; 
Kitagawa et al. 2000).   There is also some evidence to suggest that NDE1 can bind 
to dynein light chains (Feng et al. 2000; Stehman et al. 2007), while NDEL1 has 
been robustly demonstrated to complex with the heavy and intermediate chains 
(Niethammer et al. 2000; Sweeney et al. 2000; Brandon et al. 2004; Kamiya et al. 
2005).  NDE1 and NDEL1 have also both been reported to co-immunoprecipitate 
with dynactin subunits (Niethammer et al. 2000; Brandon et al. 2004; Liang et al. 
2004; Guo et al. 2006).  Overall, this strongly implies that, as in A. nidulans, NDE1 
and NDEL1 are likely to exist in the LIS1-dynein-dynactin complex.   
 
1.3.3 Functions of NDE1 and NDEL1 in the cell 
NDEL1, and to a lesser extent NDE1, have been demonstrated to play a number of 
different roles in the cell, most of them related to LIS1 and/or dynein.  One of these 
roles appears to be in the assembly of the LIS1-dynein complex itself.  Use of RNAi 
to block production of the NDEL1 protein leads to reduced association of LIS1 with 
the dynein intermediate chain in several cell lines (Shu et al. 2004; Shim et al. 2008), 
while the expression pattern of endogenous LIS1 matches that of over-expressed 
NDE1 or NDEL1 (Caspi et al. 2003).  It therefore appears that NDE1 and NDEL1 
act as recruiters for the LIS1 protein. 
 
1.3.3.1 NDE1 and NDEL1 at the centrosome 
The NDEL1 protein is consistently found at the centrosome (Niethammer et al. 2000; 
Sasaki et al. 2000) and NDE1 appears to do the same when over-expressed in cell 
lines (Feng et al. 2000).  These localisations appear to only occur during interphase 
(Toyo-Oka et al. 2005; Hirohashi et al. 2006b). NDEL1 has also been seen to be 
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specific to the mother centriole (Guo et al. 2006).  Localisation of NDEL1 to the 
centrosome appears to be regulated by kinases (Yan et al. 2003; Toyo-Oka et al. 
2005; Mori et al. 2007) with phosphorylation at sites in the C-terminal half of 
NDEL1 leading it to be absent from the centrosome.  Amino acids 256-291 of 
NDEL1, found near the C-terminus and containing its dynein binding site (Liang et 
al. 2004), have been shown to be essential for centrosomal localisation (Guo et al. 
2006). 
 
Over-expression of a mutant form of NDEL1 lacking the centrosomal localisation 
domain in HeLa cells has been shown to block the localisation of LIS1 and a 
dynactin subunit to the centrosome while not affecting “core” centrosomal proteins 
such as γ-tubulin.  This implies that NDEL1 is responsible for recruiting LIS1 and 
dynactin to the centrosome (Guo et al. 2006).  Knocking down NDEL1 expression 
using RNAi had a similar effect on LIS1 and NDEL1, but also partially disrupted the 
centrosomal localisation of pericentrin and γ-tubulin (Guo et al. 2006).  Over-
expression of Nde1 in mouse cell lines has also been seen to lead to γ-tubulin mis-
localisation (Feng et al. 2000). 
 
1.3.3.2 NDE1 and NDEL1 at the microtubules 
Like dynein and LIS1, NDEL1 is known to be anchored to the microtubules of the 
cell (Sasaki et al. 2000), and over-expressed NDE1 appears to do likewise (Coquelle 
et al. 2002).  Following the severing of a neuron, mouse Ndel1 was seen at both ends 
of the microtubules, implying that it is actively transported along it (Sasaki et al. 
2000).   
 
Expression of mutant versions of NDEL1, lacking the LIS1- or dynein-binding 
domains, led to the fragmentation of the Golgi apparatus and dispersion of lysosomes 
and endosomes (Liang et al. 2004), in a pattern similar to that which is seen when 
dynein activity is inhibited (Guo et al. 2006).  This system was sensitive to the 
microtubule-destabilising drug nocodazole (Liang et al. 2004), implying that NDEL1 
is involved in the dynein-related transport of vesicles along microtubules towards the 
nucleus.  Conditional knock-out of Ndel1 in mice again blocked the transport of 
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vesicles along the microtubules, but interestingly this could be rescued by over-
expression of Nde1 (Sasaki et al. 2005), suggesting that NDE1 may also be involved 
in this process. 
 
NDE1 and NDEL1 also appear to play a role in maintaining the structure of 
microtubules.  Over-expression of Nde1 in mouse cell lines leads to the microtubule 
network taking a disorganised shape (Feng et al. 2000).  Similarly, cells from 
conditional knock-out Ndel1 mice show amorphous microtubule networks (Sasaki et 
al. 2005; Toyo-Oka et al. 2005) and are slower to produce new networks after 
disruption of previous ones with nocodazole (Guo et al. 2006).  This may be related 
to the disruption of protein assembly at the centrosomes, which form the organising 
centre of microtubule networks. 
 
1.3.3.3 NDE1 and NDEL1 in mitosis 
Disrupting the functions of either NDE1 or NDEL1 within the cell has been shown to 
lead to the cell taking longer to undergo mitosis (Feng and Walsh 2004; Liang et al. 
2007).  Expression of truncated mutant versions of NDE1 in cells led to defects in 
the formation of the spindle (Stehman et al. 2007), while expression of NDEL1 
mutants led to cells in which the chromosomes failed to disperse correctly (Liang et 
al. 2007).   
 
During mitosis, NDE1 and NDEL1 are both known to be found at the spindle (Yan et 
al. 2003) and the kinetochores (Liang et al. 2007; Stehman et al. 2007; Vergnolle 
and Taylor 2007).  During normal mitosis, the spindle attaches to the kinetochores at 
metaphase and various proteins are transported from the spindle to the kinetochores 
through the action of dynein (Howell et al. 2000; Howell et al. 2001).  Transfer of 
these proteins may be used as part of a cellular “check” that attachment has occurred 
successfully before the cell proceeds into anaphase.  NDE1 and NDEL1 appear to be 
among the proteins transported in this way (Yan et al. 2003), but interestingly over-
expression of a NDEL1 mutant lacking the dynein binding domain actually blocked 
the transport of itself and other proteins in this manner (Liang et al. 2007).  That 
NDEL1 and possibly NDE1 are required for this process provides a mechanism for 
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NDE1/NDEL1-related mitotic disruption.  NDE1 and NDEL1 also appear to play 
roles in recruiting dynein and/or dynamitin to the kinetochores prior to the binding of 
the spindle (Liang et al. 2007; Vergnolle and Taylor 2007) 
 
1.3.3.4 NDEL1 as an endopeptidase 
In addition to these functions, NDEL1 is known to have an additional role as a 
cysteine endopeptidase (Hayashi et al. 2005), having been shown to degrade 
neuropeptides such as bradykinin in rabbit brain homogenates (Camargo et al. 1973; 
Camargo et al. 1983).  This function is performed only by the NDEL1 monomer, 
rather than the dimer which is known to interact with LIS1 (Tarricone et al. 2004; 
Hayashi et al. 2005).  It is unknown whether NDE1 possesses a similar enzymic 
activity, although the catalytic cysteine residue of NDEL1 is conserved between the 
two proteins (Hayashi et al. 2005). 
 
1.3.4 NDE1 and NDEL1 in neurodevelopment 
 
1.3.4.1 Nde1 and Ndel1 in the mouse brain 
In rodents, Nde1 and Ndel1 are both expressed in numerous parts of the body, with 
the brain, testes and heart being the most commonly described, although expression 
has also been seen in the ovary (reported for Ndel1 only), kidney, liver, eye (Ndel1) 
spleen (Nde1) and muscles (Feng et al. 2000; Kitagawa et al. 2000; Niethammer et 
al. 2000; Sasaki et al. 2000; Sweeney et al. 2001; Yamaguchi et al. 2004).  It should 
be stressed that a direct comparison of Nde1 with Ndel1 is yet to be performed.   
 
Several studies have investigated the expression pattern of the Ndel1 protein within 
the rodent brain.  Most commonly it is described as being in the cerebral cortex 
within layers II-IV (Niethammer et al. 2000; Sasaki et al. 2000; Hayashi et al. 2001; 
Sweeney et al. 2001).  Expression has also been reported in the hippocampus, where 
it is found in layers CA1-3 and the dentate gyrus (Niethammer et al. 2000; Hayashi 
et al. 2001; Sweeney et al. 2001), and at the cerebellum, where it is found in both 
migrating granular and Purkinje cells (Sasaki et al. 2000; Hayashi et al. 2001).  Other 
areas where expression has been reported include the entorhinal cortex (Hayashi et 
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al. 2001), the hypothalamus (Niethammer et al. 2000), the medulla oblongata 
(Yamaguchi et al. 2004) and the olfactory bulb (Sasaki et al. 2000). 
 
In comparison, little work has focused on the localisation of Nde1 within the rodent 
brain.  It has been described as being predominantly located in the cerebral cortex of 
the embryonic mouse, with weak but specific expression in the ventricular zone, 
subventricular zone, intermediate zone and cortical plate (Feng et al. 2000).  
 
It should be noted that in only one of the studies described above is it stated that the 
antibodies used were tested in order to ensure specificity for either Nde1 or Ndel1.  It 
is therefore possible that some of these antibodies may in fact cross-react and detect 
both proteins. 
 
1.3.4.2 Neurodevelopmental phenotypes of Nde1 and Ndel1 deficient mice 
LIS1 is well known to be linked to brain abnormalities (see section 1.3.1) and is 
known to play roles in neurite outgrowth (Taya et al. 2007) and neuronal migration 
(Hirotsune et al. 1998; Cahana et al. 2001; Kholmanskikh et al. 2003; Shu et al. 
2004; Toyo-Oka et al. 2005).  Therefore, the localisation of its interactors NDE1 and 
NDEL1 to the brain implicates them also in neurodevelopment. 
 
One dramatic piece of evidence linking NDE1 to neurodevelopment comes from 
Nde1 knock-down mice.  Mice that were homozygous negative for Nde1 had a one 
third smaller total brain mass than their wild type littermates, despite no significant 
difference in total body mass (Feng and Walsh 2004).  This loss of mass was uneven, 
affecting primarily the cerebral cortex (specifically layers II-IV), with little alteration 
of the hippocampus, midbrain or cerebellum.  This effect was even more significant 
in mice that were also heterozygous for a Lis1 knock-out mutation, which die shortly 
after birth and lack any visible layering in the neocortex (Pawlisz et al. 2008).   
 
In contrast, in Ndel1 knock-out mice, generated by a separate group, embryos die 
shortly after implantation, although heterozygous and conditional knock-out mutants 
did show some evidence of aberrant pyramidal neuron localisation (Sasaki et al. 
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2005).  This effect was again exaggerated when the mice were crossed with mutants 
that were heterozygous negative for Lis1 (Sasaki et al. 2005), although these mice 
did not show the 25% reduction in brain size seen when crossing heterozygous Nde1 
and Lis1 mutants (Pawlisz et al. 2008). 
 
1.3.4.3 The role of NDEL1 in neurite outgrowth and neuronal development 
Ndel1 is present in the outgrowing neurites of mouse neurons (Niethammer et al. 
2000; Sasaki et al. 2000).  Interestingly, knocking down Ndel1 expression by use of 
RNAi has been shown to lead to loss of cell processes (Nguyen et al. 2004b), 
reduced axonal length (Taya et al. 2007) and dendrites which were both stunted and 
incorrectly positioned (Duan et al. 2007), implying a role for NDEL1 in neuronal 
differentiation.  In contrast, when mouse NIH-3T3 cells were stimulated to 
differentiate, the amount of Nde1 in the cell processes actually decreased (Mili et al. 
2008). 
 
In culture, use of RNAi to knockdown Ndel1 levels in mouse NIH-3T3 cells led to 
cells with reduced motility  (Shen et al. 2008b) and a similar result has been seen 
when RNAi was used in the mouse brain (Shu et al. 2004).  These data fits well with 
reports that in Nde1 and Ndel1 knock-out mice localised sets of neurons show a 
reduced rate of migration (Feng and Walsh 2004; Sasaki et al. 2005; Toyo-Oka et al. 
2005). 
 
One possible explanation for this reduced rate of neuronal migration is that loss of 
NDE1 or NDEL1 may prevent the nucleus of the neuron from migrating properly 
towards the leading edge of the cell, thus inhibiting the cell migration process.  Use 
of RNAi to knock-down NDEL1, LIS1 or dynein also causes such an effect (Shu et 
al. 2004).  NDEL1 RNAi has been shown repeatably to enlarge the distance between 
the centrosome and nucleus within a cell (Shu et al. 2004; Toyo-Oka et al. 2005; 
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1.3.5 NDE1, NDEL1 and psychiatric illness 
 
1.3.5.1 The NDE1 and NDEL1 genes and major mental illness 
Both the NDE1 and NDEL1 genes also show some evidence of their being risk 
factors for psychiatric illness in their own right.  In 2004, a dense genome scan of 
Eastern Quebec families revealed chromosomal region 16p13, which includes NDE1, 
to show suggestive linkage to schizophrenia (Maziade et al. 2004).  Meanwhile in 
studies of Finnish families, two regions of 16p12, D16S769 and D16S764, have been 
shown to be linked to bipolar disorder (maximum LOD score of 3.4) and 
schizophrenia (LOD score of 3.17) respectively (Ekholm et al. 2003; Hennah et al. 
2007).  On the basis of this evidence, Hennah et al went on to look at the association 
of a particular haplotype, containing four SNPs from NDE1, on schizophrenia.  They 
found that in females carrying a known DISC1 schizophrenia risk haplotype (Cannon 
et al. 2005), this NDE1 haplotype was significantly associated with an increased risk 
of schizophrenia, p=0.011 (Hennah et al. 2007).  This could potentially suggest that 
disregulation of NDE1 function could exacerbate the psychiatric phenotypes 
associated with the DISC1 risk haplotype, resumably as a result of the proteins acting 
within the same pathway in the cell. 
 
Another study, this time of Americans of European decent, found that a particular 
four SNP haplotype of NDEL1 was significantly over-represented in schizophrenia 
patients compared to healthy controls, p=0.048 (Burdick et al. 2008).  Each of the 
four SNPs individually was also associated with disease status.  It was found that the 
effect of the NDEL1 haplotype was only significant on the background of the Ser/Ser 
genotype of the DISC1 schizophrenia risk variant S704C (see section 1.2.1.3) 
(Burdick et al. 2008).  Interestingly however, on a Cys carrying background, a SNP 
in NDE1 (rs3784859) also showed association with schizophrenia, p=0.049.  This 
SNP, however, showed no significant association unless the population was 
conditioned for DISC1 genotype (Burdick et al. 2008).  Two other association 
studies have, however, failed to detect any significant association of NDEL1 SNPs to 
schizophrenia, although neither of these studies conditioned their sample population 
on DISC1 genotype (Ikeda et al. 2008; Kähler et al. 2008). 
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It has also been shown that specific NDEL1 and LIS1 mRNA species are 
significantly down-regulated in the brains of schizophrenia patients in America 
compared to healthy controls, with a more subtle change also visible in the prefrontal 
cortex (Lipska et al. 2006).   
 
1.3.5.2 NDE1 and NDEL1 in other illnesses 
In addition to their roles in psychiatric illness, NDE1 and NDEL1 have also been 
linked to other conditions.   The expression of NDE1 transcripts have been shown to 
be mis-regulated in seminoma, salivary adenoid cystic carcinoma, glial and 
glioneural tumours and clear cell renal carcinoma (Türeci et al. 2002; Kasamatsu et 
al. 2005; Suzuki et al. 2007; Brito et al. 2008), as well as in a mouse model of breast 
cancer (Namba et al. 2006).  These findings are likely to be related to the role of 
NDE1 in the cell cycle (see section 1.3.3.3).  NDEL1 transcripts, meanwhile, were 
down-regulated in a mouse model of motor neuron disease (Nguyen et al. 2004b). 
 
1.3.5.3 NDE1 and NDEL1 interactions with DISC1 
During the initial DISC1 yeast-two-hybrid screenings, the most commonly reported 
interaction seen was that of DISC1 with NDEL1 (Millar et al. 2003; Morris et al. 
2003; Ozeki et al. 2003; Brandon et al. 2004).  This interaction has since been 
extensively investigated, having been shown to occur by co-immunoprecipitation in 
the mouse brain  and also using in vitro transcribed and translated protein (Brandon 
et al. 2004).  By comparison, the NDE1-DISC1 interaction had been demonstrated 
only in two yeast-two-hybrid screens (Millar et al. 2003; Brandon et al. 2004).  
During the preparation of this thesis, the interaction was also demonstrated using 
over-expressed protein in HEK293 cells (Burdick et al. 2008). 
 
DISC1 binds to amino acids 266-267 of NDEL1 (Kamiya et al. 2006), although the 
location of the NDEL1-binding site of DISC1 has proven more controversial, with 
two alternative potential sites suggested (Morris et al. 2003; Ozeki et al. 2003).  
Several publications have investigated this by attempting to demonstrate complexing 
of NDEL1 with truncation mutants of DISC1 and the findings of these are  
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Figure 1.3.B: Determining the location of the NDEL1-binding domain on 
DISC1.  Various studies have used co-immunoprecipitation and GST pull-
downs to demonstrate the binding of NDEL1 to truncated versions of DISC1, 
in order to identify the minimum essential binding region.  Data from yeast 
two-hybrid screening is excluded as potentially less reliable.  This figure 
summarises the DISC1 truncations tested, indicating if DISC1 and NDEL1 
could bind (green), could not bind (red) or if binding was greatly reduced 
relative to other NDEL1-DISC1 interactions tested at the same time (brown).  
The minimal essential binding region appears to be within amino acids 727-
832, although some region of 403-457 and/or 474-503 also appears 
important.  This region, which may contain the DISC1 self-association 
domain (Kamiya et al. 2005), may therefore also be required.  Delta (∆) 
indicates amino acids that were deleted from the DISC1 construct.  It is 
uncertain why Morris et al failed to detect binding of NDEL1 to DISC1 amino 
acids 697-854, while they could detect binding with 293-854.  It is possible 
that this is related to the lack of the 403-503 region, as they do not 
demonstrate NDEL1 binding to any construct which lacks this.  (Morris et al. 
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summarised in figure 1.3.B.  Based on these, we can postulate that two separate 
regions are indeed required.  The first of these is within amino acids 727-832 of 
DISC1, as constructs of amino acids 590-832 and 727-854 have both been seen to be 
sufficient for binding (Brandon et al. 2004; Taya et al. 2007).  However, deletion of 
DISC1 amino acids 403-503, but not of 458-473, has been shown to disrupt 
interaction (Brandon et al. 2004; Kamiya et al. 2006). This second site is known to 
be the region of DISC1 required for self association (Kamiya et al. 2005).  Given that 
NDEL1 has been shown to bind preferentially to DISC1 multimers (Leliveld et al. 
2008), we can hypothesise that the actual binding site is within 727-832, but that it is 
also a requirement of binding that DISC1 be able to multimerise.  With very short 
DISC1 segments multimerisation does not appear to be necessary for interaction with 
NDEL1. 
 
NDEL1 appears to bind primarily to the full length DISC1 variant (Brandon et al. 
2004).  There is also some evidence to suggest that the interaction is weaker in the 
DISC1 Lv splice variant, which lacks amino acids 748-769 (Kamiya et al. 2006).  
The interaction of DISC1 with NDE1 or NDEL1 has also been reported to be 
weakened in the DISC1 S704C variant (Kamiya et al. 2006; Burdick et al. 2008), a 
mutation previously linked to schizophrenia and major depression (Callicott et al. 
2005; Hashimoto et al. 2006).  This data is, however, open to interpretation. 
 
Looking at the various Disc1 mutant mice described earlier, it is difficult to see how 
the Q31L and L100P mutants would directly affect interactions with Nde1 or Ndel1 
(Clapcote et al. 2007).  The mice expressing DISC1 amino acids 1-597, however, 
would lack the Nde1/Ndel1 binding site (Brandon et al. 2004) and so the mutant 
DISC1 species may be able to function as a dominant negative mutant, reducing the 
number of Disc1-Nde1/Ndel1 interactions within any given cell (Hikida et al. 2007; 
Pletnikov et al. 2008).  Interestingly, in one of these mouse lines, mutant DISC1 
expression was associated with reduced Lis1 expression (Pletnikov et al. 2008).  The 
mouse line which inducibly expresses DISC1 amino acids 671-852, meanwhile, 
would be able to bind to Nde1 or Ndel1 (Li et al. 2007).  However, this mutant 
would lack many of the other cellular functions of Disc1 and so its competition with 
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full length Disc1 for Nde1/Ndel1 binding would have an adverse effect on cellular 
pathways requiring such an interaction. 
 
1.3.5.4 NDE1 and NDEL1 in the DISC1 pathway 
Between them, NDE1 and NDEL1 share a number of protein-interaction partners 
with DISC1.  These are known to include the dynein and dynactin complexes, LIS1, 
pericentrin B, 14-3-3ε and DBZ/Su48 (Feng et al. 2000; Kitagawa et al. 2000; 
Niethammer et al. 2000; Sasaki et al. 2000; Toyo-Oka et al. 2003; Guo et al. 2006; 
Hirohashi et al. 2006b).  This presents the possibility that NDE1/NDEL1 may exist 
as part of a larger DISC1 protein complex and participate in different aspects of the 
DISC1 pathway. 
 
The expression pattern of over-expressed NDEL1 alters when DISC1 is also over-
expressed, implying that DISC1 may be able to recruit NDEL1 within the cell 
(Morris et al. 2003).  Colocalisation of Disc1 and Ndel1 has been reported in 
differentiating mouse PC12 neurons, implying that the two may bind during neuronal 
differentiation (Kamiya et al. 2006).  Colocalisation of the two proteins has also been 
reported at the distal ends of PC12 axons (Taya et al. 2007).  Knockdown of Ndel1 
in mice has been shown to lead to the mis-positioning of neurons in the adult 
dendrite hippocampus (Duan et al. 2007).  A very similar effect was seen when 
Disc1 was instead knocked-down, and the effect of knocking down both was 
cumulative, implying that NDEL1 and DISC1 may co-operate also during neuronal 
migration (Duan et al. 2007). 
 
1.3.6 Contrasting the NDE1 and NDEL1 proteins 
NDE1 and NDEL1 share approximately 60% amino acid identity and 80% similarity 
with each other (see figure 1.3.A), implying that they are likely to have very similar 
functions within the cell.  Notably, several key protein interaction partners of 
NDEL1, including LIS1, dynein and dynactin are also implicated in NDE1 
interaction (Feng et al. 2000; Yan et al. 2003; Liang et al. 2004; Guo et al. 2006).  
However, in spite of these similarities, a number of differences between NDE1 and 
NDEL1 have been reported in the literature: 
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1. LIS1 has a higher binding affinity for NDEL1 than it does for NDE1 in vitro 
(Caspi et al. 2003). 
2. In mice, expression of Nde1 varies with time in the early stages of blastocyst 
growth, while Ndel1 expression is more consistent (Cahana et al. 2003). 
3. Homozygous Ndel1 knock-out mice die shortly after implantation (Sasaki et 
al. 2005), while Nde1 homozygous knock-out mice are viable (Feng and 
Walsh 2004). 
4. After treatment with a chemotactic agent, Nde1 from NIH3T3 cells became 
enriched 4.6-fold in the cell body relative to the cell processes.  No 
significant redistribution of Ndel1 was detected (Mili et al. 2008) 
5. Use of RNAi to knock-down the levels of NDE1 in the cell blocked 
recruitment of dynein to the kinetochore during mitosis.  Knock-down of 
NDEL1 in the same way did not have this effect (Vergnolle and Taylor 
2007). 
 
It therefore appears that, while NDE1 and NDEL1 are likely to play over-lapping 
roles in the cell, they nonetheless need to be treated as individual proteins.  It 
therefore cannot be assumed that the wealth of published data surrounding NDEL1 is 
directly applicable to the lesser studied NDE1 protein. 
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1.4 Aims of this PhD 
 
Given the intriguing biological and genetic information implicating both NDE1 and 
NDEL1 in neurodevelopment and potentially psychiatric illness, it seems likely that 
interactions between these proteins and DISC1 would be critical in major mental 
illness. This thesis will therefore tackle three main issues: 
 
Firstly, published data relating to the basic biology of NDE1 is limited in comparison 
to that of NDEL1.  Specifically, due to the lack of published antibodies known to 
specifically detect native NDE1 protein without also cross-reacting with NDEL1, 
almost nothing is known about the nature and localisation of endogenous NDE1 
within the cell.  The biology of NDE1 will therefore be studied by investigating the 
existence of alternatively spliced NDE1 transcripts (chapter 3), bioinformatics 
analysis of the NDE1 amino acid sequence (chapter 4) and through the generation 
and use of endogenous anti-NDE1 antibodies (chapter 5). 
 
Secondly, the relationship between NDE1 and NDEL1 in the cell is unclear.  Both 
proteins share considerable amino acid similarity, but it does not clearly follow that 
they therefore perform the same functions within the cell or that they are regulated in 
the same way.  In order to gain understanding in this area, detailed analyses of the 
two proteins using bioinformatics will be performed and the results compared 
(chapter 4).  Additionally, known protein interactions of NDEL1, such as that with 
LIS1 or self-association, will be replicated using NDE1 (chapter 6).  Given that 
NDEL1 self-associates, it will also be investigated whether NDE1 and NDEL1 are 
capable of complexing together, potentially as a heterodimer (chapter 6). 
 
Thirdly, DISC1 is known to interact with a number of proteins, besides NDE1 and 
NDEL1, which have been independently implicated in the pathogenesis of 
psychiatric illness.  In the current literature the most prominent of these is PDE4B.  
Given that it is unlikely that DISC1 would be involved in multiple cellular pathways 
which independently are involved in major mental illness, the relationships between 
NDE1, NDEL1, DISC1 and PDE4B will be investigated (chapters 6 and 7). 
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2.1.1 Identification of NDE1 and NDEL1 splice variants 
NDE1 and NDEL1 splice variants were identified using the UCSC genome browser 
(http://genome.ucsc.edu/cgi-bin/hgGateway).  Variants were carried forward for 
further analysis if at least three such transcripts were listed on the genome browser, 
or if they corresponded to a published isoform.  The nucleic acid sequence of all 
coding exons was then entered into the ExPASy translate tool in order to determine 
an amino acid sequence for the corresponding protein (Gasteiger et al. 2005). 
 
2.1.2 Molecular weight and isoelectric point prediction 
In order to determine the molecular weight and isoelectric point of a protein, its 
amino acid sequence was analysed using the ExPASy ProtParam online tool 
(Gasteiger et al. 2005). 
 
2.1.3 Structural prediction 
Amino acid sequences of proteins were entered into the online structural prediction 
programs COILS and PSIPRED (Lupas et al. 1991; McGuffin et al. 2000) and the 
results compared.  When using COILS, a significance threshold of 0.5 using a seven-
amino acid window was used to differentiate coiled from uncoiled residues.  When 
using PSIPRED, predicted helices shorter than 7 amino acids in length (equivalent to 
one complete turn of an α-helix) were assumed to be false positives.   
 
2.1.4 Disorder prediction 
Amino acid sequences of proteins were submitted into nine online protein disorder 
prediction programs.  Each amino acid was then either designated as ordered or 
disordered based on a simple consensus of the results (i.e. if five or more programs 
predicted that a given amino acid was disordered then it was considered to be 
disordered).  The programs used were as follows: 
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1. DisEMBL 1.5 (Linding et al. 2003): Facility uses three separate definitions of 
disorder, Loops/Coil, Hot-Loops and Remark-465.  For the purposes of this 
analysis, all three were considered to be separate programs.  
2. DISOPRED2 (Ward et al. 2004)  
3. DISPROT VSL2 (Obradovic et al. 2005; Peng et al. 2006) 
4. DRIP-PRED (MacCallum) 
5. FoldIndex (Prilusky et al. 2005)  
6. IUPred (Dosztányi et al. 2005a, b) 
7. PreLink (Coeytaux and Poupon 2005) 
 
2.1.5 Kozak sequence prediction 
The programs NetStart 1.0 (Pedersen and Nielsen 1997) and weakAUG (Tikole and 
Sankararamakrishnan 2008) were used to predict potential Kozak sequences (Kozak 
1987) from mRNA transcripts. 
 
2.1.6 Nuclear localisation signal prediction 
Two separate techniques were used in order to identify potential nuclear localisation 
signals (NLS) from amino acids sequences: 
 
1. Complete amino acid sequences of proteins were entered into the online 
prediction programs PredictNLS and PSORT II (Nakai and Horton 1999; 
Cokol et al. 2000), both of which identify common NLS motifs. 
2. Amino acid sequences were manually examined for clusters of basic residues.  
If a group of basic residues was similar to a known NLS motif then a 
generalised version of the amino acid sequence was used to search the NLS 
database (Nair et al. 2002) in order to see if it was enriched in nuclear 
proteins.  The “generalised” motif was determined by allowing all residues 
except for lysines and arginines to vary.  For example, a generalised version 
of the sequence KRCANTADENDTKFMRR, in which the five basic 
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2.1.7 Prediction of functional sites 
Amino acid sequences of proteins were entered into Scansite 2.0 (Obenauer et al. 
2003) in order to predict potential phosphorylation and other functional sites.  Only 
sites detected using a “Medium” stringency search were considered.  Sites that could 
also be detected using a “High” stringency search were recorded as such.  NetPhosK 
1.0 (Blom et al. 2004) was also used to investigate more weakly predicted 
phosphorylation sites. 
 
2.1.8 Web pages of online programs 
BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi 
COILS: http://www.ch.embnet.org/software/COILS_form.html  
CLUSTALW: http://align.genome.jp/ 
DisEMBL 1.5: http://dis.embl.de/ 
DISOPRED 2: http://bioinf.cs.ucl.ac.uk/disopred/disopred.html 
DISPROT VSL2: http://www.ist.temple.edu/disprot/predictorVSL2.php 
DRIP-PRED: http://www.sbc.su.se/~maccallr/disorder/ 
ExPASy - ProtParam: http://www.expasy.org/tools/protparam.html 
ExPASy - Translate Tool: http://www.expasy.org/tools/dna.html 
FASTA Comparison: http://fasta.bioch.virginia.edu/fasta_www2/fasta_list2.shtml 
Fold Index: http://bip.weizmann.ac.il/fldbin/findex/ 
IUPred: http://iupred.enzim.hu/ 
NetPhosK 1.0: http://www.cbs.dtu.dk/services/NetPhosK/ 
NetStart 1.0: http://www.cbs.dtu.dk/services/NetStart/ 
NLS database http://cubic.bioc.columbia.edu/cgi/var/nair/resonline.pl  
Operon - Oligo Analysis and Plotting: https://www.operon.com/oligos/toolkit.php 
Predict NLS http://cubic.bioc.columbia.edu/cgi/var/nair/resonline.pl  
PreLink: http://genomics.eu.org/prelink/ 
PSIPRED: http://bioinf.cs.ucl.ac.uk/psipred/psiform.html.  
PSORT II: http://psort.nibb.ac.jp/form2.html  








The following a list of chemical reagents used in this thesis, along with their source 
and, where appropriate, the buffer in which they were suspended or diluted. 
 
• Acetic acid (Fischer) 
• 30% Acrylamide/Bis solution (BioRad) 
• Agar (BD Bioscience) 
• Agarose (Invitrogen), made up in TAE buffer for most experiments, or in 
MES SDS running buffer (Invitrogen) for 2-dimensional Western blotting 
• Ammonium persulphate (Sigma), made up in dH2O 
• Ampicillin (Sigma), made up in dH2O 
• ATP solution, PCR grade (Sigma) 
• Bromophenol blue (Sigma) 
• BSA (Sigma), made up in PBS or TBS 
• CHAPS (Sigma) 
• CTP solution, PCR grade (Sigma) 
• DABCO (Sigma) 
• DAPI (Sigma), made up in mowiol mounting solution 
• DEPC (Sigma) 
• DMSO (Sigma) 
• D-PBS (Invitrogen) 
• DTT (Sigma), made up in dH2O 
• EDTA (Sigma), made up in dH2O 
• Ethanol (Fischer), diluted with dH2O where appropriate 
• Ficoll 40 (Sigma) 
• Forskolin (Sigma), made up in DMSO 
• Glycerol (Promega) 
• Glycine (Sigma) 
• Glycogen (Sigma) 
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• Goat serum (Abcam or Sigma), diluted with PBS 
• GTP solution, PCR grade (Sigma) 
• H89 (Merck), made up in dH2O 
• Hydrochloric acid (Fischer) 
• IBMX (Sigma), made up in absolute ethanol 
• IPTG (Melford) in dH2O 
• Iodoacetamide (Sigma), made up in LDS sample buffer (Invitrogen) 
• Instant milk powder (Marvel), made up in PBS or TBS wash buffer 
• Low melting point agarose (Agarose), made up in TAE buffer 
• Magnesium acetate (Fischer), made up in dH2O 
• Magnesium chloride solution, PCR grade (Invitrogen) 
• Methanol (Fischer) 
• Mowiol (Sigma) 
• NP-40 (Sigma) 
• Orange G (Sigma) 
• PBS (Sigma), made up in dH2O often as a 10x solution 
• Paraformaldehyde (Sigma), made up in PBS 
• Phenol/chloroform/isoamyl alcohol (Invitrogen) 
• Phosphatase inhibitor cocktail II (Calbiochem) 
• Ponceau S (Sigma) 
• Protease inhibitor cocktail (Roche), made up in dH2O 
• Rabbit serum (Sigma), diluted with PBS 
• SDS (Fischer) made up in dH2O 
• Sodium acetate (BDH Laboratory Supplies), made up in dH2O and pH 
adjusted using hydrochloric acid and/or sodium hydroxide  
• Sodium chloride (Fischer), made up in dH2O 
• Sodium deoxycholate (Fischer), made up in dH2O 
• Sodium fluoride (Fischer), made up in dH2O 
• Sodium hydroxide (Fischer), made up in dH2O 
• TEMED (Sigma) 
• 10x TGS (BioRad), diluted with dH2O  
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• Tris (Fischer), made up in dH2O and pH adjusted using hydrochloric acid 
and/or sodium hydroxide 
• Tris-HCl (Fischer), made up in dH2O and pH adjusted using hydrochloric 
acid and/or sodium hydroxide 
• Triton X-100 (Sigma), made up in dH2O 
• Tryptone (BD Biosciences) 
• TTP solution, PCR grade (Sigma) 
• TWEEN-20 (Sigma) 
• Urea (Gibco) 
• Yeast extract (BD Biosciences) 
 
2.2.2 Solutions and buffers 
Below are listed the recipes of all solutions used for the methods described in this 
chapter. 
 
Coomassie staining solution 
 200 ml  Methanol 
 3.5 ml  Acetic acid 
 Trace  Bromophenol blue 
 Up to 500 ml dH2O 
Solution stored at room temperature and was recovered after each stain for re-use. 
 
Coomassie de-staining solution 
 100 ml  Acetic acid 
 300 ml  Methanol 
 600 ml  dH2O 
Solution stored at room temperature 
 
DEPC-treated water 
DEPC was added to dH2O to a final concentration of 0.1% in order to inactivate any 
RNase in the water.  Solution was then left at room temperature overnight and then 
autoclaved to denature the DEPC.  It was stored at room temperature. 
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dNTP 
An equal mix of PCR-grade ATP, CTP, GTP and TTP diluted appropriately in dH2O.  
Stored at -20°C. 
 
L Agar/ampicillin 
 50 g  Tryptone 
 25 g  Yeast Extract 
 50 g  Sodium chloride 
 Up to 5 litres with dH2O 
Adjust pH to 7.2.  Pour into a bottle and add 1.5g Agar per 100ml medium.  Stored at 
4°C.  Before use, melt in a microwave and then stand at room temperature until cool 
enough to touch with gloved hands and add ampicillin to a final concentration of 50 
ng/ml.  Used immediately. 
 
L Broth/ampicillin 
 50 g  Tryptone 
 25 g  Yeast Extract 
 25 g  Sodium chloride 
 Up to 5 litres with dH2O 
Adjust pH to 7.2.  Solution stored at 4°C.  Before use add ampicillin to a final 
concentration of 50 ng/ml. 
 
Membrane blocking buffers 
The basic blocking buffer is as follows, and is used both for pre-stain blocking and 
while applying the primary antibody: 
 2.5 g   Instant milk powder 
 5 ml  10x PBS 
 100 µl  TWEEN-20 
 Up to 50 ml dH2O 
Solution was made up immediately prior to use. 
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When using the PKA substrate antibody (see table 2.4) the following was instead 
used for pre-stain blocking: 
 2.5 g  Instant milk powder (Marvel) 
 5 ml  10x TBS 
 50 µl  TWEEN-20 
 Up to 50 ml dH2O 
Solution was made up immediately prior to use. 
 
When using the PKA substrate antibody, the following was used while applying the 
primary antibody: 
 2.5 g  BSA 
 5 ml  10x TBS 
 50 µl  TWEEN-20 
 Up to 50 ml dH2O 
Solution was stored at 4°C. 
 
Membrane wash buffers 
The basic washing buffer was as follows: 
 100 ml  10x PBS 
 20 ml  TWEEN-20 
 Up to 1 litre with dH2O 
 
Where TBS-based blocking buffers were used, the following wash buffer was instead 
used: 
 100ml  10x TBS 
 10 ml  TWEEN-20 
 Up to 1 litre with dH2O 
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Mowiol mounting solution 
 7.5 g  Mowiol 
 10 ml  Glycerol 
 25 ml  dH2O 
Solution was then incubated overnight at room temperature 
 50 ml  0.2 M Tris-HCl (pH 8.5) 
Solution was then heated at 100°C for 20 minutes and allowed to cool 
 1.75 g  DABCO 
Solution was stored at -20°C, with working aliquots stored at 4°C. 
 
PBS-TX lysis buffer 
The following buffer was used to produce lysates for which it was important to 
maintain the phosphorylation state of the cellular proteins: 
 5 ml  10x PBS 
 5 ml  10% Triton X-100 
 1 ml  0.55 mM sodium fluoride 
 5 ml  Glycerol 
 Up to 50ml dH2O 
0.5 ml  Phosphatase inhibitor cocktail II 
 1 tablet Protease inhibitor cocktail 
Buffer was stored at 4°C before the addition of the inhibitor cocktails and at -20°C 
after they had been added. 
 
2x PKA reaction buffer 
 3 ml  dH2O 
 1 ml  0.4M Tris-HCl pH 7.4 
 1 ml  0.2M Magnesium acetate 
 20 µl  100mM ATP (PCR quality) 
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Ponceau S stain 
 1 g  Ponceau S 
 4 ml  Acetic acid 
 Up to 200 ml dH2O 
Solution was stored at room temperature and was recovered after each stain for re-
use. 
 
Protein sample buffer 
 6.25 ml 1M Tris pH 6.8 
 10 ml  Glycerol 
 10 ml  20% SDS 
 13.75 ml dH2O 
 1ml  0.1% Bromophenol blue 
Solution was stored at room temperate 
 
Recombinant protein storage buffer 
 40 ml  1M Tris pH 7.5 
 26.6 ml 3M Sodium chloride 
 Up to 800 ml dH2O 
Solution was stored at room temperature. 
 
RIPA buffer 
 2.5 ml  1M Tris-HCl pH 7.5 
 2.5 ml  3M Sodium chloride 
 0.5 ml  NP-40 
 2.5 ml  10% Sodium deoxycholate 
 250 µl  20% SDS 
 Up to 50ml dH2O 
 1 tablet Protease inhibitor cocktail 
Buffer was stored at 4°C before the addition of the inhibitor cocktails and at -20°C 
after they had been added. 
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Semi-dry transfer buffer 
 5.8 g  Tris 
 2.9g  Glycine 
 2 ml  20% SDS 
 200ml  Methanol 
 Up to 1 litre with dH2O 
Before use, pH was confirmed to be between 8 and 10.  Solution stored at 4°C. 
 
Stop solution 
 3 g  Ficoll 400 
 50 µl  20% SDS 
 800 µl  0.5 M EDTA 
 25 µg  Orange G 
 Up to 1 litre with dH2O 
Solution was stored at room temperature. 
 
TAE buffer 
 24.2 g  Tris 
 5.71 ml Acetic acid 
 10 ml  0.5 M EDTA 
 Make up to 5 litres with dH2O 
Buffer was stored at 4°C 
 
TE buffer 
 10 ml  1M Tris-HCl pH 7.5 
 2 ml  500mM EDTA 
 Make up to 1 litre with dH2O 
The pH of the buffer was adjusted using hydrochloric acid and/or sodium hydroxide.  
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Tris Buffered Saline (TBS) 
 1x  10x 
 8 g  40 g  Sodium chloride 
 20 ml  100 ml  1M Tris pH 7.5 
 Up to 1 litre Up to 500ml dH2O   
Solution was stored at room temperature. 
 
2xYT medium 
 16 g  Tryptone 
 10 g  Yeast extract 
 5 g  Sodium chloride 
 Up to 1 litre with dH2O 
The pH of the buffer was adjusted using hydrochloric acid and/or sodium hydroxide 
to 7.0.  Medium was stored at 4°C. 
 
2-D blot lysis buffer 
 6 g   Urea 
 0.25 g  CHAPS 
 500 µl  Protease inhibitor (one tablet in 2 ml) 
Buffer was stored at -20°C. 
 
2-D blot re-hydration buffer 
 6 g   Urea  
 0.25 g  CHAPS 
 62.5 µl  Ampholite solution* (Invitrogen) 
 1ml  0.1% Bromophenol blue 
 Up to 12.5ml dH2O 
*Ampholite solution was chosen to be appropriate for the pI range of the gel system. 
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ECACC (Gluzman 1981) 

























(Biedler et al. 1978) 
D-MEM/10% foetal calf 
serum 
 
Table 2.3.A: Media in which each cell line was grown.  All chemicals were 
from Invitrogen.  ECACC is the European Collection of Cell Cultures.  
1Bradley Research Group and the 2Genes and Development Group 
respectively, University of Edinburgh. 
 
 
2.3 Cell culture 
 
2.3.1 Cell line maintenance 
Cell lines were grown at 37°C, 5% CO2 in a Galaxy S incubator (Scientific 
Laboratory Supplies) using the media shown in table 2.3.A and in CellStar T25 or 
T75 flasks (Greiner Bio-One).  Once every 4-7 days the cells were split.  To do this, 
media was removed and cells washed briefly in a 1:1 mix of trypsin and versine 
(Invitrogen).  Cells were then incubated at 37°C for 2-10 minutes in trypsin/versine 
before having 4 volumes of medium (table 2.3.A) added.  This cell suspension was 
then split 1:5 or more to start new cell cultures.  All cell culture manipulations were 
performed in an Envair Bio2+ Class II Safety Cabinet under containment level 1 
conditions. 
 
When protein lysates were to be prepared from a cell line, the cells were split 
(typically 1:10) into 10cm tissue culture plates (Iwoki) with 10ml of appropriate 
media.  These would then be grown for 1-3 days until the cells were 75-90% 
confluent.  When cells were to be used for immunocytochemistry, 12 well Costar 
plates (Corning) were set up, each containing a single 16mm sterile glass coverslip 
(VWR).  To each well, 1ml of media and 30-200µl cells were added.  These would 
then be grown overnight. 
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2.3.2 Transfection of plasmids into eukaryotic cells 
In order to exogenously express protein in cultured cells, cells of around 75-90% 
confluence were washed twice in 37°C OptiMEM (Invitrogen) and then transfected 
with one or more plasmid constructs using Lipofectamine 2000 (Invitrogen), 
according to manufacturer’s instructions.  For a 12-well dish of cells, 0.5-1µg of 
DNA per well was used, for 10cm plates of cells 10-20µg of DNA was used.  Cells 
were incubated in the transfection media for 6 hours at 37°C and then washed with 
their normal growth media (table 2.3.A).  Cells were then allowed to grow for a 
further 18-24 hours before proceeding.  Details of plasmids used in this thesis are 
described in table 2.3.B. 
 
2.3.3 Drug treatment 
The drugs IBMX and forskolin can be used in combination to raise the level of 
cAMP within a cell, while H89 is a potent inhibitor of protein kinase A.  In order to 
treat cells with these drugs, the cells were grown in 10cm plates until they were 75-
90% confluent and then washed once with media lacking serum.  Cells would then be 
incubated for 30 minutes at 37°C with 5% CO2 in 10ml of D-MEM containing either 
5µM H89 or 250µM IBMX and 100µM forskolin.  When all three drugs were to be 
used, a 30 minute H89 pre-incubation would be performed, followed by a 30 minute 
IBMX/forskolin incubation.  In order to perform control reactions, cells would be 
treated with equivalent amounts of absolute ethanol or DMSO instead of IBMX and 
forskolin. 
 
2.4 Protein-related methods 
 
2.4.1 Antibodies 
Various antibodies were used in this project.  Details of these, and the conditions in 






    
Plasmid Protein Tag Source 
pGEX-6P1 Empty vector (GST) GE Healthcare 
pcDNA3.1-FLAG-DISC1 DISC1 N-terminal FLAG Nick Brandon
1
 (Brandon et al. 2004) 
pDEST-40-DISC1 DISC1 C-terminal V5 Kirsty Millar & Sheila Christie (Millar et al. 2005a) 
pDEST-40-NDE1 NDE1-SSSC C-terminal V5 Kirsty Millar & Sheila Christie (Bradshaw et al. 2009) 
pDEST-40-NDEL1 NDEL1-PLSV C-terminal V5 Kirsty Millar & Sheila Christie (Bradshaw et al. 2009) 
pDEST-53-ATF4 ATF4 N-terminal GFP Kirsty Millar & Sheila Christie (Bradshaw et al. 2008) 
pDEST-53-NDE1 NDE1-SSSC N-terminal GFP Kirsty Millar & Sheila Christie (Bradshaw et al. 2009) 
pDEST-53-NDEL1 NDEL1-PLSV N-terminal GFP Kirsty Millar & Sheila Christie (Bradshaw et al. 2009) 
pSV-SPORT-PDE4A10 PDE4A10 None Miles Houslay
2
 (Rena et al. 2001) 
pEE7-PDE4B1 PDE4B1 None Miles Houslay
2
 (Huston et al. 1997) 
pEE7-PDE4C2 PDE4C2 None Miles Houslay
2
 (Owens et al. 1997) 
pcDNA3-PDE4D5 PDE4D5 None Miles Houslay
2
 (Bolger et al. 1997) 
 
Table 2.3.B: Pre-existing plasmid constructs used in this thesis.  1Neuroscience Research Centre, Merck, Sharpe and Dohme 
(now at Wyeth). 2Molecular Pharmacology group, University of Glasgow. 
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10233-1-AP NDE1/NDEL1 Rabbit 
Protein Tech 
Group 
x2000 - 2 hours (G) - -   
231 NDEL1 Rabbit Nick Brandon
1
 x5000 - 1 hour x1000 - 1 hour -  
92 NDE1 Rabbit Custom x500 - 2 hours (G) x50 - 1 hour - See section 5.4 
93 NDE1 Rabbit Custom x500 - 2 hours x500 - 1 hour 10µl See section 5.4 
93-488 NDE1 Rabbit Custom N/A x100 - 1½ hours N/A 
Fluorescent (488nm), see sections 
5.4 and 6.3.3 
94 NDE1 (Mouse) Rabbit Custom x 50 - 2 hours x100 - 1 hour - See section 5.4 






 x10,000 - 18 hours - - (Ogawa et al. 2005) 
Ab57430 NDE1/NDEL1 Mouse Abcam x1000 - 2 hours (G) - -   
CENPA CENPA Mouse Abcam - x500 - 1 hour -  
GFP GFP tag Mouse Roche x500 - 2 hours N/A -   
GST GST tag Goat GE Healthcare x2000 - 2 hours (G) - -   
γ-tubulin γ-tubulin Mouse Sigma - x3000 - 1 hour -  
FLAG FLAG tag Mouse Sigma x1000 - 2 hours x1000 - 1 hour 1µl   
LIS1 LIS1 Mouse Sigma x1000 - 2 hours x100 - 1 hour -   
H00054820-M01 NDE1/NDEL1 Mouse Abnova 
x10,000 - 2 hours 
(G) 
- -   
PDE4A (MH) pan-PDE4A Sheep Miles Houslay
3
 x10,000 - 1 hour - - (MacKenzie and Houslay 2000) 
PDE4B (MH) pan-PDE4B Sheep Miles Houslay
3
 x10,000 - 1 hour - - (MacKenzie and Houslay 2000) 
PDE4C (MH) pan-PDE4C Sheep Miles Houslay
3
 x10,000 - 1 hour - - (McCahill et al. 2005) 
PDE4D (MH) pan-PDE4D Sheep Miles Houslay
3








x1000 - 18 hours - - 
Western blots performed using TBS-
based buffers. 
V5 V5 tag Mouse Invitrogen x1000 - 2 hours x2000 - 1 hour 3µg   
V5 (MBL) V5 tag Rabbit MBL - x2000 - 1 hour - 
The Invitrogen anti-V5 antibody was 
used unless otherwise stated. 65 
 
    
Y12 Smith antigen Mouse Gene Tex - x500 - 1 hour -   
Donkey-anti-
sheep 
Sheep Ig Donkey Dako x10,000 - 20 mins N/A N/A Secondary 
Rabbit-anti-goat Goat Ig Rabbit Dako x5000 - 20 mins N/A N/A Secondary 
Rabbit-anti-
mouse 
Mouse Ig Rabbit Dako x80,000 - 30 mins N/A N/A Secondary 
Swine-anti-rabbit Rabbit Ig Swine Dako x3000 - 20 mins N/A N/A Secondary 
Goat-anti-mouse 
(green) 
Mouse Ig Goat Invitrogen N/A x500 - 1 hour N/A Secondary, fluorescent (488nm) 
Goat-anti-mouse 
(red) 
Mouse Ig Goat Invitrogen N/A x800 - 1 hour N/A Secondary, fluorescent (594nm) 
Goat-anti-rabbit 
(green) 
Rabbit Ig Goat Invitrogen N/A x500 - 1 hour N/A Secondary, fluorescent (488nm) 
Goat-anti-rabbit 
(red) 
Rabbit Ig Goat Invitrogen N/A x800 - 1 hour N/A Secondary, fluorescent (594nm) 
 
 
Table 2.4: A list of all antibodies used in this thesis and the conditions under which they were used for Western blotting (WB) 
and immunocytochemistry (ICC).  “Species” refers to the species in which the antibody was originally raised.  A letter G 
indicates that this is the conditions at which recombinant GST-tagged protein was stained – this requires a far more dilute 
antibody than would be used for studying endogenous protein.  The amount of antibody that is used to immunoprecipitate (IP) 
protein from a 500µl lysate is also shown.  All antibodies detect human antigens unless otherwise stated.  All antibody dilutions 
are for typical experiments and may vary depending on the exact nature of the experiment.  1Neuroscience Research Centre, 
Merck, Sharp and Dohme (now at Wyeth).  2Laboratory of Molecular and Genetic Information, University of Tokyo.  3Molecular 





  67    
It is not possible to use two primary antibodies which were raised in the same species 
for immunocytochemistry, as an anti-immunoglobulin secondary antibody would 
bind to both.  As a solution to this problem, some antibodies were conjugated 
directly to green (488nm) fluorescent tags using an Alexa Fluor 488 Monoclonal 
Antibody Labelling Kit (Invitrogen), according to manufacturer’s instructions. 
 
2.4.2 Cell lysates 
 
2.4.2.1 Production of cell lysates 
In order to produce cell lysates, cells were grown on 10cm dishes until they were 75-
90% confluent.  The media was aspirated off and the cells were washed once with 
10ml of 4°C D-PBS.  Between 300 and 1200µl of a lysis buffer (either RIPA of PBS-
TX) was then added and the plate swirled for ~10 seconds.  A disposable cell scraper 
was then used to dislodge all of the remaining adherent cells from the plate into the 
buffer.  This crude lysate was then transferred to a micro-centrifuge tube.  The 
lysates were then mixed at 15-30 rpm for 30 minutes at 4°C on a rotary wheel.  After 
this, the lysates were centrifuged at 13,000 rpm for 30 minutes on a desk-top 
centrifuge (a Biofuge Fresco, Heraeus Instruments), and the residual pellet discarded.  
Lysates were typically stored at either -20°C or -70C. 
 
2.4.2.2 Measuring the protein concentration in cell lysates 
The concentration of total protein in lysates was measured using a variation on the 
BioRad protein assay.  Six standard reactions of 25µl were prepared containing from 
0 to 1.0 mg/ml of protein standard (in 0.2 mg/ml increments).  Meanwhile, 2.5µl of 
each lysate was made up to 25µl with dH2O.  To each of these reactions, both 
standards and lysates, 125µl of Reagent A and 1ml of Reagent B were added.  
Reactions were left to stand for 25 minutes at room temperature before their 
absorbance readings at 750nm (OD750 readings) were measured using an Ultrospec 
3000 optical reader (Pharmacia Biotech).  The OD750 value for each protein 
standard was plotted against the corresponding protein concentration in Microsoft 
Excel, and a standard curve was generated.  This curve was then used to determine 
the concentrations of the protein lysates. 
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2.4.3 In vitro transcription and translation of protein 
The TNT coupled reticulocyte lysate system (Promega) was used to produce protein 
from plasmid constructs in a cell-free system.  Reactions were set up as follows.  All 
chemicals and solutions were from the TNT kit, with the exception of the plasmids. 
 
 38 µl  dH2O 
 4 µl  TNT buffer 
 1 µl  Amino acid mix, minus leucine 
 1 µl  Amino acid mix, minus methionine 
 4 µl  500 ng/µl plasmid 
 50 µl  TNT rabbit reticulocyte lysate 
 2 µl  T7 polymerase 
 
Reactions were incubated for 90 minutes at 30°C, before being placed on ice.  
Typically, Reactions were either used immediately for immunoprecipitation. or 
stored at -20°C or -70°C.  These reactions are generally of low yield, but allow for 




In order to immunoprecipitate specific proteins, cell lysates or in vitro transcribed 
and translated proteins (both referred to simply as lysates from here on) were first 
produced as described above.  An antibody was added to the lysate (see table 2.4 for 
concentrations) which was then mixed at 15-30rpm on a rotary wheel at 4°C for 3-18 
hours.  The antibody should bind to the protein of interest during this time.  As a 
negative control, rabbit or mouse IgG (Dako) was used in place of the antibody.  
Following the antibody incubation, 30µl of protein G sepharose beads (Sigma) in 
PBS were added and the samples mixed for a further hour.  Thus the antibody-
antigen complex should be captured by interaction with protein G.  Typically, a 30µl 
sample of each lysate was removed and stored for use as a loading control. 
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Once the bead incubation was complete, immunocomplexes were pelleted by 
spinning at 13,000rpm for 2 minutes on a desk-top centrifuge.  The supernatant was 
then carefully removed using a manual pipette with a glass tip.  This tip will have 
been sharpened by heating and stretching.  The beads were then re-suspended in 
500ml of PBS-TX lysate buffer and mixed for a further 15 minutes on the rotary 
wheel at 4°C.  This washing procedure was repeated three further times.  After the 
final wash, beads were resuspended in protein sample buffer and prepared for 
Western blotting (see below). 
 
2.4.5 Western blotting 
 
2.4.5.1 Sample preparation 
Cell lysates (see section 2.4.2), in vitro transcribed and translated protein (see section 
2.4.3) or bacterially purified protein (see section 2.5.7.4) were prepared for Western 
blotting by mixing 1:1 with protein sample buffer (see section 2.2.2) and 1:10 with 
1M DTT.  In order to denature the proteins and disrupt protein-protein interactions, 
samples were then heated at 100°C for 5 minutes. 
 
2.4.5.2 BioRad system 
Separating gels were produced using one of the following recipes depending on the 
molecular weight of the protein under investigation.  7% gels were used to separate 
proteins of 60kDa or higher (such as DISC1) and 10% gels to separate proteins of 
25-60kDa (such as NDE1 and NDEL1). 
 
  7% 10% 
  1.9ml 2.6ml  30% acrylamide/bis solution 
  2ml 2ml  1.5M Tris pH 8.8 
  4.04ml 3.34 ml dH2O 
  40µl 40µl  20% SDS 
  5µl 5µl  TEMED 
  20µl 20µl  25% ammonium persulphate 
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The gel solution was mixed and then poured between two BioRad glass plates, 
calibrated to produce a 1.0mm gel, leaving 1-2 cm at the top.  This gap initially filled 
with dH2O.  After an hour, when the gel has set, the water was removed from the top 
and replaced with 4% a stacking gel solution: 
 
  870 µl  30% acrylamide/bis solution 
  1.5 ml  0.5M Tris pH 6.8 
  3.57 ml dH2O 
  30 µl  20% SDS 
  3 µl  TEMED 
  30 µl  25% ammonium persulphate   
 
A comb of either 10 or 15 wells (BioRad) was added to the top and gel left to set for 
30 minutes. 
 
Once set, gel(s) were then inserted into a Mini TransBlot Cell (BioRad) which was 
filled with 400ml 1x TGS.  Samples were loaded into the gel along with a 
standardised protein size maker (BioRad’s Precision Plus Protein All Blue Standard).  
Gels were then run at 150V for between 60 and 100 minutes using a Power Pac 3000 
(BioRad) in order to separate the proteins in the sample by molecular weight.  Gel(s) 
were then carefully removed and soaked in semi-dry transfer buffer at room 
temperature for 30 minutes.  Meanwhile, a 6cm by 8cm slice of Hybond-P PVDF 
membrane (Amersham) was cut out, soaked briefly in methanol and then soaked in 
semi-dry transfer buffer for 15 minutes.  Eight 6cm by 8cm pieces of 1.7mm card 
(Whatman) were also cut out and soaked briefly in the transfer buffer. 
 
Four pieces of card were then placed onto a Trans-Blot Semi-Dry Transfer Cell 
(BioRad).  On top of them were placed the membrane, the gel (face up) and finally 
the remaining four pieces of card.  This was then run at 20V for 90 minutes in order 
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The membrane was then removed and washed twice briefly with dH2O.  Membrane 
was then soaked for ~5 minutes with Ponceau S stain in order to confirm the 
presence of the protein and to facilitate labelling of the membrane.  Stain was washed 
off with dH2O and the membrane was then blocked with a membrane blocking 
buffer, either for one hour at room temperature or over-night at 4°C. 
 
2.4.5.3 Invitrogen system 
For some experiments, an alternative system was used to run and blot gels.  In this 
case, one or two pre-cast Tris-Acetate 7% gels were inserted into an XCell Surelock 
Electrophoresis Cell and then loaded with the samples and marker (as above).  400ml 
of 1x NuPage Tris-Acetate SDS Running Buffer was added to each of the gels and 
electrophoresis was performed at 150V on a Power Pac 3000 (BioRad) for 60-90 
minutes in order to separate proteins in the sample by molecular weight. 
 
After this, 500ml 1x NuPage Transfer Buffer containing 20% methanol (or 40% if 
two gels were to be transferred at once) was prepared.  An Invitrolon PVDF 
membrane was soaked briefly in methanol and then, along with five sponge pads, 
was soaked in the transfer buffer for ~5 minutes.  Each gel was then extracted from 
the cell and loaded (face down) into an XCell II Blot Module with the membrane and 
two sponges below it and the remaining three sponges above it.  When two 
membranes were loaded, one sponge was placed between them and two on either 
side.  The module was then filled with the transfer buffer and placed back in the 
electrophoresis cell.  Exterior of the cell was cooled with water.  30V was then 
applied from the power pack for 90 minutes in order to transfer proteins from the gel 
to the membrane.  After this, the membranes were washed and blocked as above.  All 
apparatus and buffers used in this section were from Invitrogen. 
 
2.4.5.4 Immunostaining 
After blocking, membranes were transferred to an appropriately sized shallow dish or 
box and incubated with a primary antibody in blocking buffer for between one and 
18 hours.  Antibody dilutions and conditions are shown in table 2.4.  Incubations of 
two hours or less were carried out at room temperature, longer incubations were 
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carried out at 4°C.  The membrane was then washed five times with wash buffer: 
once briefly, once for 15 minutes and then three further washes for 5 minutes.  The 
membrane was then incubated with secondary antibody diluted in wash buffer for 
20-30 minutes at room temperature.  The membrane was then washed five times as 
before.  During all incubations and washes, the membrane was rocked gently at 15-
40rpm. 
 
The membrane was then removed from the medium, air-dried on cling film and 
incubated with ECL Plus solution (Amersham) for five minutes.  After removal of 
the ECL Plus, pieces of photosensitive film (Scientific Laboratory Supplies) were 
exposed to the membrane for between one second and 16 hours.  Films were 
developed on an Amersham Hyperprocessor, in order to visualise the antibody-
labelled proteins on the membrane 
 
2.4.5.5 Densitometry 
In order to quantitatively analyse Western blot results, images were transferred to a 
computer by scanning and the signal intensity of the bands was measured using the 
program ImageJ (downloaded from http://rsbweb.nih.gov/ij/).  These results were 
then be compared and analysed statistically. 
 
2.4.5.6 Re-probing of membranes 
In order to re-probe a membrane with an additional antibody, then the membranes 
were first cleaned as follows.  The membrane was incubated for 30 minutes at room 
temperature in Restore western blot stripping buffer (Perbio Science) with gentle 
shaking.  The membrane was then washed three times with wash buffer for five 
minutes each.  The membrane was then blocked and stained with the new antibody, 
as in section 2.4.5.4. 
 
2.4.5.7 Pre-absorption of antibodies 
In order to test if an antibody binds to the amino acid sequence against which it was 
raised, pre-absorption analysis can be used.  In order to do this, blocking buffer was 
prepared, containing the antibody at an appropriate concentration for Western 
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blotting (see table 2.4) and 100ng/µl of the peptide to which the antibody had 
originally been raised against.  A positive control was also prepared that was 
identical to the pre-absorption solution, but lacking the antigenic peptide.  Solutions 
were incubated for 18 hours at 4°C, while mixing at 20-30rpm on a rotary wheel.  
Meanwhile a Western blot was performed with two lanes, each containing an 
identical amount of the same lysate or recombinant protein.  Each of these lanes was 
then immunostained using either the pre-absorption or positive control antibody 
solution.  If the antibody is working as anticipated, the pre-absorbed antibody should 
detect significantly less signal on the Western blot than the positive control does. 
 
2.4.5.8 Two-dimensional Western Blotting 
A conventional Western blot is unable to differentiate between two protein isoforms 
of similar molecular weights that are both detectable by the same antibody.  In order 
to get round this problem, two-dimensional (2-D) Western blots can be performed in 
which the protein species of a lysate are separated both vertically by molecular 
weight and also horizontally by isoelectric point (pI). 
 
Lysates were prepared as in section 2.4.2.1, but using the 2-D Western blot lysis 
buffer.  The protein concentrations of the lysates were then measured (see section 
2.4.2.2).  200-400µg of the sample and 15µl of 1M DTT were then diluted in 
rehydration buffer to a total volume of 155µl.  This solution was then applied to a 
ZOOM strip which was left to rehydrate in the solution over-night at room 
temperature in a ZOOM IPGRunner cassette. 
 
An electrode wick was then added over each end of the strip and 650µl of deionised 
water was added (dH2O containing 1/60 tap water).  The cassette was then loaded 
into a ZOOM IPGRunner, the external section of which was filled with 600ml 
deionised water.  A current of 500V, 1W and 3mA was then run applied through the 
strip for four hours using a Power Ease 500 power pack (East Mains Pilot Plant) in 
order to sort the proteins on the strip by pI.  After this the cassette was broken open 
and the strips removed. 
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The membrane strips were then each incubated in 4.5ml 1x LDS sample buffer with 
500µl sample reducing agent for 15 minutes at room temperature.  Strips were then 
transferred to 5ml 1xLDS containing 116mg iodoacetamide and incubated for a 
further 15 minutes.  The strips were then each inserted into a ZOOM 4-12% Bis-Tris 
gel.  A 50°C 0.5% agarose solution in MES SDS running buffer was the applied and 
left to cool into a gel around each strip.  The gels were then inserted into an XCell 
Surelock electrophoresis cell and were loaded with a protein marker (BioRad).  The 
cell was filled with MES SDS running buffer.  The gel was then subjected to 
electrophoresis at 200V for 50 minutes on a Power Pac 3000 (BioRad) in order to 
separate proteins by molecular weight.  Following this, the protein was transferred to 
a membrane which was immunostained as described in section 2.4.5.4.  All reagents 
and apparatus used in this section were from Invitrogen unless otherwise stated. 
 
2.4.5.9 Direct staining of protein on gels 
Following electrophoresis, the protein content of a gel could be stained directly by 
washing in coomassie staining solution at room temperature for 20 minutes with 
gentle rocking (typically 15rpm).  Staining solution was then removed and the gel 
was washed several times in coomassie de-staining solution in order to remove all of 
the non-specific blue staining.  These washes were typically carried out over a period 
of 1-2 hours at room temperature to ensure efficient destaining.  Gels were then dried 
on a Drygel Sr gel dryer (Hoefer Scientific). 
 
2.4.6 Immunocytochemistry 
A well-established technique for visualising the expression patterns of proteins 
within individual cells is immunocytochemistry.  The procedure involves growing a 
mono-layer of cells on a glass cover-slip, typically until they are 70-90% confluent, 
fixing the cells and then applying primary antibodies specific to the protein(s) of 
interest.  Secondary antibodies conjugated to coloured fluorescent molecules can 
then be applied, allowing the expression patterns of the protein(s) to be viewed using 
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2.4.6.1 Cell fixation 
Before antibodies can be applied to cells for viewing by immunocytochemistry, the 
cells must be fixed in order to terminate cellular processes and to expose epitopes for 
antibody binding.  Two separate techniques were used for fixing cells in this thesis.   
 
For the first technique, coverslips were washed once with 37°C D-PBS and then 
fixed, after removal of media, by the application of -20°C methanol for 10 minutes 
(500µl methanol per well).  Coverslips were then washed three times with room 
temperature PBS/0.02%BSA before being processed for immunocytochemistry. 
 
In the alternative protocol, coverslips were washed with 37°C D-PBS and then 500µl 
of room temperature 4% paraformaldehyde (PFA) was added for ten minutes.  
Coverslips were then washed three times with room temperature PBS/0.02%BSA 
before being incubated for a further 15 minutes in a solution containing 0.5% Triton.  




The entire procedure was performed at room temperature.  After fixation, coverslips 
were blocked in 200µl PBS/10% serum each for 20-30 minutes.  Serum was selected 
to match that in which the secondary antibodies were raised (typically goat).  
Coverslips were then incubated in 100µl of appropriately diluted primary antibodies 
in PBS/0.02%BSA for 1-2 hours.  See table 2.4 for details of antibodies and 
concentrations.  Up to two primary antibodies were incubated with each coverslip at 
a time.   Coverslips were then washed once and then three additional times for 5 
minutes with PBS/0.02%BSA.  Coverslips were then incubated for one hour with 
100µl of appropriately diluted fluorescent secondary antibodies (see table 2.4) in 
PBS/10% serum.  The dishes containing the coverslips were wrapped in foil 
throughout the secondary incubation in order to keep out light.  Coverslips were then 
washed and given three further 5 minute washes with PBS/0.02%BSA.  The 
coverslips were mounted onto glass slides using mowiol mounting solution 
containing 250 ng/µl DAPI.  Coverslips were then stored in the dark at 4°C.  In the 
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majority of cases, after immunocytochemistry, cells were viewed on a Zeiss 
Axioskop 2 microscope using Smart Capture 2 software. 
 
One exception to this procedure is when using cells transfected with constructs 
encoding GFP-tagged proteins.  In this case, the GFP group emits green fluorescence 
on its own and so no antibodies are necessary in order to detect this signal. 
 
For some experiments primary antibodies with conjugated fluorescent tags were used 
(see section 2.4.1).  In this case, the cells were processed exactly as above using any 
non-fluorescent primary antibodies.  After secondary antibody application and 
washing, cover slips were then blocked for a further 20 minutes with PBS/10% 
serum.  Serum matched that of the animal in which the fluorescent antibody was 
raised (typically rabbit).  Coverslips were then incubated in 100µl of appropriately 
diluted conjugated antibodies in PBS/10% serum for 90 minutes.  Coverslips were 
then washed and applied to slides as described above. 
  
2.4.6.3 Confocal Microscopy 
Some light microscopy results were confirmed by confocal microscopy.  This 
technique involved taking a number of photographs of a cell, each focused on a 
different vertical “slice” of the cell.  By doing this, it can be assumed that any 
colocalisation of fluorescent antibody signals seen at a specific two-dimensional 
point is representative of colocalisation in the three-dimensional cell.  Typically, the 
relative intensities of the fluorescent antibodies would be measured along a one-
dimensional line within the image, in order to confirm localisation.  Confocal 
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2.4.7 In vitro phosphorylation by PKA 
GST or GST-fusion protein solutions were produced as described in section 2.5.7.4.  
Reactions were set up as follows: 
  
   19.25 µl dH2O 
   25 µl  2x PKA reaction buffer 
   2 µl  GST or GST-tagged recombinant protein 
   3.75 µl  Recombinant PKA solution 
 
The PKA solution was made up by diluting recombinant PKA (Promega) 60-fold in 
1x PKA reaction buffer.  Reactions were then incubated at 30°C for 5 minutes and 
then placed immediately on ice.  To each reaction, 50µl of protein sample buffer 
(section 2.2.2) and 5µl of 1M DTT was then immediately added and the reactions 
boiled at 100°C for 5 minutes to denature the PKA and the GST or GST-fusion 
protein.  These reactions were then analysed by Western blotting (section 2.4.5), 
using the PKA substrate and anti-GST antibodies. 
 
2.5 Molecular biology methods 
 
2.5.1 Primers 
A complete list of all oligonucleotude primers used in this thesis can be seen in table 
2.5.A.  Primers were supplied by Sigma or Invitrogen.  Primer design was assisted by 
use of Operon’s Oligo Analysis and Plotting tools and the predicted specificity of 
primers was investigated using BLAST (Altschul et al. 1990). 
 
2.5.2 PCR reactions 
It is often necessary to amplify a specific segment of DNA, either because it is 
needed in the generation of a plasmid construct or in order to determine the extent to 
which it is present in a cDNA pool.  In order to do this, different versions of the 




        
Name Direction Sequence Purpose 
NDE1 (pan) F 5' GAAGGATGAAGCCAGAGATTTGCGGC Detection of all known NDE1 transcripts 
NDE1-SSSC R 3' CAACTCGTGTCCAACCCCTTATCACC Detection of NDE1-SSSC transcripts 
NDE1-KMLL R 3' GTGTGAAGGCGGCTTCCCAAATTCC Detection of NDE1-KMLL transcripts 
NDE1-KRHS R 3' CCGCCAGCGAGAGGTTTATTAGAAGG Detection of NDE1-KRHS transcripts 
NDE1-S2 R 3' GAAGGCACCAAACGCCAGGAAAGTG Detection of NDE1-S2 transcripts 
NDEL1 F 5' GGAGCGAGCCAAAAGGGCAACAATAG Detection of all known NDEL1 transcripts 
NDEL1-PLSV R 3' CTGACGATGGACGCGAGGAGC Detection of NDEL1-PLSV transcripts 
NDEL1-FMGQ R 3' CTGCCCCATGAACAACGTGGGAAATATG Detection of NDEL1-FMGQ transcripts 
NDE1-FL F 5' GGAGCTGGAAACCATCAAGGAGAAGTTTG Detection of NDE1 FL transcripts only 
NDE1-S1 F 3' GCTGGAAACCATCAAGCGCCACG Detection of NDE1-S1 transcripts only 
NDE1-BamHI F 5' GATCGGATCCGAGGACTCCGGAAAGACTTTC Cloning of NDE1 with a 5' BamHI for insertion into pGEX-6PI 
NDE1-SalI R 3' GATCGTCGACTCAGCAGGAGCTGGACGAC Cloning of NDE1 with a 3' SalI for insertion into pGEX-6PI 
NDEL1-BamHI F 5' GATCGGATCCGATGGTGAAGATATACCAG Cloning of NDEL1 with a 5' BamHI for insertion into pGEX-6PI 
NDEL1-SalI R 3' GATCGTCGACTTATCACACACTGAGAGGCAG Cloning of NDEL1 with a 3' SalI for insertion into pGEX-6PI 
NDE1-Seq A 5' CGAGGAGGAAGAAGCTAACTATTGG Sequencing of NDE1 from constructs 
NDE1-Seq B 5' GATGACCTCGCGCAGACCAAAG Sequencing of NDE1 from constructs 
NDE1-Seq C 5' CTTCAGACGTGGCCTGGACG Sequencing of NDE1 from constructs 
NDE1-Seq D 3' CTTTGGTCTGCGCGAGGTCATC Sequencing of NDE1 from constructs 
NDE1-Seq E 3' CGTCCAGGCCACGTCTGAAG Sequencing of NDE1 from constructs 
NDE1-Seq F 3' CTGGACGACCTGGTTGTTGATTTGG Sequencing of NDE1 from constructs 
NDEL1-Seq A 5' GGAGGAAACTGCTTATTGGAAGG Sequencing of NDEL1 from constructs 
NDEL1-Seq B 5' GTCAGACTCGGGCCATTAAGGAG Sequencing of NDEL1 from constructs 
NDEL1-Seq C 5' GTTGGCAAAGGAACGGAGAACAC Sequencing of NDEL1 from constructs 
NDEL1-Seq D 3' CTCCTTAATGGCCCGAGTCTGAC Sequencing of NDEL1 from constructs 
NDEL1-Seq E 3' GTGTTCTCCGTTCCTTTGCCAAC Sequencing of NDEL1 from constructs 
NDEL1-Seq F 3' CATACCCGGCGCTGACGATG Sequencing of NDEL1 from constructs 
6PI-Seq F 5' GCTGGCAAGCCACGTTTGGTG Sequencing of pGEX-6PI vectors 
6PI-Seq R 3' GTGTCAGAGGTTTTCACCGTCATCAC Sequencing of pGEX-6PI vectors 
pD40-Seq F 5' GAGACCCAAGCTGGCTAGTTAAGC Sequencing of pDEST-40 vectors 
pD40-Seq R 3' GCGTAGAATCGAGACCGAGG Sequencing of pDEST-40 vectors 
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T131A F 5’ GGAAAGAGCCAAGCGGGCTGCGATCATGTCTCTCGAAG 
Introduction of a T131A mutation into NDE1 constructs and 
removal of a BssHII site 
T131A R 3’ CTTCGAGAGACATGATCGCAGCCCGCTTGGCTCTTTCC 
Introduction of a T131A mutation into NDE1 constructs and 
removal of a BssHII site 
T131E F 5’ GGAAAGAGCCAAGCGGGCTGAGATCATGTCTCTCGAAG 
Introduction of a T131E mutation into NDE1 constructs and 
removal of a BssHII site 
T131E R 3’ CTTCGAGAGACATGATCTCAGCCCGCTTGGCTCTTTCC 
Introduction of a T131E mutation into NDE1 constructs and 
removal of a BssHII site 
S306A F 5’ GAGAGACGGCCAAGCGCCACCAGCGTGCCTTTG 
Introduction of an S306A mutation into NDE1 constructs and 
removal of an AleI site 
S306A R 3’ CAAAGGCACGCTGGTGGCGCTTGGCCGTCTCTC 
Introduction of an S306A mutation into NDE1 constructs and 
removal of an AleI site 
 
Table 2.5.A: Details of all primers used in this thesis. 
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2.5.2.1 Standard PCR reaction 
The following PCR reaction was used for the majority of applications.  Each PCR 
reaction was set up using the following: 
 
2 µl  10x PCR reaction buffer (Sigma) 
 1.2 µl  25 mM magnesium chloride 
 1.4 µl  10 mM dNTP 
 1.3 µl  60 ng/µl 5’ primer 
 1.3 µl  60 ng/µl 3’ primer 
 ~1 µl  Template (variable depending on the nature and concentration  
of the template cDNA or plasmid) 
 10.3 µl  dH2O 
 1.5 µl  Taq polymerase (Sigma) 
 
Reactions were then processed on a PTC-225 Peltier Thermal Cycler (MJ Research), 
using the following program: 
 
  1. 93°C 1 minute 
  2. 93°C 40 seconds 
  3. 64°C 30 seconds 
  4. 72°C 30-60 seconds* 
  5. Repeat steps 2-4 an additional 34 times 
  6. 72°C 10 minutes 
  7. 4°C For ever 
 
* The length of the extension step (step 4) varied depending on the expected length 
of the PCR product.  30 seconds was used for products of 500 base pairs or less, 60 
second for products of approximately 1000 base pairs. 
 
2.5.2.2 Touch down PCR 
In order to improve the efficiency of amplification of some “problem” PCRs, 
reactions were set up as above, but the following program was used instead: 
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  1. 93°C 1 minute 
  2. 93°C 40 seconds 
  3. 69°C 30 seconds 
  4. 72°C 30-60 seconds 
5. Repeat steps 2-4 an additional 4 times, reducing the 
temperature of step 3 by 2°C each time. 
  6. 93°C 40 seconds 
  7. 59°C 30 seconds 
  8. 72°C 30-60 seconds 
  9. Repeat steps 6-8 an additional 29 times 
  10. 72°C 10 minutes 
  11. 4°C For ever 
 
2.5.2.3 BigDye pre-sequencing PCR  
For the sequencing of existing PCR products, the BigDye Terminator Ready 
Reaction Mix v3.1 system was used.  Each reaction was set up as follows. 
 
  1.5 µl  5x Sequencing buffer (Applied Biosystems) 
  1 µl  2.5x Ready Reaction mix (Applied Biosystems) 
1µl  Template (typically a PCR product) 
0.5 µl  60 ng/µl primer 
6 µl  dH2O 
 
Reactions were then processed using the following program: 
 
  1. 96°C 1 minute 
  2. 96°C 10 seconds 
  3. 50°C 5 seconds 
  4. 60°C 4 minutes 
  5. Repeat steps 2-4 an additional 24 times 
  6. 4°C For ever 
 
  82    
 
2.5.2.4 PfU Ultra fusion PCR 
In order to amplify open reading frames while simultaneously incorporating a 
restriction site, PCR reactions were set up as follows: 
 
  5 µl  10x PfU Ultra Fusion buffer (Stratagene) 
  1.25 µl  10 mM dNTP 
  1.3 µl  300 ng/µl 5’ primer 
  1.3 µl  300 ng/µl 3’ primer 
  1-3 µl  DNA template (plasmid or PCR product) 
  Up to 49µl dH2O 
  1 µl  PfU Ultra Fusion enzyme (Stratagene) 
 
Reactions were then processed using the following program: 
 
  1. 95°C 1 minute 
  2. 95°C 40 seconds 
  3. 60°C 30 seconds 
  4. 72°C 15 seconds 
  5. Repeat steps 2-4 an additional 34 times 
  6. 72°C 10 minutes 
  7. 4°C For ever 
 
2.5.2.5 Site-Directed Mutagenesis PCR 
In order to introduce one or more nucleotide substitutions into an existing plasmid 
construct, PCR reactions were set up using the Quikchange II Site-Directed 
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  5 µl  10x Reaction buffer (Stratagene) 
  1 µl  10-50 ng/µl template plasmid 
  1µl  125 ng/µl 5’ primer 
  1 µl  125 ng/µl 3’ primer 
  1 µl  dNTP mix (Stratagene) 
  Up to 49 µl dH2O 
  1 µl  Pfu Ultra high fidelity DNA polymerase (Stratagene) 
 
Reactions were then processed using the following program: 
 
  1. 95°C 30 seconds 
  2. 95°C 30 seconds 
  3. 63°C 1 minute 
  4. 68°C 10 minutes 
  5. Repeat steps 2-4 an additional 15 times 
  6. 68°C 10 minutes 
  7. 4°C For ever 
 
2.5.3 Sequencing PCR products and plasmids 
In order to sequence a plasmid construct or PCR product, the DNA region of interest 
was first amplified by one or more PCR reactions (sections 2.5.2.1 or 2.5.2.2).  
Having obtained a pool of the DNA to be sequenced, one or more pre-sequencing 
PCR reactions were then performed on it using the Big Dye 3.1 system (section 
2.5.2.3).  Each such PCR reaction would make use of a different single primer 
(which could be either 5’ or 3’) in order to amplify different regions of the DNA and 
hopefully allow the entire section to be included in one or more of the reaction 
products. 
 
The products of these PCR reactions were then processed as follows.  Each product 
was added to a 0.5ml tube containing 2.5µl of sterilised 125mM EDTA and 30µl 
absolute ethanol.  Tubes were briefly shaken (by hand) to mix them and were then 
incubated at room temperature for 10-15 minutes.  Tubes were spun at 13,000rpm on 
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a desktop centrifuge for 20 minutes at 4°C and the supernatant was carefully 
removed with a hand held pipette.  The tubes were then spun for an additional two 
minutes and any remaining supernatant removed.  The pellets were then gently 
resuspended in 30µl of 70% ethanol.  These tubes were then centrifuged once for 5 
minutes at 13,000rpm and again for two minutes, removing the supernatant carefully 
after each spin.  The tubes were then left to air dry in the dark for 8-10 minutes at 
room temperature before being stored at -20°C. 
 
The nucleic acid sequence of these DNA samples was then determined by either 
Agnes Gallacher or Alison Condie (Medical Research Council Human Genetics Unit 
or Wellcome Trust Clinical Research Facility, University of Edinburgh).  Results 
were viewed using the program Chromas Lite version 2.01 (Technelysium Pty Ltd).  
The online program ExPASy Translate Tool was used to convert nucleic acid 
sequences into amino acid sequences (Gasteiger et al. 2005), while BLAST, FASTA 
Sequence Comparison and CLUSTALW were used to compare results to known 
DNA or protein sequences (Pearson and Lipman 1988; Altschul et al. 1990; 
Thompson et al. 1994). 
 
2.5.4 Purification of PCR products 
In some circumstances (such as prior to a ligation or recombination reaction), PCR 
products need to be purified in order to remove other elements of the PCR reaction 
mix.  This was done using a QIAquick PCR Purification kit according to the 
manufacturers’ instructions. 
 
2.5.5 DNA gels 
 
2.5.5.1 Making and running agarose gels 
Agarose gels were prepared by adding agarose powder to TAE buffer to a final 
concentration of 1-2%.  This suspension was then heated in a microwave until all the 
powder had dissolved.  Once the solution had cooled down enough to touch, SYBR 
Safe DNA Gel stain (Invitrogen) was added to a final dilution of 1/5000, and the 
solution was gently mixed.  The solution was then poured into a tray (Bioscience 
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Service); a comb was added and the gel was allowed to set.  The gel was then placed 
in a tank (Bioscience Service) which was filled with TAE buffer.  The comb was 
removed and the DNA samples, along with a 1kb ladder, were loaded into the wells.  
Depending on the size of the DNA product to be viewed, gel was run for between 10 
minutes and 3 hours at 50-100V.  Gels were then viewed under ultra-violet light 
using a Uvidoc light box (Uvitec) and photographed. 
  
If the gel had been run for longer then 90 minutes and the DNA signal had faded, 
then the intensity of the DNA signal was restored by washing the gel for 30-120 
minutes at room temperature in TAE buffer containing SYBR Safe DNA Gel Stain 
(Invitrogen) at a dilution of 1/5000. 
 
2.5.5.2 Isolation of DNA fragments from agarose gels 
Agarose gels can also be used in order to separate DNA of a certain size from a 
sample.  In order to do this, the sample was run on a gel made using low-melting 
point agarose, but otherwise as described above.  After the gel has been run, the 
DNA was visualised on a Safe Imager box (Invitrogen), and the band of interest 
excised using a sterile scalpel.  This gel fragment was then transferred to a 1.5ml 
tube and processed using a QIAquick Gel Extraction kit (QIAGEN), in order to 
isolate the DNA contained within it.  Procedure performed according to 
manufacturers’ instructions (spin protocol). 
 
2.5.6 cDNA production 
The First Strand cDNA Synthesis kit (Roche) was used to produce cDNA from RNA 
as follows.  Numbers in brackets refer to the component numbers of the kit.  The 
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 2 µl  10x Reaction buffer (1) 
 4 µl  25mM Magnesium chloride (2) 
 2 µl  Deoxynucleotide mix (3) 
 1 µl  Oligo-p(dT)15 primers (5) 
 1 µl  Random primers p(dN)6 (6) 
 1 µl  RNase inhibitor (7) 
 0.8 µl  AMV reverse transcriptase (8) 
 1-5 µl  RNA 
 Up to 20µl DEPC-treated water 
 
All solutions were from the kit except for the DEPC treated water and RNA.  Total 
RNA from human brain was obtained from Ambion. Reactions were subjected to 
four incubations as follows and then transferred to -20°C for storage: 
 
1. Room temperature 10 minutes  
2. 42 °C   60 minutes 
3. 95 °C   5 minutes 
4. 4 °C   5 minutes 
 
Negative controls were processed in exactly the same way, but without the use of the 
AMV reverse transcriptase. 
 
2.5.7 Culture of bacteria transformed with plasmid constructs 
 
2.5.7.1 Transformation of bacteria with plasmid constructs 
1µl of a plasmid construct was transformed into chemically competent JM109 cells 
(Promega) as follows: Cells were thawed on ice, the plasmid DNA was added to 
them and the whole mixture was incubated on ice for 30 minutes.  Cells were then 
heat-shocked by incubation at 42°C for 45 seconds, before chilling once again on ice 
for a further 2 minutes.  900µl of room temperature L Broth/ampicillin media was 
then added to the cells.  This suspension was then immediately incubated at 37°C 
with 200rpm shaking for 45-120 minutes in an Innova 4300 incubator shaker (New 
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Brunswick Scientific).  After the incubation, 50-150µl of the bacterial culture was 
placed in the centre of an L Agar/ampicillin plate and spread across the plate using a 
sterile scraper.  Plates were sealed and incubated until colonies were visible 
(typically 16-22 hours) at 37°C with 5% CO2 in a Plus II incubator (Gallencamp). 
 
For constructs that had just been subjected to site-directed mutagenesis, XL1-Blue 
super-competent cells (Stratagene) were instead used, with 2xYT medium being used 
for the initial growth step. 
  
2.5.7.2 Amplification of plasmid constructs 
Cultures of bacteria, transformed as described above, can be set up by selecting a 
single colony from an L Agar/ampicillin plate and then allowed to grow in L 
Broth/ampicillin media at 37°C with 200rpm shaking.  Small cultures of 1-5 ml 
media were centrifuged at 13,000rpm for 1 minute in a desktop centrifuge in order to 
pellet the bacteria.  The supernatant was then discarded and the plasmids harvested 
from the bacterial pellet using a Spin Miniprep Kit (QIAGEN) according to the 
manufacturer’s instructions.  Alternatively, 200ml cultures were centrifuged using an 
Avanti J-20I centrifuge (Beckman Coulter) at 5000rpm, 4°C for 10 minutes.  The 
supernatants were discarded and the bacterial pellet processed using a Plasmid 
Maxiprep kit (QIAGEN), according to the manufacturer’s instructions.  After 
purification, plasmid DNA was suspended in dH2O (or in some cases pH 7.5 TE 
buffer) and stored at either 4°C or at -20°C. 
 
2.5.7.3 Measuring plasmid DNA concentration 
In order to determine the concentration of a plasmid construct or other DNA 
solution, an Ultrospec 3000 optical reader (Pharmacia Biotech) was used.  The 
device was set to measure absorbance readings of 260nm (OD260 readings), and 
calibrated so that dH2O, or the buffer in which the DNA was dissolved, gave an 
absorbance reading of zero.  The DNA solution was then diluted (typically 50-fold) 
and an OD260 reading taken.  DNA concentration was then calculated using the 
following equation: 
  DNA concentration (µg/µl)    =     OD260 reading    x    Dilution factor   x   0.05 
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2.5.7.4 Production of bacterially expressed protein 
JM109 cells (Promega) were transformed with constructs encoding either GST or 
GST-tagged proteins and grown overnight on L Agar plates containing ampicillin 
(see section 2.5.7.1).  A 5ml L Broth/ampicillin culture was then set up using one of 
the colonies and incubated over-night at 37°C.  Half of each culture was then diluted 
to 50 ml with fresh L Broth/ampicillin and incubation was continued for three hours.  
50µl of 100mM IPTG was then added in order to induce production of the 
recombinant protein and cultures were incubated for a further two hours.  The culture 
was then spun on a table-top centrifuge at 13,000rpm for 30 minutes at 4°C in order 
to pellet the bacterial cells and the supernatant was discarded.   
 
The bacterial pellet was then resuspended in 2.5ml of PBS.  600µl aliquots of the 
solution were taken, 12µl of lysosyme (Sigma) were added to each and these were 
then incubated at room temperature for 5 minutes.  After this time, 6µl of DNase 
(Roche) was added to each.  Bacteria were then lysed by a freeze-thaw procedure 15 
times by snap freezing on dry ice followed by incubation at 37°C.  Following this, 
solutions were spun at 13,000rpm for 10 minutes on a desktop centrifuge and the 
pellets discarded.  The recombinant GST or GST-tagged protein was then purified 
from the supernatants using GST SpinTrap Purification Modules (GE Healthcare) 
according to the manufacturers instructions.  Finally, the solutions were dialysed in 
order to transfer the proteins to a suitable recombinant protein storage buffer, using 
Slide-A-Lyzer Dialysis Cassettes (Pierce) according to manufacturer’s instructions. 
 
2.5.8 Cloning techniques  
 
2.5.8.1 Site-directed mutagenesis 
Single amino acid point substitutions were introduced to existing plasmid constructs 
by using the QuikChange II Site-Directed Mutagenesis kit (Stratagene).  Primer pairs 
were designed across the relevant region of the open reading frame so as to introduce 
one or more nucleotide substitutions.  These in would then alter a single amino acid  
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Enzyme Target site Buffer Source 
AleI C A C N N
>
<N N G T G 4 New England Biolabs 
BamHI G
>
G A T C<C H Roche 
BssHII G
>
C G C G<C H Roche 
SalI G
>
T C G A<C H Roche 
 
Table 2.5.B: Restriction enzymes used in this thesis and the buffers in which 
they were used. 
 
 
of the derived protein.  PCR reactions were performed (section 2.5.2.5) and the PCR 
product was digested using 1µl DpnI (Stratagene) at 37°C for 90 minutes in order to 
destroy the template DNA.  The PCR products were then transformed into XL1-Blue 
cells and plated (section 2.5.7.1).  Cultures were then grown from individual colonies 
and the plasmids harvested by Miniprep (section 2.5.7.2).  In some cases, primers 
used for mutagenesis also added or removed a unique restriction site from the 
protein, allowing the presence of the desired mutation to be tested for by restriction 
digest (section 2.5.8.2).  Mutations were confirmed by sequencing (section 2.5.3). 
 
2.5.8.2 Restriction digests 
In order to digest DNA at selective sites, specific restriction enzymes were used.  
The DNA to be digested was made up in a buffer appropriate for the enzyme and the 
enzyme was added.  The reaction was then incubated at 37°C for 1-18 hours.  A list 
of enzymes used, along with their corresponding buffers, is shown in table 2.5.B.  In 
order to terminate the reaction, EDTA was sometimes added to a final concentration 
of 10mM.  These products could then be run on an agarose gel and the pattern of the 
digested bands visualised (see section 2.5.5.1). 
 
2.5.8.3 Phenol-Chloroform extraction 
In order to precipitate plasmid DNA from solution following a restriction digest (see 
above) and prior to cloning, proteins were first removed by phenol-chloroform 
extraction.  100µl of phenol/chloroform/isoamyl alcohol mix was added to the digest.  
The digest was then briefly vortexed and spun at 13,000 rpm for two minutes on a 
desk-top centrifuge.  40µl of the aqueous phase was then removed off and stored.  
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40µl of TE buffer was added to the remaining mixture.  This was then vortexed, 
centrifuged and a further 80µl removed and pooled with the original 40µl fraction.   
 
1.2µl of 3M pH5.2 sodium acetate, 240µl absolute ethanol and 2µl glycogen was 
then added and the solution frozen at -20°C for at least 15 minutes.  Following this, 
the solution was thawed and spun at 13,000rpm for 30 minutes on a table-top 
centrifuge.  The supernatant was discarded and the DNA pellet resuspended in 70% 
ethanol.  This was then spun at 13,000rpm for a further 5 minutes and the supernatant 
once again discarded.  Finally, the pellet was air dried for 15 minutes and then 
resuspended in 30µl dH20. 
 
2.5.8.4 SAP treatment 
Following phenol-chloroform extraction and DNA precipitation (see above), DNA 
was treated with shrimp alkaline phosphatase (SAP) in order to remove any 
phosphate groups.  10µl of the DNA was made up to 20µl with SAP buffer (USB) 
and 1.5µl of the SAP enzyme added (USB).  The reaction was incubated at 37°C for 
30 minutes and terminated by heating at 70°C for a further 10 minutes, denaturing 
the enzyme. 
 
2.5.8.5 Ligation reaction 
In order to ligate DNA inserts containing restriction sites into plasmids, both the 
insert and plasmid were first restriction digested, phenol-chloroform extracted and 
SAP treated as described above.  A 10µl ligation reaction was then set up containing 
1µl T4 ligase (Roche), vector and insert in T4 ligase buffer (Roche).  Approximately 
2µl of the vector was used, along with insert in a 1:3 molar ratio with it.  Reactions 
were incubated at room temperature for four fours and then transformed into JM109 
cells (section 2.5.7.1). 
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Chapter 3 - Alternate splicing of NDE1 and 
NDEL1 
 
3.1 Identification of potential NDE1 and NDEL1 splice variants 
 
3.1.1 Alternatively spliced NDE1 and NDEL1 transcripts 
The UCSC genome browser (http://genome.ucsc.edu/) lists a number of alternatively 
spliced transcripts of both the NDE1 and NDEL1 genes.  To date, however, only one 
isoform of each protein has been investigated in the literature for any given species.  
Three transcripts encoding NDE1 full length isoforms were selected from the 
genome browser, all of which shared the same N-terminal seven exons but had 
unique 3’ regions (see figure 3.1.A).  In addition there is a short NDE1 transcript 
which shares exons 4, 5 and 6 of the full length isoforms (see figure 3.1.A).  Two 
NDEL1 transcripts, encoding proteins which again differed from each other only at 
the 3’ end, were also identified (see figure 3.1.A).  These transcripts were selected 
because they feature three or more times on the genome browser, or because they 
appear in published literature.  The full length species will be referred to by the C-
terminal four amino acids they are predicted to encode, while the short NDE1 species 
will be referred to as NDE1-S2.  Figures 3.1.B.a and 3.1.B.b show alignments of all 
of these isoforms. 
 
3.1.2 A potential alternate start codon in NDE1 
One early NDE1/NDEL1 publication made reference to a transcript in mouse 
encoding a 212 amino acid homologue of the Aspergillus nidulans protein NUDE 
(Sasaki et al. 2000).  This protein appears to be mouse Nde1, but makes use of an 
alternative methionine, at position 133, as a start codon.  Looking at the 
corresponding transcript (GenBank AF290473) on the UCSC genome browser, this 
protein was predicted based on a transcript lacking exon 3 and some of the 5’ 
untranslated region (figure 3.1.C).  Such a transcript would theoretically be able to 
produce a protein starting at exon 1, with a premature stop codon shortly into exon 4 
as a result of shift in the reading frame (figure 3.1.D).  The only functional region of  
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Figure 3.1.A: Exon structure of the NDE1 (red) and NDEL1 (blue) genes.  
Coloured exons indicate sequence conserved across the isoforms, while 
white indicates sequence that is unique to that splice variant.  Exon 7 of 
NDE1-KMLL, as well as exons 4 and 6 of NDE1-S2 contain both conserved 
and unique sections.  Arrows represent the location of the primers used in 
detecting these isoforms in section 3.2.1. 
 
 
this protein likely to be conserved from the full length variants is the dimerisation 
site (based on the known corresponding domain in NDEL1 (Sasaki et al. 2000)).  To 
date, however, there is no experimental evidence to confirm the implication that, as a 
result of this, the alternative methionine 133 start codon would be used instead.  The 
use of “internal” start codons is not uncommon however, with one study estimating 
that 41% of transcripts studied contain at least one unused AUG motif upstream of 
the actual start codon (Peri and Pandey 2001).  As a result of this uncertainty, the 
transcript will be referred to as Nde1-∆ex3, while the theoretical methionine-133 
based 212-amino acid protein it may encode will be referred to as Nde1-S1a and the 
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a) 
 
NDE1-SSSC    MEDSGKTFSSEEEEANYWKDLAMTYKQRAENTQEELREFQEGSREYEAELETQLQQIET 
NDE1-KMLL    MEDSGKTFSSEEEEANYWKDLAMTYKQRAENTQEELREFQEGSREYEAELETQLQQIET 
NDE1-KRHS    MEDSGKTFSSEEEEANYWKDLAMTYKQRAENTQEELREFQEGSREYEAELETQLQQIET 
NDEL1-PLSV  MDGEDIPDFSSLKEETAYWKELSLKYKQSFQEARDELVEFQEGSRELEAELEAQLVQAEQ 
NDEL1-FMGQ  MDGEDIPDFSSLKEETAYWKELSLKYKQSFQEARDELVEFQEGSRELEAELEAQLVQAEQ 
 
NDE1-SSSC   RNRDLLSENNRLRMELETIKEKFEVQHSEGYRQISALEDDLAQTKAIKDQLQKYIRELEQ 
NDE1-KMLL   RNRDLLSENNRLRMELETIKEKFEVQHSEGYRQISALEDDLAQTKAIKDQLQKYIRELEQ 
NDE1-KRHS   RNRDLLSENNRLRMELETIKEKFEVQHSEGYRQISALEDDLAQTKAIKDQLQKYIRELEQ 
NDEL1-PLSV  RNRDLQADNQRLKYEVEALKEKLEHQYAQSYKQVSVLEDDLSQTRAIKEQLHKYVRELEQ 
NDEL1-FMGQ  RNRDLQADNQRLKYEVEALKEKLEHQYAQSYKQVSVLEDDLSQTRAIKEQLHKYVRELEQ 
 
NDE1-SSSC   ANDDLERAKRATIMSLEDFEQRLNQAIERNAFLESELDEKENLLESVQRLKDEARDLRQE 
NDE1-KMLL   ANDDLERAKRATIMSLEDFEQRLNQAIERNAFLESELDEKENLLESVQRLKDEARDLRQE 
NDE1-KRHS   ANDDLERAKRATIMSLEDFEQRLNQAIERNAFLESELDEKENLLESVQRLKDEARDLRQE 
NDEL1-PLSV  ANDDLERAKRATIVSLEDFEQRLNQAIERNAFLESELDEKESLLVSVQRLKDEARDLRQE 
NDEL1-FMGQ  ANDDLERAKRATIVSLEDFEQRLNQAIERNAFLESELDEKESLLVSVQRLKDEARDLRQE 
 
NDE1-SSSC   LAVQQKQE---KPRTPMPSSVEAERTDTAVQATGSVPSTPIAHRGPSSSLNTPGSFRRGL 
NDE1-KMLL   LAVQQKQE---KPRTPMPSSVEAERTDTAVQATGSVPSTPIAHRGPSSSLNTPGSFRRGL 
NDE1-KRHS   LAVQQKQE---KPRTPMPSSVEAERTDTAVQATGSVPSTPIAHRGPSSSLNTPGSFRRGL 
NDEL1-PLSV  LAVRERQQEVTRKSAPSSPTLDCEKMDSAVQASLSLPATPVG-KGTENTFPSP----KAI 
NDEL1-FMGQ  LAVRERQQEVTRKSAPSSPTLDCEKMDSAVQASLSLPATPVG-KGTENTFPSP----KAI 
 
NDE1-SSSC   DDSTGGTPLTPAARISALNIVGDLLRKVGALESKLASCRNLVYDQSPNRTGGPASGRSSK 
NDE1-KMLL   DDSTGGTPLTPAARISALNIVGDLLRKVGALESKLASCRNLVYDQSPNRTGGPASGRSSK 
NDE1-KRHS   DDSTGGTPLTPAARISALNIVGDLLRKVGALESKLASCRNLVYDQSPNRTGGPASGRSSK 
NDEL1-PLSV  PNGFGTSPLTPSARISALNIVGDLLRKVGALESKLAACRNFAKDQASRKSYISGNVNCGV 
NDEL1-FMGQ  PNGFGTSPLTPSARISALNIVGDLLRKVGALESKLAACRNFAKDQASRKSYISGNVNCGV 
 
NDE1-SSSC   NRDGGERRPSSTSVPLGDKG----LDTSCRWLSKSTTRSSSSC------- 
NDE1-KMLL   NRDGGERRPSSTSVPLGDKGLGKRLEFGKPPSHMSSSPLPSAQGVVKMLL 
NDE1-KRHS   NRDGGERRPSSTSVPLGDKG----SVPSNKPLAGGENPP--APGKRHS-- 
NDEL1-PLSV  LNGNGTKFSRSGHTSFFDKGAVNGFDPAPPPPGLGSSRPSSAPGMLPLSV 




NDE1-SSSC  MEDSGKTFSSEEEEANYWKDLAMTYKQRAENTQEELREFQEGSREYEAELETQLQQIETR 
NDE1-S2   
 
NDE1-SSSC  NRDLLSENNRLRMELETIKEKFEVQHSEGYRQISALEDDLAQTKAIKDQLQKYIRELEQA 
NDE1-S2       MMSPILQVKSPCPRRLRDLAHSVASRKFGAGTCAQVCLTLRTSWIRGAGGMLRFVLL 
 
NDE1-SSSC  NDDLERAKRATIMSLEDFEQRLNQAIERNAFLESELDEKENLLESVQRLKDEARDLRQEL 
NDE1-S2    DNSAFLFASATIMSLEDFEQRLNQAIERNAFLESELDEKENLLESVQRLKDEARDLRQEL 
 
NDE1-SSSC  AVQQKQEKPRTPMPSSVEAERTDTAVQATGSVPSTPIAHRGPSSSLNTPGSFRRGLDDST 
NDE1-S2    AVQQKQEKPRTPMPSSVEAERTDTAVQATGSVPSTPIAHRGPSSSLNTPGSFRRGLDDST 
 
NDE1-SSSC  GGTPLTPAARISALNIVGDLLRKVGALESKLASCRNLVYDQSPNRTGGPASGRSSKNRDG 
NDE1-S2    GGTPLTPAARISALNIVGDLLRKVGVRPHFPGVWCLPACLSGCVKGVDLVPSLSSFLFF   
 
NDE1-SSSC  GERRPSSTSVPLGDKGLDTSCRWLSKSTTRSSSSC 
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c) 
 
NDE1-KMLL        LGKRLEFGKPPSHMSSSPLPSAQGVVKMLL 




NDE1-KRHS        ----SVPSNKPLAGGENPP--APGKRHS-- 
NDEL1-PLSV       AVNGFDPAPPPPGLGSSRPSSAPGMLPLSV 
 
 
Figure 3.1.B: a) Sequence alignment of all the long isoforms of NDE1 and 
NDEL1 studied here.  Amino acids in red indicate residues conserved 
between NDE1 and NDEL1.  Amino acids in blue indicate residues 
conserved amongst NDE1 isoforms only.  Amino acids in green indicate 
residues conserved amongst NDEL1 isoforms only.  b) Sequence alignment 
of the long NDE1-SSSC isoform and the short NDE1-flff isoform.  Amino 
acids conserved between the two are shown in red.  c) Alignment of the C-
terminal regions of NDE1-KMLL and NDEL1-PLSV with identical residues 
shown in red and similar residues in blue.  d) A similar alignment of NDE1-




Figure 3.1.C:  Exon structure of the NDE1-∆ex3 transcript, which is predicted 
to encode NDE1-S1.  Also shown is the exon structure of full length NDE1-
KMLL for comparison.  The two methionine residues which may be used as 
start codons are indicated by vertical arrows.  Horizontal arrows indicate the 
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atggaggactccggaaagactttcagctccgaggaggaagaagctaactattggaaagat 60 
 M  E  D  S  G  K  T  F  S  S  E  E  E  E  A  N  Y  W  K  D  20 
ctggcgatgacctacaaacagagggcagaaaatacgcaagaggaactccgagaattccag 120 
 L  A  M  T  Y  K  Q  R  A  E  N  T  Q  E  E  L  R  E  F  Q  40 
gagggaagccgagaatatgaagctgaattggagacgcagctgcaacaaattgaaaccagg 180 
 E  G  S  R  E  Y  E  A  E  L  E  T  Q  L  Q  Q  I  E  T  R  60 
aacagagacctcctgtccgaaaataaccgccttcgcatggagctggaaaccatcaagcgc 240 
 N  R  D  L  L  S  E  N  N  R  L  R  M  E  L  E  T  I  K  R  80 
cacgatcatgtctctcgaagactttgagcagcgcttgaatcaggccatcgaaagaaatgc 301 
 H  D  H  V  S  R  R  L  -                                   100         
        M  S  L  E  D  F  E  Q  R  L  N  Q  A  I  E  R  N  A 18 
cttcctggaaagtgaacttgatgaaaaagagaatctcctggaatctgttcagagactgaa 113 
  F  L  E  S  E  L  D  E  K  E  N  L  L  E  S  V  Q  R  L  K 38 
ggatgaagccagagatttgcggcaggaactggccgtgcagcagaagcaggagaaacccag 173 
  D  E  A  R  D  L  R  Q  E  L  A  V  Q  Q  K  Q  E  K  P  R 58 
gacccccatgcccagctcagtggaagctgagaggacagacacagctgtgcaggccacggg 233 
  T  P  M  P  S  S  V  E  A  E  R  T  D  T  A  V  Q  A  T  G 78 
ctccgtgccgtccacgcccattgctcaccgaggacccagctcaagtttaaacacacctgg 293 
  S  V  P  S  T  P  I  A  H  R  G  P  S  S  S  L  N  T  P  G 98 
gagcttcagacgtggcctggacgactccaccggggggacccccctcacacctgcggcccg 353 
  S  F  R  R  G  L  D  D  S  T  G  G  T  P  L  T  P  A  A  R 118 
gatatcagccctcaacattgtgggagacctactgcggaaagtcggggcactggagtccaa 413 
  I  S  A  L  N  I  V  G  D  L  L  R  K  V  G  A  L  E  S  K 138 
actcgcttcctgccggaacctcgtgtacgatcagtccccaaaccgaacaggtggcccagc 473 
  L  A  S  C  R  N  L  V  Y  D  Q  S  P  N  R  T  G  G  P  A 158 
ctctgggcggagcagcaagaacagagatggcggggagagacggccaagcagcaccagcgt 533 
  S  G  R  S  S  K  N  R  D  G  G  E  R  R  P  S  S  T  S  V 178 
Ggcctttgggtgataaggggttggggaagcgcctggaatttgggaagccgccttcacacat 593 
  P  L  G  D  K  G  L  G  K  R  L  E  F  G  K  P  P  S  H  M  198 
gtcttcatcgccgctgccgtcagcccagggggtagtcaagatgttgctttag  645 
  S  S  S  P  L  P  S  A  Q  G  V  V  K  M  L  L  -    214 
 
Figure 3.1.D: The nucleic acid sequence of a human NDE1-∆ex3 transcript 
(using the “KMLL” C-terminus) is shown in black.  The amino acid sequences 
of the two potentially derived proteins are shown below in single letter code.  
The blue sequence makes use of methionine-1 (S1b) and the red sequence 
makes use of methionine-133 (S1a, numbered based on full length NDE1).  
The break where exon 3 would otherwise lie is marked with a green line. 
 
 
NDE1 contains a Kozak sequence (Kozak 1987), conserved in both mouse and 
human, around methionine-133 (table 3.1.A),  Of the five bases preceding the start 
codon and the one after, only three match the canonical Kozak sequence, however 
this may well be close enough, as one study found 48.9% of proteins to have four or 
more mismatches in this region (Peri and Pandey 2001).  Thus a NDE1-S1a protein 
remains a realistic possibility in both organisms.  By entering the nucleic acid 
sequence (including the untranslated regions at the 5’ and 3’ ends) of NDE1 into the  
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  -9 -8 -7 -6 -5 -4 -3 -2 -1 1 2 3 4 
Canonical sequence   G C C G C C A C C A T G G 
Methionine-133 Human G C C A C G A T C A T G T 
Methionine-133 Mouse G C C A C A A T C A T G T 
Methionine-1 Human G T T T T C A C A A T G G 
Methionine-1 Mouse C A T T T T A C C A T G G 
 
Table 3.1.A:  The canonical Kozak sequence (Kozak 1987), compared to the 
sequence surrounding the potential start codon at methionine-133 of NDE1 in 
mice and humans.  The sequence surrounding methionine-1, the canonical 
start codon, is also shown.  Bases in bold indicate those that are most highly 
conserved in the Kozak sequences of vertebrates.  Yellow indicate 
conservation with the canonical Kozak sequence, while red indicates the 
essential ATG methionine codon. 
 
 
online program NetStart 1.0 (Pedersen and Nielsen 1997), methionine-133 was rated 
as the most likely start codon in the protein (more so even than methionine 1).  The 
Kozak sequence is not predictable using the online program weakAUG, however this 
program cannot detect a Kozak sequence at exon 1 either (Tikole and 
Sankararamakrishnan 2008). 
 
Methionine-133 of NDE1 is substituted by a valine in NDEL1.  Indeed, this is 
actually the only residue out of amino acids 115-161 of NDE1 which is not precisely 
conserved in NDEL1.  An equivalent isoform of NDEL1 is thus not expected to 
exist. 
 
3.1.3 Molecular weights and isoelectric points of the isoforms 
The predicted amino acid sequences of all theoretical NDE1 and NDEL1 isoforms 
were entered into the online program ProtParam (Gasteiger et al. 2005) which gives 
theoretical predictions of the molecular weights (MW) and isoelectric points (pI) of 
peptides.  These are shown in table 3.1.B.  Full length NDE1 and NDEL1 isoforms 
are seen to share similar MW and pI values, which is expected given their high degree 
of amino acid similarity.  The slightly higher MW of the NDE1-KMLL and NDEL1-
PLSV isoforms may allow them to be distinguished from other isoforms by Western  
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Protein Isoform Mw (kDa) pI 
NDE1 SSSC 37.7 5.09 
NDE1 KMLL 38.8 5.20 
NDE1 KRHS 37.8 5.14 
NDE1 S1a 23.0 9.13 
NDE1 S1b 10.7 4.81 
NDE1 S2 25.8 8.85 
NDEL1 PLSV 38.3 5.16 
NDEL1 FMGQ 37.0 5.16 
 
Table 3.1.B:  Molecular weights (MW) and isoelectric points (pI) of theoretical 
NDE1 and NDEL1 isoforms, predicted by ProtParam (Gasteiger et al. 2005). 
 
 
blot.  Notably, the short NDE1-S1a and NDE1-S2 splice variants are considerably 
more basic than the full length species, while the NDE1-S1b protein is slightly more 
acidic. 
 
3.1.4 Alignment of the unique C-terminal domains 
A CLUSTALW (Thompson et al. 1994) alignment of the C-terminal isoforms is 
shown in figure 3.1.B.a.  In this region, the highest degree of sequence similarity 
appears to be between the NDE1-KMLL and NDEL1-PLSV isoforms (figure 
3.1.B.c) and the NDE1-KRHS and NDEL1-PLSV isoforms (figure 3.1.B.d).  It is 
therefore possible that these isoforms may therefore have C-terminal regions 
homologous to the “original” C-terminal region of a common ancestral gene, with 
the alternative C-terminal regions appearing later in evolution.  The short nature of 
the C-terminal tails prevents the generation of a meaningful phylogenetic tree, 
however. 
 
3.1.5 Nde1 transcripts described in other organisms are orthologues of 
the NDE1-KMLL splice variant 
The “canonical” human NDE1 protein studied to date in the literature is the NDE1-
SSSC isoform (Feng et al. 2000).  However, when the NDE1-SSSC amino acids 
sequence was compared to known rodent forms of Nde1 (Feng et al. 2000; Kitagawa 
et al. 2000) and other NDE1 orthologues, very little sequence similarity was 
observed at the extreme C-terminus (see figure 3.1.E.a).  A similar comparison was  
 
        
a) 
 
NDE1-SSSC          LRKVGALESKLASCRNLVYDQSPNRTGGPASGRSSKNRDGGERRPSSTSVPLGDKGLDTSCRWLSKSTTRSSSSC----------- 
Chimpanzee         LRKVGALESKLASCRNLVYDQSPNRTGGPASGRSSKNRDGGERRPSSTSVSLGDKGLGKRLEFGKPPSHMSSSPLPSAQGVVKMLL 
Rhesus monkey      LRKVGALESKLASCRNLVYDQSPNRTGGPASGRSSKNRDGGERRPSSSSVPLGDKGLGKCLEFGKPPSHMSSSPLPSAQGVVKMLL 
Cattle             LRKVGALESKLASCRNFVYDQSPGRASGPASGRGSKNRDSVDRRPGGSNVPLGDKGLGKRLEFGKPSSNVSSPSLPSAQGVVKMLL 
Mouse              LRKVGALESKLASCRNFMYDQSPSRTSGPASGRGTKNRDGVDRRPG--STSVGDKGSGKRLEFGKPASEPASPALPSAQGVVKLLL 
Rat                LRKVGALESKLASCKNFMYDQSPSRKSGPALGRGTKNRDGIDRRPG--STAVGDKGSGKRLEFAKPSSQLSSPALPSTQGVVKLLL 
Chicken            LRKVGALESKLASCRNFVYDQSPDR----TTVSMYMNRDALETRMSP-HQPLCDTGLVKRLEFGTRPSSTPGPMSHPSQSVVKMLL 




NDE1-KMLL          LRKVGALESKLASCRNLVYDQSPNRTGGPASGRSSKNRDGGERRPSSTSVPLGDKGLGKRLEFGKPPSHMSSSPLPSAQGVVKMLL 
Chimpanzee         LRKVGALESKLASCRNLVYDQSPNRTGGPASGRSSKNRDGGERRPSSTSVSLGDKGLGKRLEFGKPPSHMSSSPLPSAQGVVKMLL 
Rhesus monkey      LRKVGALESKLASCRNLVYDQSPNRTGGPASGRSSKNRDGGERRPSSSSVPLGDKGLGKCLEFGKPPSHMSSSPLPSAQGVVKMLL 
Cattle             LRKVGALESKLASCRNFVYDQSPGRASGPASGRGSKNRDSVDRRPGGSNVPLGDKGLGKRLEFGKPSSNVSSPSLPSAQGVVKMLL 
Mouse              LRKVGALESKLASCRNFMYDQSPSRTSGPASGRGTKNRDGVDRRPG--STSVGDKGSGKRLEFGKPASEPASPALPSAQGVVKLLL 
Rat                LRKVGALESKLASCKNFMYDQSPSRKSGPALGRGTKNRDGIDRRPG--STAVGDKGSGKRLEFAKPSSQLSSPALPSTQGVVKLLL 
Chicken            LRKVGALESKLASCRNFVYDQSPDR----TTVSMYMNRDALETRMSP-HQPLCDTGLVKRLEFGTRPSSTPGPMSHPSQSVVKMLL 
Xenopus            LRKVGALESKLASCRNFVHEQSPNRPLTSVSARMNKTREGIENRLSMASGSSVEKGLIKRLEFGSLPSNTPVQGMHSPQGVVKMII 
 
Figure 3.1.E:  a) Sequence alignment of the C-terminal region of human NDE1-SSSC with those of known NDE1 homologues 
from other species demonstrates that there is very little sequence similarity at the extreme C-terminus.  b) Sequence 
alignment of NDE1-KMLL with the same homologues shows far better amino acid similarity.  Red amino acids indicate 




  99    
between NDE1-KMLL and the same orthologues revealed better amino acid 
conservation (see figure 3.1.E.b).  It therefore appears that while NDE1-SSSC is the 
splice variant studied to date in humans, the isoform studied in other organisms is in 
fact more similar to the NDE1-KMLL isoform.  At the time of writing, however, 
GenBank lists four human mRNAs corresponding to NDE1-SSSC, and only one 
corresponding to NDE1-KMLL, implying that NDE1-SSSC may still be the more 
prominently expressed of the two in humans.   While no protein binding domain or 
phosphorylation site has yet been definitively mapped to the isoform-specific region 
of the NDE1 protein, the possibility has to be acknowledged that some results in the 
literature ascribed to “rodent Nde1” may not also apply to “human NDE1” or vice 
versa simply due to the fact that different isoforms have been studied in each.  A 
theoretical analysis of potential functions of these C-terminal tails will be undertaken 
in chapter 4. 
 
In contrast, NDEL1-PLSV is the isoform which has been studied to date in all 
species (Niethammer et al. 2000; Sasaki et al. 2000; Sweeney et al. 2001). 
 
3.2 Splice variants of NDE1 and NDEL1 in the human brain 
 
3.2.1 Transcripts of several NDE1 and NDEL1 splice variants in human 
brain cDNA 
Four NDE1 splice variants (SSSC, KMLL, KRHS and S2) and two putative NDEL1 
splice variants (PLSV and FMGQ) are predicted.  In order to investigate the 
existence of these transcripts in vivo, primers were generated that were specific to 
each splice variant (see table 2.5.A).  5’ primers were selected that spanned introns 4 
and 5 of NDE1 and NDEL1 (introns 1 and 2 of NDE1-S2) in order to ensure 
detection of only spliced mRNA and not unspliced genomic DNA.  3’ primers were 
selected from the unique sequences at the 3’ end of each variant.  Figure 3.1.A shows 
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Figure 3.2.A: Expression of transcripts of four NDE1 and two NDEL1 splice 
variants in cDNAs raised from seven different regions of the human brain. 
 
 
Commercially available RNA from seven different regions of the human brain were 
reverse transcribed.  PCR reactions were then performed on each of these cDNA 
samples in order to test the presence of the predicted splice variants.  As a negative 
control, a mock reverse transcription reaction was performed that lacked any RNA 
template.  For each splice variant, equal quantities of PCR reaction from each brain 
region, as well as the negative control, were electrophoresed on an agarose gel (see 
figure 3.2.A).  For each isoform, a sample of the PCR product which yielded the 
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Transcripts encoding all six of the investigated isoforms were detected in cDNA 
raised from several brain regions.  In the case of the three “canonical” splice variants, 
NDE1-SSSC, NDE1-KMLL and NDEL1-PLSV, transcripts appeared to be expressed 
in all the brain regions, while for the remaining isoforms, the pattern of staining 
appeared to be more specialised.  It should be noted, however, that these PCR 
reactions were not quantitative and therefore direct comparisons cannot be 
definitively made.  Nevertheless, this suggests that transcripts encoding each of these 
isoforms could be expressed in the brain.  Given that both the NDE1 and NDEL1 
proteins show evidence of neurodevelopmental functions (see section 1.3.4), any or 
all of these isoforms could therefore potentially play roles in these processes. 
 
3.2.2 Multiple bands of NDEL1-FMGQ 
The NDEL1-FMGQ primers detected PCR products of three distinct sizes (see figure 
3.2.A), some of which were specific to certain regions of the brain.  These products 
were run on another gel and eight discrete DNA bands excised (see figure 3.2.B), 
with each band then being sequenced.  Bands B2, C2, D2, F2 and G2 all correspond 
to full length NDEL1-FMGQ transcripts.  The anterior cingulate cortex, thalamus, 
amygdala, entorhinal cortex and cerebellum therefore clearly all express full length 
NDEL1-FMGQ transcripts. 
 
The remaining bands were unfortunately very faint and, in spite of an extensive 
optimisation effort, it has not yet proven possible to fully sequence these products.  
Nevertheless, partial sequencing has confirmed that the bands do at least represent 
genuine NDEL1 transcripts.  It can be speculated that the varying band sizes may be 
as a result of additional, as yet uncharacterised, splicing of the NDEL1 gene. 
 
3.2.3 Transcripts of the NDE1-∆ex3 (S1) splice variant in human brain 
cDNA 
The NDE1-∆ex3 transcript, which has the potential to encode the NDE1-S1a protein 
isoform (Sasaki et al. 2000), was originally seen in mouse.  To investigate if the 
transcript also exists in human, two primers were designed, one that spans the exon 
2-3 splice junction and one that spans exon 2-4 splice junction, as seen in only in the  
 








                 
 
 
Figure 3.2.B:  Eight bands were excised from a gel containing the NDEL1-




Figure 3.2.C: Expression of the ∆ex3 splice variant of NDE1 (with the KMLL 
C-terminal region) in cDNAs from various regions of the human brain.  Full 
length NDE1-KMLL is shown for comparison. 
NDE1-∆ex3 (S1) 
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NDE1-∆ex3 transcript (see figure 3.1.C).  These should therefore detect either ∆ex3 
or full length NDE1 transcripts respectively.  These two primers were then each 
partnered with a primer that detects the NDE1-KMLL 3’ end.  This 3’ end was 
chosen as it most closely resembled that of the original mouse Nde1-∆ex3 transcript.   
When used on the human brain cDNA, the full length transcript was seen throughout 
the brain, while the ∆ex3 transcript was seen in at least two locations (see figure 
3.2.C).  While these PCR reactions were not done in a quantitative manner, it 
nonetheless appears that the full length transcript is expressed at a greater abundance 
than the ∆ex3 transcript in all brain regions tested.  It therefore appears that the 
NDE1-∆ex3 transcript does exist in the human brain, although the nature of the 
protein it encodes remains to be determined.   
 
3.3 Discussion 
Numerous cDNAs representing potential NDE1 and NDEL1 have been listed on the 
UCSC genome browser for some time, but to date the only published evidence of 
multiple protein isoforms came from a single early paper which mentioned a NDE1 
isoform shorter than that described elsewhere (Sasaki et al. 2000).  An additional 
clue to the existence of multiple NDE1 isoforms, however, came from the fact that 
the canonical human NDE1 isoform (SSSC) did not appear to be a direct orthologue 
of the Nde1 proteins from other species described in the literature or listed as a 
standard splice variant on the UCSC Genome Browser.   These in fact more closely 
resemble NDE1-KMLL (see figure 3.1.E). 
 
It is unclear at this time whether these splice variants also exist in other organisms.  
Certainly the KMLL isoform is well conserved across many species, but in addition 
NDE1-∆ex3 transcripts have been described in both human and mouse (Sasaki et al. 
2000).  It therefore seems likely that other mammals may express isoforms 
equivalent to at least some of these splice variants.  Determining which of these 
splice variants are conserved across species may yield clues as to which of the 
protein isoforms are likely to play the most essential biological roles.  The similarity 
between the NDE1-KMLL and NDEL1-PLSV C-terminal regions does, however, 
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suggest that these isoforms are the most closely related to the common gene from 
which NDE1 and NDEL1 diverged.  It should be stated that the isoforms described 
here are unlikely to be the only splice variants of human NDE1 and NDEL1 found in 
the body, with cDNAs containing several other potential splice variants also listed on 
the genome browser. 
 
A theoretical analysis of potential differences between the isoforms will be 
performed in chapter 4, while an anti-NDE1 antibody will be used to look for 
evidence of these isoforms in cell lines in chapter 5.  The existence of transcripts 
encoding multiple NDE1 and NDEL1 isoforms suggests that regulation of their 
function is likely to be complex.  That at least low levels of each of these transcripts 
appear to be present in the brain furthermore provides the possibility that any of 
these isoforms could play roles in the neurodevelopmental phenotypes previously 
ascribed to NDE1 and NDEL1 (Feng and Walsh 2004; Shu et al. 2004; Kamiya et al. 
2006; Duan et al. 2007; Taya et al. 2007; Shim et al. 2008).  It would be interesting 
to, at a later date, perform a quantitative real time PCR experiment in order to 
determine how prevalent each of these isoforms is in the brain, particularly with 
regard to NDE1-SSSC which is the most commonly reported on human isoform and 
NDE1-KMLL which is the most widely reported on in all other species. 
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Chapter 4 – Predicting the structure and 
function of the NDE1 and NDEL1 proteins 
 
4.1 Introduction 
It is a central dogma of structural biology that the amino acid sequence of a protein 
determines how it is folded and thus the three-dimensional (3-D) structure of the 
protein, and that this structure determines the in vivo properties of the protein.  
Therefore in order to understand the cellular roles of the NDE1 and NDEL1 proteins 
and how those functions may be regulated, it is helpful to build a theoretical model 
of their structure. 
 
In several of the initial papers characterising NDE1 and NDEL1 it was observed that 
their N-terminal region had the potential to form a helical or coiled-coil structure 
(Feng et al. 2000; Niethammer et al. 2000; Sasaki et al. 2000).  The 3-D structure of 
this region of NDEL1 has since been solved and does indeed form a large coiled-coil 
domain which can interact with the coiled-coils of other NDEL1 monomers 
(Derewenda et al. 2007).  To date, a similar structural investigation has not been 
performed on NDE1 or on the remaining portions of NDEL1.  Another key aspect of 
a protein’s structure with respect to function is the location of sites at which it 
interacts with its protein binding partners.  A number of such binding sites have been 
mapped for both NDE1 and NDEL1 (see table 4.1), but for the majority of 
interactions, a site has only been established on one or the other of NDE1 and 
NDEL1.  In addition, a number of phosphorylation sites have been identified on each 
protein, but to date, none of these have been confirmed to exist in both. 
 
Considering that NDE1 and NDEL1 are so similar to each other (approximately 60% 
amino acid identity, 80% similarity depending on the method of alignment), it is 
reasonable to assume that many of these features will be shared between them.  
Comparing the amino acid sequences of the two proteins (figure 1.3.A), it can be 
seen that certain regions are more closely conserved than others.  For example in the  
 
          
Protein Binds NDE1? Binds NDEL1? NDE1 site NDEL1 site References 
 Self-association O/E Yes  22-159 56-104  (Sasaki et al. 2000; Feng and Walsh 2004) 
 14-3-3ε ? Yes - 189-256  (Toyo-Oka et al. 2003) 
Cdc42GAP ? O/E - 114-133 (Shen et al. 2008b) 
CENPF O/E O/E 167-287 ?  (Yan et al. 2003; Soukoulis et al. 2005; Vergnolle and Taylor 2007) 
 DISC1 O/E * Yes ?  266-267 (Millar et al. 2003; Brandon et al. 2004; Burdick et al. 2008) 
DBZ/Su48 O/E O/E  176-335 ?  (Hirohashi et al. 2006b) 
 Dynactin O/E Yes ?  256-291 (Liang et al. 2004; Guo et al. 2006) 
 Dynein In vitro Yes ?  256-291 (Sasaki et al. 2000; Stehman et al. 2007) 
 Katanin p60 O/E O/E ?  195-256 (Toyo-Oka et al. 2005) 
 Katanin p80 ? O/E -  63-189 (Toyo-Oka et al. 2005) 
 LIS1 O/E Yes  90-159  114-133 (Feng et al. 2000; Yan et al. 2003) 
NF-L ? Yes - 191-345 (Nguyen et al. 2004b) 
Pericentrin In vitro O/E ? 256-293 (Feng et al. 2000; Guo et al. 2006) 
 p78/MCRS1 O/E O/E  176-335 ?  (Hirohashi et al. 2006a) 
 
Table 4.1:  Binding sites of NDE1 and NDEL1 interactors as mapped experimentally in the literature.  “In vitro” designates that 
this interaction has been shown by either yeast-2-hybrid screen or GST in vitro pull-down, but has not been demonstrated in 
the cell.  “O/E” designates that this interaction has been seen using over-expressed protein in the cell, but not yet using 
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regions of NDE1 containing amino acids 112-181 and 244-276, sequence 
conservation with NDEL1 is near identical.  The region between these two conserved 
sections, meanwhile, shows only limited conservation with NDEL1.  It can therefore 
be speculated that certain functional properties of NDE1/NDEL1, those lying within 
the conserved regions, are likely to be shared between the two proteins.  The 
presence of less conserved regions, meanwhile, may imply the existence of protein-
specific functions, interactions and/or regulation. 
 
In this chapter bioinformatics software will be utilised in order to predict the 
structural features of NDE1 and NDEL1, as well as their likely functional domains.  
These theoretical analyses are intended to aid the generation of a model for the 
proteins structure, their function and how these functions may be regulated.  The 
hypotheses generated in this way can be used as a framework on which to base future 
experiments. 
 
4.2 Coiled-coil and α-helix forming potential of NDE1 and NDEL1 
 
4.2.1 Introduction to α-helices and coiled-coils 
The α-helix is a common protein secondary structure in which an amino acid chain is 
arranged as a spiral.  These helices make one complete rotation every 3.4 amino 
acids and are held together by hydrogen bonding between the C=O group of a 
residue and the N-H group of the residue four amino acids in front of it. 
 
In some proteins, two α-helices spiral around each other to form a structure known as 
a coiled coil.  Such structures serve a variety of biological roles, as well as often 
being the sites of protein-protein interactions.  In a coiled-coil, some residues 
(typically hydrophilic) will be facing outwards of the coiled coil, while those 
involved in the interaction of the two helices and typically hydrophobic, will be 
internal.  The amino acid sequence of the coiled-coil is thought of as existing in units 
of seven residues (each known as a heptad repeat) as each residue occupies an 
equivalent position in the coil (internal or external) to the residue seven amino acids 
ahead of it. 
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4.2.2 COILS analysis of full length NDE1 and NDEL1 
Given the fact that NDEL1 possesses a long N-terminal coiled-coil region 
(Derewenda et al. 2007), the online program COILS (Lupas et al. 1991) was used to 
evaluate the helix-forming potential of a NDE1-SSSC monomer.  An equivalent 
helix was indeed strongly predicted (see figure 4.2.A.a), in agreement with a 
previously published prediction (Feng et al. 2000), implying that NDE1 would also 
be able to form coiled-coil structures.  In addition, the COILS program also shows 
the potential, albeit at a lower probability, for an additional short helical domain 
nearer the C-terminus, around amino acids 252-278.  This feature is also seen when 
the amino acid sequence of NDEL1-PLSV was investigated in the same way (see 
figure 4.2.A.b).  However, this C-terminal helix is only detectable when the sequence 
is analysed using a “sliding window” of 14 amino acid “blocks”.  The helix is weak 
when a 21 amino acid “window” is used and not detectable at all with a 28 amino 
acid one.  This may be due to the short length, approximately 36 amino acids, of this 
region or may indicate that the result is a false positive. 
 
4.2.3 PSIPRED analysis of full length NDE1 and NDEL1 
In order to assess the reliability of these helix predictions, the sequences of NDE1-
SSSC and NDEL-PLSV were analysed using the PSIPRED protein structure 
prediction server (McGuffin et al. 2000).  This program predicts the secondary 
structure of each amino acid in a sequence, with an accuracy independently measured 
at 77.3% (Moult et al. 1999).  Results are shown in figure 4.2.B.  Both proteins are 
predicted to have α-helical domains covering most of their N-terminal regions, 
matching the coiled-coil predicted using the COILS program.  A short C-terminal 
helix is predicted in both proteins, running from amino acids 247-278 of full length 
NDE1 and 246-278 of NDEL1, matching the coiled-coil predicted using COILS.  
Interestingly, this region is extremely well conserved between NDE1 and NDEL1 



































Figure 4.2.A: Regions of a) NDE1-SSSC and b) NDEL1-PLSV with coil-
forming potential, predicted using the program COILS (Lupas et al. 1991). 
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Figure 4.2.B: Predictions of the secondary structure of a) NDE1-SSSC and b) 
NDEL1-PLSV made using the program PSIPRED (McGuffin et al. 2000).  
“Conf” is the level of confidence the program has in its position (from 0% with 
no blue bar to 100% with a full height bar).  “H” or a green cylinder indicates 
that the residue is predicted to be part of an α-helix.  “E” or a yellow arrow 
indicates that the amino acid is part a β-strand. “C” or a thin black line 
indicates that this amino acid is classified by the program as “coiled”, in this 
case meaning a loose structure (as opposed to a helical coiled-coil). 
 
 
There are some differences between the predicted NDE1-SSSC and NDE1-KMLL 
structures, such as the presence of a couple of 2-3 amino acid “helices” near the C-
terminus of NDE1.  Given the extremely short nature of these predicted structures, 
less than the 3.6 residues required for one turn of an α-helix, it is doubtful that these 
correspond to genuine structures. 
 
4.2.4 Lack of isoform specific α-helices in the full length isoforms 
The amino acid sequences of the remaining three full length NDE1/NDEL1 isoforms 
(described in chapter 3) were investigated using PSIPRED.  The results at the C-
terminal tails of all five isoforms are shown in figure 4.2.C.  None of the three NDE1 
full length isoforms contains any predicted α-helixes within their unique C-terminal 
domains.  With NDEL1, there are only minor predicted differences between the two 
isoforms, consisting of very short “structured” regions which may be false positives. 
  
4.2.5 Helical structure of the NDE1-S2 isoform 
The amino acid sequence of NDE1-S2 was analysed using PSIPRED.  At least three 
separate α-helical regions were predicted to exist (see figure 4.2.D.a).  One of these 
is found in the N-terminal half of the protein (amino acids 62-122) and is a fragment 
of the major coiled-coil seen in the full length NDE1 isoforms.  In addition, two or 
more distinct α-helical regions were predicted at the extreme N- and C-termini of the 
protein (amino acids 13-46 and 184-235).  Analysis of the same amino acid sequence 
using COILS however, detected only the one region with helix-forming potential, the  
 











   
  
   
 
Figure 4.2.C:  a) The complete amino acid sequences of each of the three full 
length NDE1 isoforms were analysed using PSIPRED.  Only the results from 
the extreme C-terminus (amino acid 307 onwards) are displayed here.  b) 
The two NDEL1 isoforms were analysed in the same way.  Sequence is 
shown from amino acid 306 onwards.  Green cylinders indicate α-helices, 















         
  
 



































Figure 4.2.D: a) The secondary structure of NDE1-S2 as 
predicted by PSIPRED (McGuffin et al. 2000).  Green 
cylinders indicate α-helices, yellow arrows indicate β-
strands.  b) The coil structure of NDE1-S2 as predicted by 
COILS (Lupas et al. 1991). 
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central coiled-coil which is conserved in full length NDE1 (see figure 4.2.D.b).  
Whether or not the remaining two helical regions exist in vivo is therefore unclear. 
 
4.2.6 Helical structure of the theoretical NDE1-S1 isoforms 
In order to investigate the potential effects of the NDE1-∆ex3 transcript (see section 
3.1.2) on the secondary structure of NDE1, a NDE1-S1a amino acid sequence was 
created by removing the first 132 amino acids from NDE1-KMLL.  The KMLL C-
terminal domain was chosen as it is homologous to that of the originally reported 
Nde1-∆ex3 transcript in mouse (Sasaki et al. 2000).  When this sequence was 
analysed using PSIPRED (figure 4.2.E.a) a structure similar to that of full length 
NDE1 was seen, with an α-helix at the extreme N-terminus, corresponding to the 
large N-terminal coiled-coil of full length NDE1.  There are a few minor differences 
between this and the corresponding sections of full length NDE1, but none more than 
a few amino acids long.  Analysis of the alternative S1a protein reveals it to be 
almost entirely formed of α-helices (figure 4.2.E.b), matching the corresponding 
regions of full length NDE1. 
 
4.3 NDE1 and NDEL1 are predicted to have intrinsically unstructured 
regions 
 
4.3.1 Introduction to intrinsically unstructured proteins 
As stated previously, the rationale behind structural biology is that the function of a 
protein is derived form its 3-D structure.  However many protein regions lack a 
definitive structure and are difficult or impossible to crystallise, as they are 
intrinsically unstructured or “disordered”.  It has been predicted that a third or more 
of eukaryotic proteins may have such “disordered” regions of 30 amino acids or 
longer (Dunker et al. 2000; Ward et al. 2004).  Such regions are often flexible and 
are likely to aid in protein binding (Wright and Dyson 1999).  Indeed the presence of 
disordered regions is enriched in “hub” proteins, those with many binding partners 
(Haynes et al. 2006), particularly those that are involved in large protein complexes 
(Hegyi et al. 2007), but possess few distinct protein binding sites themselves (Kim et 
al. 2008). 
 










Figure 4.2.E: The secondary structure of a) NDE1-S1a and b) NDE1-S1b as 




Given that NDE1 and NDEL1 both have numerous protein interactors and at least 
two distinct protein binding sites (Sasaki et al. 2000), it would be interesting to know 
if they also possess intrinsically disordered regions. 
 
4.3.2 Disordered regions of full length NDE1 and NDEL1 
Various programs exist in order to predict disorder based on the amino acid sequence 
of a protein.  As many of these work by comparing the amino acid sequence to large 
datasets of proteins known to have such intrinsic disorder, it is difficult to generate 
an independent dataset with which to analyse their accuracy.  One technique which 
can be used to minimise the false positive rate of such analyses, however, is to 
analyse the same protein with a variety of different disorder prediction programs, 
which define disorder in a variety of different ways, and to look for regions which 
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are consistently predicted to be disordered by a majority of the programs (Dosztányi 
and Tompa 2008). 
 
The amino acid sequences of NDE1-SSSC and NDEL1-PLSV were entered into nine 
online predictors of protein disorder (MacCallum; Linding et al. 2003; Ward et al. 
2004; Coeytaux and Poupon 2005; Dosztányi et al. 2005b, a; Obradovic et al. 2005; 
Prilusky et al. 2005; Peng et al. 2006).  Based on these results, a consensus was 
determined as to whether each amino acid position is predicted to be ordered or 
disordered in each of the two proteins.  These results are shown in figure 4.3.A. 
 
The predicted pattern of order and disorder in NDE1 and NDEL1 is similar.  Each 
has a short predicted region of disorder at their immediate N-terminus, followed by 
two more substantial ones in the C-terminal half of the protein.  Interestingly, these 
regions all corresponds to regions of poor sequence homology between NDE1 and 
NDEL1 (see figure 1.3.A).  It therefore appears that the location of disordered 
regions in NDE1 and NDEL1 is evolutionarily conserved, while the exact amino acid 
composition of these regions is not.  These variations in the disordered regions could 
potentially lead to differences in the functions of the two proteins. 
 
4.3.3 Disorder variation across the full length isoforms 
The complete amino acid sequences of NDE1-KMLL, NDE1-KRHS and NDEL1-
FMGQ were next analysed using the disorder predictors, the C-terminal regions of 
which are shown in figure 4.3.B.  Comparing these to the NDE1-SSSC and NDEL1-
PLSV, variations in the level of disorder at the isoform specific C-terminal regions 
can be seen.  Specifically a short predicted ordered region near the C-terminus of 
NDE1-SSSC is reduced in NDE1-KMLL and absent completely from NDE1-KRHS.  
Additionally, while NDEL1-PLSV has a disordered C-terminus, NDEL1-FMGQ has 
an ordered one. 
 
4.3.4 Disorder in the short NDE1 isoforms 
Given that much of the amino acid sequence of the NDE1-S2 isoform is not 
conserved in the full length variants (see figure 3.1.A), its sequence was also  
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Sequence  ANDDLERAKRATIVSLEDFEQRLNQAIERNAFLESELDEKESLLVSVQRLKDEARDLRQE 
Consensus ------------------------------------------------------------ 
DisEMBL HL -------------------------------DDDDDDDDD-------------------- 
DisEMBL L/C   ------------------------------------------------------------ 
DisEMBL R465  ------------------------------------------------------------ 
DISO-PRED ------------------------------------------------------------ 
DISPROT VSL2  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED ------------------------------------------------------------ 
FoldIndex     ------------------------------------------------------------ 
IUPRED   ------D----------------------DD-------------------------DDDD 
PreLink ------------------------------------------------------------ 
                     130       140       150       160       170       180 
 
Sequence      LAVRERQQEVTRKSAPSSPTLDCEKMDSAVQASLSLPATPVGKGTENTFPSPKAIPNGFG 
Consensus -----DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL HL --DDDDDDDDDDDDDDDDDDDDD------------------------------------- 
DisEMBL L/C   --------DDDDDDDDDDDDDDDDD-------DDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL R465  ---DDDDDDDDDDDDDDDDDDDDD------------------------------------ 
DISO-PRED -----DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DISPROT VSL2  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED --------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
FoldIndex     ----------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
IUPRED   DDDDDDDDDDDDDDDDDDDDDDDD-D--D----DDDDDDDDDDDDDDDDDDDDDDDDDDD 
PreLink ------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD------------- 
                     190       200       210       220       230       240 
 
Sequence    TSPLTPSARISALNIVGDLLRKVGALESKLAACRNFAKDQASRKSYISGNVNCGVLNGNG 
Consensus DDDD-----------------------------------------------------DD- 
DisEMBL HL ------------------------------------------------------------ 
DisEMBL L/C   DDDDDDDD---------------------------------DDDDDDDDDDDDDDDDDDD 
DisEMBL R465  ------------------------------------------------------------ 
DISO-PRED DDDDDD-------------------------------DDDDDDDDDDDDDDDDDDDDDDD 
DISPROT VSL2  DDDD-----------------------------------DDDDDD------------DDD 
DRIP-PRED DDDDDDDD------------------------------DDDDDDDDDDDDDDDDDDDDDD 
FoldIndex     DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD------D------D------ 
IUPRED   DDD------------------------------------------------------DD- 
PreLink ------------------------------------------------------------ 
                     250       260       270       280       290       300 
 
Sequence      TKFSRSGHTSFFDKGAVNGFDPAPPPPGLGSSRPSSAPGMLPLSV 
Consensus --DDDDDDD------------DDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL HL ----------------------------DDDDDDDDDDDDDDDDD 
DisEMBL L/C   DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL R465  ---------------------------DDDDDDDDDDDDDDDDDD 
DISO-PRED DDDDDDDDDDD----------DDDDDDDDDDDDDDDDDD-----D 
DISPROT VSL2  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED DDDDDDDDD-------------DDDDDDDDDDDDDDDD------- 
FoldIndex     --DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
IUPRED   ------DD-----DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD-- 
PreLink -----------------------DDDDDDDDDDDDDDDDDDDDDD 
                     310       320       330       340 
 
 
Figure 4.3.A: Predicted regions of order (-) and disorder (D) in a) NDE1-
SSSC and b) NDEL1-PLSV.  Predictions were made using nine separate 
programs and for each amino acid a consensus of either ordered or 
disordered was determined (shown in blue). 
 
 





Sequence     GERRPSSTSVPLGDKGLDTSCRWLSKSTTRSSSSC 
Consensus  DDDDDDDDDDDDD----------DDDDDDDDDDDD 
DISEMBL HL  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL L/C  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL R465 DDDDDDDDDDD-------------DDDDDDDDDDD 
DISOPRED     DDDDDDDDDDDD-----------DDDDDDDDDDDD 
DISPROT VSL2 DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED  DDDDDDDDDDDDD----------DDDDDDDDDDDD 
FoldIndex    ----------------------------------- 
IUPRED  DDDDDDDDDDDDD-------D-D----------DD 
PreLink  DDDDDD-----------------DDDDDDDDDDDD 




Sequence     GERRPSSTSVPLGDKGLGKRLEFGKPPSHMSSSPLPSAQGVVKMLL 
Consensus  DDDDDDDDDDDDDDDDD-----DDDDDDDDDDDDDDDDDDDDDDDD 
DISEMBL HL  DDDDDDDDDDDDDDDDD------DDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL L/C  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL R465 DDDDDDDDDD---------------DDDDDDDDDDDD--------- 
DISOPRED     DDDDDDDDDDD-----------DDDDDDDDDDDDDDDDD------- 
DISPROT VSL2 DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED  DDDDDDDDDDDDDDDD-------DDDDDDDDDDDDDDD-------D 
FoldIndex    DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
IUPRED  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD---- 
PreLink  DDDDDD-----------------DDDDDDDDDDDDDDDDDDDDDDD 




Sequence     GERRPSSTSVPLGDKGSVPSNKPLAGGENPPAPGKRHS 
Consensus  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DISEMBL HL  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL L/C  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL R465 DDDDDDDDDDDDDDD---------DDDDDDDDDDDDDD 
DISOPRED     DDDDDDDDDDD----------DDDDDDDDDDDDDDDDD 
DISPROT VSL2 DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED  DDDDDDDDDDDD----DDDDDDDDDDDDDDDDDDDDDD 
FoldIndex    DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
IUPRED  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
PreLink  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 












Sequence     TKFSRSGHTSFFDKGAVNGFDPAPPPPGLGSSRPSSAPGMLPLSV 
Consensus  --DDDDDDD------------DDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL HL  ----------------------------DDDDDDDDDDDDDDDDD 
DisEMBL L/C  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL R465 ---------------------------DDDDDDDDDDDDDDDDDD 
DISO-PRED  DDDDDDDDDDD----------DDDDDDDDDDDDDDDDDD-----D 
DISPROT VSL2 DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED  DDDDDDDDD-------------DDDDDDDDDDDDDDDD------- 
FoldIndex    --DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
IUPRED  ------DD-----DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD-- 
PreLink  -----------------------DDDDDDDDDDDDDDDDDDDDDD 




Sequence     TKFSRSGHTSFFDKGQEKVIFPTLFMGQ 
Consensus  D-----DDDD------------------ 
DisEMBL HL  ------DDDDDDDDDDDDDDDDDDDDDD 
DisEMBL L/C  DDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL R465 ---------------------------- 
DISO-PRED  DDDDDDDDDD------------------ 
DISPROT VSL2 DDDDDDDDDDDDD------------DDD 
DRIP-PRED  DDDDDDDDDDDD--------------DD 
FoldIndex    D--------------------------- 
IUPRED  ------D--------------------- 
PreLink  ---------------------------- 
 
Figure 4.3.B: Disorder predictions for the unique C-terminal regions of the full 
length a) NDE1 and b) NDEL1 isoforms.  All amino acid sequences are 
shown from residue 301 to the C-terminus. 
 
analysed using the disorder prediction programs.  Results are shown in figure 
4.3.C.a.  With the exception of a few amino acids at the extreme N-terminus, this 
splice form does not appear to have any novel predicted regions of disorder.  It does 
however possess the central disordered region seen in the full length isoforms. 
 
The potential for disorder in the theoretical NDE1-S1 proteins was also investigated.   
NDE1-S1b had short disordered regions at each end of the protein (see figure 
4.3.C.a).  NDE1-S1a had two distinct regions of disorder (see figure 4.3.C.c) which 
correspond to the central and C-terminal disordered regions of full-length NDE1-
KMLL.
 





DisEMBL HL DDDDDDDDDDDDDDD-------DDDDDDDDDD---------------------------- 
DisEMBL L/C   DDDDDDDDDDDDDDDD-------------------------------------------- 
DisEMBL R465  ------------------------------------------------------------ 
DISO-PRED DDDD—D------------------------------------------------------ 
DISPROT VSL2  DDDDDDDDDDDDDDDDDD------------------------------------------ 
DRIP-PRED DDDD----------------------DDDDDDDDD---------DD-------------- 
FoldIndex     ------------------------------------------------------------ 
IUPRED   ------------------------------------------------------------ 
PreLink ------------------------------------------------------------ 




DisEMBL HL ---------------------------------------------------------DDD 
DisEMBL L/C   ------------------------------------------------------------ 
DisEMBL R465  ---------------------------------------------------------DDD 
DISO-PRED ---------------------------------------------------------DDD 
DISPROT VSL2  ------------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED ------------------------------------------------------------ 
FoldIndex     ---------------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
IUPRED   -------------------------DD------------DD—-DD-----D-DDDDDDDD 
PreLink ----------------------------------------------------------DD 




DisEMBL HL DDDDDDDDDDDDDDDDDD---------DDDDDDDDDDDDDDDDDDDD------------- 
DisEMBL L/C   -DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL R465  DDDDDDDDDDDDDDDDDDDDDD-------------------------------------- 
DISO-PRED DDDDDDDDDDDDDDDDDDDDDDDD------DDDDDDDDDDDDDDDDDDDDDDDDDD---- 
DISPROT VSL2  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED ---DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
FoldIndex     DDDDDDDDDDDDDDDDDDDDDDDDDDDDD------------------------------- 
IUPRED   DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
PreLink DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD----------------- 




DisEMBL HL --------------------------------------------------------- 
DisEMBL L/C   DDDDD-------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL R465  --------------------------------------------------------- 
DISO-PRED --------------------------------------------------------- 
DISPROT VSL2  DDD----------------------------------------------------DD 
DRIP-PRED DDDD-------------------------DD-----------------DDDDDDDDD 
FoldIndex     --------------------------------------------------------- 
IUPRED   D-------------------------------------------------------- 
PreLink --------------------------------------------------------- 















Full length ------------------------------------------------DDDDDDDDDDDD 
DisEMBL HL ---------------DDDDDDDDDDD----------------------DDDDDDDDDDDD 
DisEMBL L/C   ----------------------------------------------------DDDDDDDD 
DisEMBL R465  ------------------------------------------------DDDDDDDDDDDD 
DISO-PRED DDDDDDD------------------------------------------DDDDDDDDDDD 
DISPROT VSL2  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED -----------------------------------------------------DDDDDDD 
FoldIndex     DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
IUPRED   DDDDDDDD-DDDD-DDDDDDDDDDDDDDDDDDDDDDDD--DDDDDDDDDDDDDDDDDDDD 
PreLink -------------------------------------------------DDDDDDDDDDD 




Full length DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD-----DDDD------------- 
DisEMBL HL DDDDDDDDD---------DDDDDDDDDDDDDDDDDDDD---------------------- 
DisEMBL L/C   DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD---- 
DisEMBL R465  DDDDDDDDDDDDD----------------------------------------------- 
DISO-PRED DDDDDDDDDDDDDD--------DDDDDDDDDDDDDDDDDDDDDDD--------------- 
DISPROT VSL2  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD----- 
DRIP-PRED DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD-- 
FoldIndex     DDDDDDDDDDDDDDDDDDDD---------------------------------------- 
IUPRED   DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
PreLink DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD-------------------------- 




Full length -------------------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL HL -------------------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL L/C   ------------------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL R465  -------------------------------DDDDDDDDDDDDDDDDDDDDDDDDDDD-- 
DISO-PRED -------------------------------DDDDDDDDDDDDDDDDDDDDDDDDDDD-- 
DISPROT VSL2  ----------------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED -----------------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
FoldIndex     -----------------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
IUPRED   -------------------DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
PreLink ---------------------------------DDDDDDDDDDDDDDDDDDDDD------ 




Full length DDDDD-----DDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL HL DDDDD------DDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL L/C   DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL R465  -------------DDDDDDDDDDDD--------- 
DISO-PRED ----------DDDDDDDDDDDDDDDDD------- 
DISPROT VSL2  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED D-----------DDDDDDDDDDDDDD-------- 
FoldIndex     DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
IUPRED   DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD---- 
PreLink -----------DDDDDDDDDDDDDDDDDDDDDDD 











Full length DDDDDDDDDDDDD----------------------------------------------- 
DisEMBL HL DDDDDDDDDDDDDDD-----------------------------------------DDDD 
DisEMBL L/C   DDDDDDDDDDDD------------------------------------------------ 
DisEMBL R465  DDDDDDDDDDDDDD---------------------------------------------- 
DISO-PRED DDDDDD-D---------------------------------------------------- 
DISPROT VSL2  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED DDDDDDDD---------------------------------------------------- 
FoldIndex     DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
IUPRED   DDDDDDDDDDDDDD----DDDDDD----DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
PreLink ------------------------------------------------------------ 





Full length ------------------- 
DisEMBL HL DDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DisEMBL L/C   -----------------DDDDDDDDDDD 
DisEMBL R465  ---------------------------- 
DISO-PRED ---------------------DDDDDDD 
DISPROT VSL2  DDDDDDDDDDDDDDDDDDDDDDDDDDDD 
DRIP-PRED ---------------------DD--DDD 
FoldIndex     DDDDDDDDDDDDDDDDDDDDDDDDDDDD 
IUPRED   DDDDDDDDDDDDDDDDDD----D--D-- 
PreLink ---------------------------- 
                     70        80 
Figure 4.3.C: Predicted regions of order (-) and disorder (D) in a) NDE1-S2, 
b) NDE1-S1a and c) NDE1-S1b.  For the NDE1-S1 isoforms, the 
order/disorder in the corresponding sections of full-length NDE1-KMLL is 
shown in red for comparison.  Predictions were made using nine separate 
programs and for each amino acid a consensus of either ordered or 
disordered was determined (shown in blue). 
 
 
4.4 Phosphorylation potential of NDE1 and NDEL1 
 
4.4.1 Introduction to NDE1 and NDEL1 phosphorylation 
Both NDE1 and NDEL1 have been predicted to have multiple phosphorylation sites 
(Feng et al. 2000; Kitagawa et al. 2000; Niethammer et al. 2000; Sweeney et al. 
2001), and a number of these have been experimentally demonstrated (Niethammer 
et al. 2000; Yan et al. 2003; Rush et al. 2005; Beausoleil et al. 2006; Larkin et al. 
2007; Mori et al. 2007).  These are all summarised in table 4.4.A.  The known effects  
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Site Protein Kinases Reference 
S198 NDEL1 cdc2 
(Niethammer et al. 2000; Mori et al. 
2007) 
T219 NDEL1 cdc2, erk2 
(Niethammer et al. 2000; Yan et al. 
2003; Mori et al. 2007; Toyo-Oka et 
al. 2008) 
S231 NDEL1 cdc2 
(Niethammer et al. 2000; Mori et al. 
2007) 
S242 NDEL1 cdc2 (Yan et al. 2003) 
T245 NDEL1 cdc2, erk2 (Yan et al. 2003) 
S251 NDEL1 Aurora-A kinase (Mori et al. 2007) 
T279 NDE1 ? (Rush et al. 2005) 
S282 NDE1 ? (Beausoleil et al. 2006) 
* NDE1 cdc2 (Yan et al. 2003) 
? NDEL1 cdk5 (Niethammer et al. 2000) 
? NDE1 erk2 (Yan et al. 2003) 
 
Table 4.4.A: Known phosphorylation sites of the NDE1 and NDEL1 proteins 
from the literature.  * NDE1 is known to be phosphorylated by cdc2 at one or 
more sites out of S196, T215, S231, S239 and T246, which correspond to 
S198, T219, S231, S242 and T245 of NDEL1. 
 
 
of these phosphorylations in NDEL1 vary and include regulating its protein-protein 
interactions and cellular localisation (Niethammer et al. 2000; Yan et al. 2003; Toyo-
Oka et al. 2005; Hirohashi et al. 2006a; Hirohashi et al. 2006b).  Some are also 
known to be specific to certain points in the cell cycle (Toyo-Oka et al. 2005; Mori et 
al. 2007).  It still remains to be determined, however, whether these phosphorylations 
are conserved between NDE1 and NDEL1, and we cannot rule out the existence of 
additional phosphorylation sites. 
 
4.4.2 ScanSite analysis of full length NDE1 and NDEL1 
In order to predict potential phosphorylation and other functional sites, the amino 
acid sequences of all five full length NDE1/NDEL1 isoforms were analysed using 
the online program ScanSite Motif Scan (Obenauer et al. 2003).  The results are 
shown in table 4.4.B.  A large number of potential phosphorylation sites were 
predicted, including two that have been demonstrated experimentally (Yan et al. 
2003).  Interestingly, no more than a third of these are conserved between NDE1 and 
NDEL1, in spite of their high amino acid similarity.  Additionally, each of the unique  
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 NDE1 NDE1 NDE1 NDEL1 NDEL1 
 SSSC KMLL KRHS PLSV FMGQ 
GSK3 Kinase (kinase site) S10 S10 S10 - - 
PKC delta (kinase site) - - - S23 S23 
PKC epsilon (kinase site) - - - S29 S29 
DNA PK (kinase site) T32 T32 T32 - - 
ATM kinase (kinase site) T32 T32 T32 - - 
Calmodulin dependent kinase (kinase 
site) - - - S95 S95 
ATM kinase (kinase site) - - - S102 S102 
DNA PK (kinase site) - - - S102 S102 
PKC delta (kinase site) T131 T131 T131 T132 T132 
PKA (kinase site) T131 T131 T131 T132 T132 
Erk D-domain (kinase binding group) - - - V134 V134 
PKC epsilon (kinase site) S134 S134 S134 - - 
Casein kinase 2 (kinase site) S154 S154 S154 S155 S155 
GSK3 Kinase (kinase site) T191 T191 T191 - - 
Erk1 (kinase site) - - - S198 S198 
Abl SH3 (SH3 site) - - - P217 P217 
Cdk5 (kinase site) T215 T215 T215 - - 
Cdc2 kinase (kinase site) T215 T215 T215 *T219* T219 
Erk1 (kinase site) T228 T228 T228 - - 
PKC alpha/beta/gamma (kinase site) S231 S231 S231 - - 
Erk1 binding (kinase binding site) - - - P232 P232 
GSK3 Kinase (kinase site) - - - T241 T241 
Casein kinase 1 (kinase site) T243 T243 T243 - - 
Cdk5 (kinase site) T246 T246 T246 T245 T245 
Cdc2 kinase (kinase site) T246 T246 T246 *T245* T245 
Erk1 (kinase site) T246 T246 T246 T245 T245 
PKA (kinase site) S306 S306 S306 - - 
Ajt kinase (kinase site) S309 S309 S309 - - 
Erk D-domain (kinase binding group) V310 V310 V310 - - 
PKC epsilon (kinase site) - - - S310 S310 
PKC delta (kinase site) - - - S310 S310 
PKC alpha/beta/gamma (kinase site) - - - - S310 
Clk2 kinase (kinase site) - - - - S310 
Itk SH3 (SH3 site) - - - P324 - 
Nck 2nd SH3 (SH3 site) - - - P324 - 
Src SH3 (SH3 site) - - - P324 - 
Cb1-assocaited protein SH3 (SH3 site) - - - P327 - 
PKC alpha/beta/gamma (kinase site) T328 - - - - 
GSK3 Kinase (kinase site) - - - S331 - 
Itk SH3 (SH3 site) - - P331 - - 
Nck 2nd SH3 (SH3 site) - - P331 P332 - 
14-3-3 (pS/T binding group) - - - S336 - 
 
Table 4.4.B:  Predicted phosphorylation sites and functional residues of full 
length NDE1 and NDEL1 isoforms, according to Scansite (Obenauer et al. 
2003) on a stringency setting of “Medium” (normal type) or “High” (bold).  
 
  129    
Conservation across orthologues of NDE1 (green), NDEL1 (yellow), both 
(blue) or between individual isoforms only (purple) are indicated.  * 
Phosphorylation has been demonstrated experimentally (Yan et al. 2003). 
 
 
C-termini is distinct in its predicted functional sites from the others, although one 
potential SH3-binding site appears to be shared between the NDE1-KRHS and 
NDEL1-PLSV isoforms. 
 
4.4.3 Many of the potential phosphorylation sites are evolutionarily 
conserved 
Potential phosphorylation sites and other motifs that are conserved throughout 
various species are likely to serve an evolutionarily conserved function in vivo.  The 
amino acid sequences of homologues of NDE1-KMLL and NDEL1-PLSV from 
various species were therefore analysed using ScanSite.  The majority of the 
predicted sites are conserved across most of the mammals studied, and some are seen 
in additional species (table 4.4.C).  
 
 
4.4.4 Phosphorylation of the short NDE1 isoforms 
The amino acid sequences of NDE1-S2, NDE1-S1a and NDE1-S1b were also 
investigated using ScanSite (see table 4.4.D).  All three proteins are predicted to be 
phosphorylated in the same manner as the corresponding sections of full length 
NDE1.  In addition, NDE1-S2 is predicted to contain two unique phosphorylatable 









         




Site / Motif Human Monkey Cow Mouse Rat Chicken Xenopus 
Casein kinase 2 S10 S10 S10 S10 S10 - - 
DNA PK T32 T32 T32 T32 T32 - - 
ATM kinase T32 T32 T32 T32 T32 - - 
PKC delta T131 T131 T131 T131 T131 - T132 
PKA T131 T131 T131 T131 T131 - T132 
PKC epsilon S134 S134 S134 S134 S134 - S135 
Casein kinase 2 S154 S154 S154 S154 S154 S155 S155 
GSK3 Kinase T191 T191 T191 - T191 - - 
Cdk5 T215 T215 T215 T215 T215 T216 - 
Cdc2 kinase T215 T215 T215 T215 T215 T216 - 
Erk1 T228 T228 T228 T228 T228 - S231 
PKC alpha/beta/gamma S231 S231 S231 - - - S234 
Casein kinase 1 T243 T243 T243 T243 - - - 
Cdk5 T246 T246 T246 T246 T246 - T249 
Cdc2 kinase T246 T246 T246 T246 T246 T247 T249 
Erk1 T246 T246 T246 T246 T246 - - 
PKA S306 S306 - - - - - 
Ajt kinase S309 S309 - - - - - 
Erk D-domain V310 V310 V310 V310 V310 - - 
 
Table 4.4.C:  Predicted phosphorylation and other functional sites in orthologues of a) NDE1-KMLL and b) NDEL1-PLSV from 
various species.  All sites shown were  predicted by Scansite (Obenauer et al. 2003) on a stringency setting of “Medium”.  
Sites in bold were also detectable using the “High” setting.  Blue indicates conservation in primates, yellow conservation in 
other mammals and green conservation in other species.  Functional sites found only in non-human species were excluded 
from the table. 
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b)  NDEL1-PLSV 
Site / Motif Human Chimp Orangutan Monkey Dog Rabbit Mouse Rat Chicken Xenopus Zebrafish Bee 
PKC delta S23 S23 S23 S88 S87 S23 S23 S23 S23 - - - 
PKC epsilon S29 S29 S29 S94 S93 S29 S29 S29 S29 - - - 
Calmodulin-dependent 
kinase S95 S95 S95 S160 S159 S95 S95 S95 - - - - 
ATM kinase S102 S102 S102 S167 S166 S102 S102 S102 S102 - - - 
DNA PK S102 S102 S102 S167 S166 S102 S102 S102 S102 - - - 
PKC delta T132 T132 T132 T197 T196 T132 T132 T132 T132 T132 T132 - 
PKA T132 T132 T132 T197 T196 T132 T132 T132 T132 T132 T132 - 
Erk D-domain V134 V134 V134 V199 V198 V134 V134 V134 V134 V134 - - 
Casein kinase 2 S155 S155 S155 S220 S219 S155 S155 S155 S155 S155 S155 S151 
Erk1 S198 S198 S198 S263 S262 S198 S198 S198 S198 S198 S198 - 
Abl SH3 P217 P217 P217 P282 P281 P217 P217 P217 P217 - P217 - 
Cdc2 kinase T219 T219 T219 T284 T283 T219 T219 T219 T219 - T219 - 
Erk1 binding P232 P232 P232 P297 P296 P232 P232 P232 P232 P232 - - 
GSK3 Kinase T241 T241 T241 T306 - T241 T241 T241 T241 T241 - - 
Cdk5 T245 T245 T245 T310 - T245 T245 T245 T245 T245 T246 T257 
Cdc2 T245 T245 T245 T310 T309 T245 T245 T245 T245 T245 T246 T257 
Erk1 T245 T245 T245 T310 T309 T245 T245 T245 T245 T245 T246 T257 
PKC S310 S310 S310 S375 S374 S310 - - - - - - 
PKC S310 S310 S310 S375 S374 S310 T310 T310 - - - - 
Itk P324 P324 P324 - P324 P324 P324 P324 - - - - 
Nck 2nd SH3 P324 P324 P324 - P388 P324 P324 P324 - - - - 
Src SH3 P324 P324 P324 - P388 P324 P324 P324 - - - - 
Cb1-assocaited protein SH3 P327 P327 P327 - P391 P327 P327 P327 - - - - 
GSK3 Kinase S331 S331 S331 - S395 S332 S331 S331 - S332 - - 
Nck 2nd SH3 P332 - - P387 - - - - - P335 - - 
14-3-3 binding S336 S336 S336 S403 S400 S336 S336 S336 S334 - S335 - 131 
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 KMLL S1a S1b S2 
Casein kinase 2 (kinase site) S10 - S10 - 
DNA PK (kinase site) T32 - T32 - 
ATM kinase (kinase site) T32 - T32 - 
PKC alpha/beta/gamma (kinase site) - - T77 - 
Cdk5 (kinase site) - - - S10 
Cdc2 kinase (kinase site) - - - S10 
PKC zeta (kinase site) - - - S22 
PKC delta (kinase site) T131 - - - 
PKA (kinase site) T131 - - - 
PKC epsilon (kinase site) S134 - - - 
Casein kinase 2 (kinase site) S154 S22 - S91 
GSK3 Kinase (kinase site) T191 T59 - T128 
Cdk5 (kinase site) T215 T83 - T152 
Cdc2 kinase (kinase site) T215 T83 - T152 
Erk1 (kinase site) T228 T96 - T165 
PKC alpha/beta/gamma (kinase site) S231 S99 - S168 
Casein kinase 1 (kinase site) T243 T111 - T180 
Cdk5 (kinase site) T246 T114 - T183 
Cdc2 kinase (kinase site) T246 T114 - T183 
Erk1 (kinase site) T246 T114 - T183 
PKA (kinase site) S306 S174 - - 
Ajt kinase (kinase site) S309 S177 - - 
Erk D-domain (kinase binding group) V310 V178 - - 
 
Table 4.4.D:  Predicted phosphorylation and other functional sites in full 
length NDE1-KMLL, NDE1-S1a, NDE1-S1b and NDE1-S2.  All sites shown 
were predicted by Scansite (Obenauer et al. 2003) on a stringency setting of 
“Medium” (normal type) or “High” (bold). 
 
 
4.5 Specific NDE1 isoforms have potential nuclear localisation signals 
 
4.5.1 Introduction to nuclear localisation 
To date most studies have described NDE1 and NDEL1 as being found at the 
cytoplasm or at the centrosome (see section 1.3.3.1), however two papers have  
mentioned low levels of NDE1 and/or NDEL1 being seen at the nucleus (Yan et al. 
2003; Suzuki et al. 2007).  In both papers antibodies were used that were unable to 
differentiate between NDE1 and NDEL1.  One interpretation of these results is that 
one or more isoforms of NDE1 or NDEL1 localise to the nucleus, but that these 
isoforms are undetectable using the antibodies used to date by other research groups.  
An indication of whether a protein has the ability to enter the nucleus can be gained 
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by searching for a nuclear localisation signal (NLS).  These are conserved motifs 
consisting of a number of basic amino acids which are recognised by karyopherins, a 
class of transport receptor which are required to transport proteins through the 
nuclear pore complex and into the nucleus (Sorokin et al. 2007). 
 
4.5.2 NDE1-KMLL may localise to the nucleus 
Analysis of the full length sequences of the NDE1 isoforms using the online signal 
prediction programs PredictNLS and PSORT II (Nakai and Horton 1999; Cokol et al. 
2000) detected no potential canonical NLS sequences.  However, NDE1-KMLL does 
contain an RRX10KX3KR motif that is very similar to a bipartite NLS (Dinesh 
Soares, personal communication).  Such an NLS typically consists of two basic 
residues, followed 10 residues later by at least three basic amino acids out of five 
(Robbins et al. 1991).  The NDE1-KMLL motif follows a similar pattern, except that 
its C-terminal three basic amino acids are spread over six.  Searching the NLS 
database (Nair et al. 2002), it can be seen that this exact motif is also present in at 
least two other proteins, CHDM and HIPK2, both of which are also found in the 
nucleus (Kim et al. 1999; Khattak et al. 2002).  In the latter example the motif 
contains the only basic residues of a 61 amino acid fragment which is known to be 
essential for nuclear localisation.  When a more generalised (K/R)2X10(K/R)X3(K/R)2 
motif is searched for, the NLS database yields 620 proteins from various species 
(including multiple orthologues of some proteins), of which 76.6% are known to be 
found at the nucleus.  This proportion of nuclear proteins is considerably higher than 
that across the complete database of 21,498 proteins, of which 21.9% are known to 
localise to the nucleus (Nair et al. 2002). 
 
It therefore appears likely that this motif is capable of acting as a functional NLS.  
Interestingly, the final two basic amino acids of the NDE1-KMLL NLS are found 
only in the isoform-specific exon 8 and not in any other NDE1 or NDEL1 isoform 
examined.  Looking at homologues of NDE1 from other species, these basic residues 
are conserved in several mammals (although the exact spacing between the basic 
residues varies slightly in rodents) adding evidence that the motif may have an in 
vivo function (figure 4.5). 
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Homo sapiens   RRPSSTSVPLGDKGLGKR 
Pan troglodytes  RRPSSTSVSLGDKGLGKR 
Bos taurus   RRPGGSNVPLGDKGLGKR 
Mus musculus   RRPG--STSVGDKGSGKR 
Rattus norvegicus  RRPG--STAVGDKGSGKR 
Gallus gallus   ETRMSPHQPLCDTGLVKR 
Xenopus tropicallis  NRLSMASGSSVEKGLIKR 
Aspergillus nidulans TRTQGDSRPSSRTSFSSS 
NDEL1 (Human)    KFSRSGHTSFFDKGAVNG 
 
Figure 4.5: The five basic residues (shown in red) that make up the potential 
NLS in human NDE1-KMLL are seen to be conserved in orthologues from 
several mammalian species.  They are not conserved in orthologues from 
some other species or in human NDEL1-PLSV.  Alignment performed using 
CLUSTALW (Thompson et al. 1994) 
 
 
4.5.3 NDE1-S2 may localise to the nucleus 
Analysis by eye of the NDE1-S2 sequence revealed a PRRXR motif at amino acids 
13-17.  This motif, consisting of a proline followed shortly by three basic residues 
out of four is similar to a classic NLS signal.  It is found in a region that is not 
conserved with any of the full length isoforms.  NDE1-S2 may therefore have a 
unique function in the nucleus.  This motif could be detected using PSORT II, but 
not PredictNLS (Nakai and Horton 1999; Cokol et al. 2000).  A search for “PRRXR” 
on the NLS database yielded 216 proteins (including multiple orthologues of some 
proteins) of which 52.8% are known to localise to the nucleus, a greater than two 
fold enrichment compared to the 21.9% seen in the complete database (Nair et al. 
2002). 
 
4.5.4 No sign of localisation signals in NDEL1 
The amino acid sequences of NDEL1-PLSV and NDEL1-FMGQ were investigated 
for potential NLS sequences, however none were found either by manual 
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4.6 Discussion 
 
4.6.1 The secondary structure of full-length NDE1 and NDEL1 
NDEL1 is known to have a large N-terminal coiled-coil (Derewenda et al. 2007), and 
from this analysis NDE1 is predicted to possess a similar structure.  This coiled-coil 
is known to be the site of self-association in NDEL1 (Sasaki et al. 2000), and also 
contains the LIS1 binding site of both NDE1 and NDEL1 (Feng et al. 2000; Yan et 
al. 2003).  In addition, both proteins are predicted to have a shorter helical or coiled-
coil region near the C-terminus.  This region also appears to be involved in protein 
interactions, with NDEL1 known to bind DISC1 as well as probably cytoplasmic 
dynein heavy chain and dynamitin at this site (Sasaki et al. 2000; Brandon et al. 
2004; Liang et al. 2004).  This structure is very well conserved between NDE1 and 
NDEL1, in spite of poor conservation in the surrounding regions, implying it to be of 
evolutionary significance. 
 
In both proteins, the two coiled-coils/helices appear to be separated by a disordered 
region.  The lack of overlap between predicted helices and predicted disordered 
regions reinforces the validity of both analyses.  This central disordered region could 
theoretically act as a flexible “linker”, potentially allowing the protein to adjust its 
structure to accommodate the interactions of different protein binding partners.  This 
fits well with a previously published observation that “hub” proteins (those with 
numerous protein interactors) frequently have sizable regions of disorder, but that 
their interaction domains themselves are often structured (Kim et al. 2008).  This 
region is known to contain phosphorylation sites in both NDE1 and NDEL1 
(Niethammer et al. 2000; Yan et al. 2003; Mori et al. 2007).  Several proteins may 
also bind in this region, notably 14-3-3ε and katanin p60, the protein products of the 
YWHAE and KATNA1 genes respectively (Toyo-Oka et al. 2003; Toyo-Oka et al. 
2005).  Binding of these proteins could potentially impart structure on this region. 
 
Previously published analyses of the location and function of disordered proteins 
showed that they are most commonly found in the nucleus, however they are also 
enriched among microtubule-bound proteins and in those involved in mitosis, 
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neurogenesis and protein transport (Vucetic et al. 2007; Xie et al. 2007).  Thus the 
identification of disordered regions within NDE1 and NDEL1 fits well with their 
roles in these processes. 
 
The crystal structure of the N-terminal coiled-coil of NDEL1 has already been solved 
(Derewenda et al. 2007).  However, as a consequence of these disordered regions, it 
is unlikely that a complete structure for full length of NDE1 or NDEL1 will be 
producible using these techniques. 
 
It is interesting to note that the helical regions of NDE1 and NDEL1 are 
exceptionally well conserved, suggesting that these regions contain the “core” 
functional elements of the proteins e.g. self association, LIS1 binding and potentially 
dynein, dynactin and/or DISC1 binding.  In comparison, the disordered regions show 
poor amino acid similarity between the two proteins.  In both proteins, the disordered 
regions are of similar length which, combined with the flexible nature of such 
regions, suggests NDE1 and NDEL1 are likely to be of a similar basic structure.  
However any protein interactors which bind in this region, such as 14-3-3ε or katanin 
p60 (Toyo-Oka et al. 2003; Toyo-Oka et al. 2005) may be specific to one or the 
other of NDE1 and NDEL1 and may impose specific three-dimensional 
configurations on the region, thus altering the relative positions of the two helical 
regions.  All of this information is summarised in figure 4.6.A. 
 
4.6.2 NDE1 and NDEL1 are predicted to be heavily phosphorylated 
Full length NDE1 and NDEL1 are both predicted to be phosphorylated by a variety 
of kinases and at a number of different sites.  A summary of all the predicted 
phosphorylation sites and their conservation is shown in table 4.6 and figure 4.6.A.  
Only two of the previously demonstrated phosphorylations (cdc2 at threonine 
residues 219 and 245 of NDEL1) are predicted by this analysis, although changing 
the stringency of the prediction program to “Low” does predict the remaining 
experimentally demonstrated cdc2 sites.  This implies a high false negative rate, and 
also emphasises that experimental data is needed to confirm these predictions. 
 
 





Figure 4.6.A Schematics of the structural and functional regions of a) NDE1 
and b) NDEL1, derived from both this analysis and from published 
experimental evidence.  Isoforms shown are human NDE1-SSSC and 
NDEL1-PLSV.  Data was taken from the following papers: (Feng et al. 2000; 
Niethammer et al. 2000; Sasaki et al. 2000; Toyo-Oka et al. 2003; Yan et al. 
2003; Brandon et al. 2004; Liang et al. 2004; Nguyen et al. 2004a; Hayashi et 
al. 2005; Soukoulis et al. 2005; Toyo-Oka et al. 2005; Guo et al. 2006; 
Hirohashi et al. 2006a; Hirohashi et al. 2006b; Derewenda et al. 2007; Mori et 
al. 2007; Shen et al. 2008b) 
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a) NDE1 
 
Site Potential kinases Conserved Species 
    in NDEL1? conservation 
S10 Casein kinase 2 - ++ 
T32 DNA PK, ATM kinase - ++ 
T131 PKA, PKCδ + +++ 
S134 PKCε - +++ 
S154 Casein kinase 2 + +++ 
T191 GSK3 - ++ 
T215 Cdc2, Cdk5 + ++ 
T228 Erk1 - +++ 
S231 PKCα,β,γ - + 
T243 Casein kinase 1 - ++ 
T246 Cdc2, Cdk5, Erk1 + +++ 
S306 PKA - + 





Site Potential kinases Conserved Species 
    in NDE1? conservation 
S23 PKCδ - ++ 
S29 PKCε - ++ 
S95 CaM kinase - ++ 
S102 ATM kinase, DNA PK - ++ 
T132 PKCδ, PKA + +++ 
S155 Casein kinase 2 + +++ 
S198 Erk1 - +++ 
T219 Cdc2 + +++ 
T241 GSK3 - ++ 
T245 Cdk5, Cdc2, Erk1 + +++ 
S310 PKCδ,ε - ++ 
S331 GSK3 - ++ 
 
Table 4.6:  Summary of predicted phosphorylation sites in full length a) NDE1 
and b) NDEL1.  Kinases in bold type indicates this site was predictable by a 
“High” stringency scan, sites in bold type indicates that this has been 
demonstrated experimentally in the literature.  Species conservation of a 
given site is rated as “+” if it is conserved in primates, “++” if it is conserved in 
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Four potential phosphorylation sites are conserved between NDE1 and NDEL1, all 
of which show good conservation across species, implying that these residues are of 
potential evolutionary importance.  However at least twice as many such predicted 
sites on each protein are not present in the other one, and this includes a number of 
sites with strong species conservation.  Given the high degree of amino acid 
similarity between NDE1 and NDEL1, this could imply that they perform similar 
functions within the cell, but that each has its own evolutionarily conserved 
mechanisms of post-translational regulation. 
 
One result of particular interest it that NDE1 is predicted to be phosphorylated by 
protein kinase A (PKA) on two sites, one of which is also present in NDEL1.  PKA 
is a cAMP-dependent kinase and is regulated by a negative feedback system 
involving PDE4B (see figure 1.2.D), a known DISC1-interactor and independent 
candidate gene for major mental illness (Millar et al. 2005b; Pickard et al. 2007; 
Fatemi et al. 2008; Numata et al. 2008a; Numata et al. 2008b).  One of these sites 
(T131) is well conserved across species and so may play a key regulatory function.  
The other (S306) is found only in primates and so, if genuine, is likely to supply an 
extra level of regulation that has only developed recently in evolution. 
 
Such phosphorylation prediction programs have a high false positive rate, normally 
calculated on a kinase-by-kinase basis.  For example, Scansite on a stringency setting 
of medium has been reported to return 98.1% of serine and threonine residues as not 
being substrate sites for PKA correctly, i.e. 1.9% of such residues are reported as 
false positives.  Therefore as NDE1-SSSC and NDEL1-PLSV contain 58 and 43 
serine/threonine residues respectively, this analysis could be expected to incorrectly 
predict 1.10 sites on NDE1 and 0.87 sites on NDEL1 as being phosphorylatable by 
PKA.  Therefore the fact that NDEL1 is predicted to contain a single PKA 
phosphorylation site is unremarkable, while the fact that NDE1 was predicted to 
contain two such sites warrants further attention. 
 
Such theoretical analysis of phosphorylation should therefore be treated primarily as 
hypothesis-generating, revealing the locations of potential sites which should then be 
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investigated experimentally in order to determine whether or not they are genuine.  
The two putative PKA sites described in NDE1, T131 and S306, will be subjected to 
such an investigation in chapter 7. 
 
4.6.3 Potential roles of the isoform specific C-terminal tails 
In chapter 3, six NDE1/NDEL1 full length isoforms were described, each with a 
unique C-terminal “tail” domain.  To date, no protein has been shown to definitively 
bind NDE1 or NDEL1 in these regions, although for a few proteins it is a possibility 
(Nguyen et al. 2004b; Hirohashi et al. 2006a; Hirohashi et al. 2006b). 
  
Interestingly two of the isoforms, NDE1-KRHS and NDEL1-PLSV are also 
predicted to have isoform-specific aliphatic-proline-X-aliphatic-proline motifs which 
may allow them to bind to proteins with SH3 domains. NDEL1-PLSV is also 
predicted to have a 14-3-3 binding region.  Other potential differences between the 
isoforms include the potential for protein kinase C α, β and γ to phosphorylate 
NDE1-SSSC and glycogen synthase kinase 3 to phosphorylate NDE1-PLSV.  One 
major difference in the NDE1-KMLL isoform is the presence of a putative conserved 
NLS, suggesting that this isoform may perform unique cellular functions within the 
nucleus. 
 
Together these analyses point to the isoform-specific C-terminal tails having little 
effect on the basic functions of NDE1 and NDEL1.  However, they are likely to add 
an extra layer of regulation, in terms of phosphorylation, localisation and potentially 
protein binding, that would affect only a subpopulation of full length NDE1 or 
NDEL1 proteins in any given cell.  In order to determine whether these predicted 
features are genuine or not, the isoforms should be cloned into expression vectors, so 
that these putative isoform-specific features can be investigated experimentally, for 
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4.6.4 A model of full length NDE1 and NDEL1 in the cell 
NDEL1 is well established to exist as a dimer, forming a parallel coiled-coil with its 
N-terminal coiled domain (Efimov and Morris 2000; Sasaki et al. 2000; Maiolica et 
al. 2007).  More recently, it has been shown that NDEL1 dimers can multimerise 
further in vitro, with the coiled coils of two dimers binding in an anti-parallel manner 
to form a tetramer (Derewenda et al. 2007).  The existence of an in vivo tetramer 
remains to be investigated.  NDE1 is also believed to dimerise (Feng and Walsh 
2004), and the high conservation of sequence with NDEL1 suggests tetramerisation 
is also likely.  Due to the conserved structure and amino acid sequence of the 
multimerisation domains of NDE1 and NDEL1, it may even be possible that they 
form heterodimers or heterotetramers.  Regardless, the basic structure of any NDE1 
and/or NDEL1 multimer is likely or be similar.  Figure 4.6.B shows predicted 
models of such dimers and tetramers based on the analyses performed in this chapter 
and experimental evidence from the literature. 
 
The dimer and tetramer both appear to consist of a “backbone” coiled-coil domain, 
the centre of which may bind LIS1.  At the end of the dimer backbone are two 
flexible “arms”, each containing a protein binding helix.  In the tetramer, four such 
arms come out from part-way along the backbone.  The positioning of these arms is  
likely to be phosphorylation-dependent, facilitating the binding of various 
combinations of proteins.  At the tip of each arm is an exposed isoform-specific 
region which is likely to provide regulation.   
 
In a NDE1/NDEL1 heteromultimer, it is also possible that the extreme N-terminus, 
which varies between the two proteins, may provide some additional regulatory 
function, as NDE1 and NDEL1 are predicted to have unique phosphorylation sites in 
this region.  Similarly the unique natures of the NDE1/NDEL1 “arms” may provide 
for protein-specific phosphorylation and binding partner interactions in these regions, 
thus imposing three-dimensional structures on these arms which are specific for 









Figure 4.6.B: A model of NDE1/NDEL1 dimers (a) and tetramers (b).  The 
binding domain information on the diagram incorporates known protein-
binding sites from both NDEL1.  On the tetramer, experimentally 
demonstrated NDEL1 phosphorylation sites are shown.  “LIS1”, “dynein”, 
“dynactin” and “pericentrin” refer to the protein products of the PAFAH1B1, 
DYNC1H1/DYNC2H1, DCTN2 and PCTN2 genes respectively.  Graphics by 
Sarah West. 
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4.6.5 The NDE1-S1 isoforms 
In the previous chapter, PCR was used to detect the NDE1-∆ex3 transcript in several 
cDNA samples.  This demonstrates that at least some examples of such alternatively 
spliced transcripts exist, although such an analysis is not quantitative and does not 
demonstrate whether or not expression is substantial compared to the full length 
NDE1 variants.  In order to investigate potential functions for NDE1-∆ex3, the 
hypothetical NDE1-S1a protein, which uses methionine-133 as an alternate start site 
and is based on this transcript, was analysed.  Alternatively, the NDE1-S1b protein 
could be translated, consisting of exons 1 and 2 of full length NDE1, plus a short 
amount of novel sequence derived from exon 4 (see figure 3.1.D).  This too was 
analysed.  There were no significant predicted secondary structure differences 
between either of these and the corresponding sections of full length NDE1. 
 
The LIS1-binding site on NDEL1 is within amino acids 114-133 (Yan et al. 2003).  
Assuming that this site is conserved in NDE1 (and the amino acid sequence here is 
virtually identical), then it can be presumed that both NDE1-S1a and NDE1-S1b 
should be unable to bind LIS1.  It is thus interesting to note that Nde1-∆ex3 was 
identified in a yeast-2-hybrid screen for mouse Lis1 interactors (Sasaki et al. 2000).  
The reason for this anomaly remains a mystery.  The most likely explanation is that 
the interaction was a false positive, possibly due to contamination by other Nde1 
transcripts. 
 
Additionally, based on the corresponding region on NDEL1 (Sasaki et al. 2000), loss 
of the N-terminal 132 amino acids is likely to prevent NDE1 homodimerisation.  
Should NDE1 possess any cellular functions that can only occur when it is in a 
monomeric state, such as the ability of the NDEL1 monomer to act as an 
oligopeptidase (Hayashi et al. 2005), then these would occur preferentially in the 
NDE1-S1a isoform. 
 
Looking at the NDE1-S1b isoform, based on the known binding sites of full length 
NDE1 and NDEL1 (see table 4.1), it should still be able to form dimers with itself 
and/or full length NDE1.  It would not be able to bind any of the NDE1/NDEL1 
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protein interactors for which a binding site has been described to date, however. 
Theoretically it could therefore compete for dimer-formation with full length NDE1.  
It is difficult to predict the properties of a full length/S1b heterodimer, but interaction 
with LIS1 is unlikely, as it is known to bind preferentially to NDEL1 dimers 
(Tarricone et al. 2004).  It can be theorised that this heterodimer may therefore have 
similar cellular properties to a full length NDE1 monomer, except that it would be 
unable to easily convert to a conventional dimer.  In addition, NDE1-S1b is predicted 
to contain a unique residue which can be phosphorylated by PKC, providing an 
additional layer of regulation. 
 
4.6.6 The NDE1-S2 isoform 
The NDE1-S2 protein is predicted to consist of one or more helical regions (figure 
4.2.D), separated by a central disordered region (figure 4.3.C).  As was the case with 
the full length isoforms, this suggests that it may bind multiple protein interactors 
(probably using both helical regions) with the disordered region allowing for 
additional flexibility.  Many of the potential phosphorylation sites of full length 
NDE1 are conserved in NDE1-S2, implying that post-translational regulation is 
likely to be similar (see table 4.4.D).  The remainder of NDE1-S2 is predicted to be 
sparsely phosphorylated by comparison, although two potential unique 
phosphorylation sites are seen. 
 
No NDE1-interactors have been mapped entirely to the regions contained within 
NDE1-S2, but it is likely that CENPF would be able to bind it (Soukoulis et al. 
2005).  Based on known NDEL1 interactors in this region, it is also possible that 
NDE1-S2 may be able to bind 14-3-3ε and katanin p60 (Toyo-Oka et al. 2003; Toyo-
Oka et al. 2005).  However, based on their established NDEL1 binding sites, dynein, 
LIS1 and DISC1 are all unlikely to be NDE1-S2 interactors (Sasaki et al. 2000; Yan 
et al. 2003; Brandon et al. 2004).  The presence of a putative NLS, however, implies 
that this short variant may well be a nuclear protein and therefore perform different 
functions to those of many of the full length isoforms.  This is consistent with the 
potential loss of binding regions related to microtubule and centrosome-based 
proteins. 
 
  146    
Chapter 5 - The cellular localisation of the 




The cellular localisation of NDEL1 has been well studied, with the protein being 
reported most commonly at the centrosome (Niethammer et al. 2000; Toyo-Oka et 
al. 2003; Toyo-Oka et al. 2005; Guo et al. 2006; Kamiya et al. 2006; Toyo-Oka et al. 
2008), along the microtubule network (Sasaki et al. 2000; Yamaguchi et al. 2004) 
and in cell processes (Niethammer et al. 2000; Sasaki et al. 2000; Toyo-Oka et al. 
2003; Nguyen et al. 2004b; Toth et al. 2008).  Localisation of NDEL1 to the synapse 
(Niethammer et al. 2000) and the mitochondria (Brandon et al. 2005) has also been 
reported. 
 
In contrast, data regarding NDE1 localisation is currently limited to studies which 
made use of over-expressed protein.  Such studies have suggested that, like NDEL1, 
NDE1 is found primarily at the centrosome of interphase cells (Feng et al. 2000; 
Feng and Walsh 2004; Hirohashi et al. 2006a; Hirohashi et al. 2006b), although large 
cytoplasmic puncta of NDE1 have also been reported (Yan et al. 2003).  A thorough 
study of the localisation of endogenous NDE1 has yet to be performed. 
 
5.2 Generation of novel NDE1 and NDEL1 constructs 
 
NDE1-SSSC and NDEL1-PLSV inserts were cloned from pDEST-40-NDE1-SSSC 
and pDEST-40-NDEL1-PLSV vectors (see table 2.3.B), using primers that added a 
BamHI restriction digest site to the 5’ end of the cDNA and a SalI site at the 3’ end 
(see table 2.5.A for primer details).  These inserts and the pGEX-6PI vector, were 
then digested using BamHI and SalI enzymes.  Phenol-chloroform extraction was 
then performed on the clones and vector.  The vector was treated with shrimp 
alkaline phosphatase (SAP) and the clones were inserted into the vector through a 
ligation reaction.  The resulting constructs were named pGEX-6PI-NDE1 and pGEX-
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6PI-NDEL1.  Sequencing was performed in order to confirm the nature of the 
derived plasmid vectors using the NDE1-Seq, NDEL1-Seq and 6PI-Seq primers as 
appropriate.  These vectors when then used to produce GST-NDE1 and GST-NDEL1 
protein in bacteria. 
 
5.3 Investigating NDE1 localisation using commercial antibodies 
 
5.3.1 The localisation of over-expressed NDE1 
Before attempting to analyse the cellular distribution of endogenous NDE1, 
previously published investigations of the expression patterns of over-expressed 
NDE1 were replicated.  V5-tagged NDE1-SSSC was over-expressed in COS7 cells 
and immunocytochemistry was performed.  In these cells NDE1 localised to a 
number of large structures in the cell body (see figure 5.3.A.a) which do not 
resemble any reported NDEL1 localisation.  These structures may therefore be 
protein aggregates, an artefact of protein over-expression, and thus not represent the 
expression pattern of endogenous NDE1.   
  
When the protein was instead over-expressed in HEK293T cells, a pattern more 
resembling that of endogenous NDEL1 was seen (see figure 5.3.A.b).  In these cells 
the V5-NDE1-SSSC took on a primarily diffuse pattern in the cell body, often with a 
large peri-nuclear puncta.  Given the known expression patterns of endogenous 
NDEL1, this is likely to be the centrosome, although co-staining with a marker 
would be required in order to be certain.  Other punctate structures, similar to those 
in COS7 but smaller and less abundant, were sometimes also seen.  A similar 
expression pattern was seen when V5-NDE1-SSSC was instead over-expressed in 
SH-SY5Y cells, except that in approximately 10% of cells there were also signs of 
large nuclear NDE1 structures (see figure 5.3.A.c). 
 
5.3.2 Commercially available NDE1 antibodies cross-react with NDEL1 
A difficulty in studying endogenous NDE1 and NDEL1 is the problem of antibody 
cross-reactivity.  That is, because of their highly similar amino acid sequences, many 
antibodies raised against NDE1 will also detect NDEL1 and vice versa.  Indeed, of  
 







Figure 5.3.A: Localisation of over-expressed V5-NDE1-SSSC in the following 
cell lines: a) COS7, b) HEK293T and c) SH-SY5Y.  Parts (a) and (c) are 
shown at 50% and 70% respectively of the magnification of part (b). 
 
  149    
 
Figure 5.3.B:  Equal amounts of GST-NDE1-SSSC and GST-NDEL1-PLSV 
were subjected to Western blotting.  Three commercial anti-NDE1 antibodies 
showed immunoreactivity to GST-NDEL1 as well as to GST-NDE1.  The anti-
NDEL1 231 antibody was largely specific to GST-NDEL1.  The possibility that 
one or more of these antibodies detects GST cannot be formally excluded. 
 
the four published papers that describe testing the specificity of their NDE1 
antibodies, only two report no NDEL1 cross-reactivity and of these, only one shows 
data to back this up (Yan et al. 2003; Yamaguchi et al. 2004; Stehman et al. 2007; 
Burdick et al. 2008).   
 
The three commercially available anti-NDE1 antibodies (as of time of writing) were 
tested to see whether they cross-reacted with NDEL1 or not.  To do this, equal 
amounts of bacterially produced GST-NDE1-SSSC and GST-NDEL-PLSV were run 
on an acrylamide gel, Western blotted and the membrane stained with the three 
antibodies: ab57430 (Abcam), H00054820-M01 (Abnova) and 10233-1-AP (Protein 
Tech Group).  All three antibodies cross-reacted substantially with NDEL1 (see 
figure 5.3.B) and are therefore of limited use in investigating exogenous NDE1.  In  
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92 EP072192 GRSSKNRDGGERRPS Human 9/15, 14/15 292-306 
93 EP072193 EKPRTPMPSSVEAERT Human 10/15, 13/15 187-201 
94 EP072194 MTYKQRAENTQE Mouse 12/12, 12/12 23-34 
95 EP072195 GKRLEFGKPASEPAS Mouse 11/15, 13/15 316-330 
 
Table 5.4.A:  Peptides used as antigens to produce the NDE1 antibodies 92, 
93, 94 and 95.  In the case of the mouse antibodies, the peptides were from 
the mouse homologue of NDE1-kmll. “Species conservation” indicates amino 
acid identity and similarity between mouse and human NDE1 at this peptide. 
 
contrast the NDEL1 231 antibody (a gift from Dr. Nick Brandon) was largely 
specific for NDEL1. 
 
5.4 Generation and testing of NDE1-specific antibodies 
 
5.4.1 Selection of antigenic peptides and production of antibodies 
In order to investigate endogenous NDE1, four new antibodies were produced, two 
against human NDE1 and two against mouse Nde1.  As stated previously it is always 
a danger that NDEL1 will also be detected by any anti-NDE1 antibody.  In order to 
minimise the risk of this, antibodies were raised against short peptides taken from 
NDE1, rather than using full length NDE1 itself as the antigen.  Several regions of 
NDE1 were therefore identified that shared limited homology with the corresponding 
regions of NDEL1.  These were amino acids 1-37, 65-95, 183-243 and 277-313 of 
human NDE1-SSSC and 1-34, 182-243 and 282-344 of mouse Nde1-KMLL.  From 
these regions, and following consultation with Eurogentec, four antigenic peptides 
were selected.  These are shown in table 5.4.A.  
 
Antibodies were raised and purified by Eurogentec according to the following 
schedule, summarised in figure 5.4.A.  In total four rabbits were immunised: rabbits 
5069 and 5070 were immunised with both of peptides EP072192 and EP072193 (see 
table 5.4.A), while rabbits 5041 and 5042 were immunised with peptides EP072194 
and EP072195.  Further “booster” immunisations, using the same pair of peptides per 
animal, were performed after 2, 4 and 8 weeks.  At 12 weeks the animals were bled.    
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Figure 5.4.A: Schematic of the generation of the four anti-NDE1 antibodies 
 
Samples of the serum from rabbit 5069 and 5070 were pooled together, as was serum 
from rabbits 5041 and 5042.  The remainder of the serum was stored.  The pooled 
serum from rabbits 5069 and 5070 was divided in half.  One half was affinity 
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purified using peptide EP072192 to generate an antibody entitled “92”, while the 
other half was affinity purified using peptide EP072193 to generate antibody 93.  
Similarly, samples of the 5041-5042 pooled serum were affinity purified using either 
peptides EP072194 or EP072195 to generate antibodies 94 or 95 respectively. 
 
Antibodies 92, 93 and 95 were raised against peptides with some similarity between 
human and mouse and so may potentially detect both the human and mouse versions 
of NDE1.  The peptide from which antibody 94 was raised is identical in both 
species and therefore can be expected to react with both. Based on the regions of 
NDE1 that they were raised against, antibody 93 should be able to detect all full 
length NDE1 variants as well as the S1a and S2 short variants.  92 should be able to 
detect all of these except for NDE1 S2.  95 should be specific to NDE1-KMLL and 
NDE1-S1b.  94 should be able to detect S1b and the full length variants only. 
 
5.4.2 The new antibodies detect over-expressed NDE1 
In order to determine whether the antibodies do indeed detect NDE1 in the cell, 
COS7 cells were transfected with V5-NDE1-SSSC and their lysates Western blotted.  
All four of the 92-95 antibodies correctly detected a band of slightly over 37kDa (see 
figure 5.4.B).  To reinforce this result, further transfected cells were analysed, this 
time by immunocytochemistry.  All four antibodies displayed the same expression 
pattern of large cytoplasmic puncta as did an anti-V5 antibody (see figure 5.4.C).  
The V5 antibody also detected additional staining in the cell body that none of the 
anti-NDE1 antibodies could detect and so this may represent non-speific staining.  
Together these results suggest that all four antibodies can detect human NDE1. 
 
5.4.3 Pre-absorption testing of the NDE1 antibodies 
As this work will focus on primarily on human NDE1, the 92 and 93 antibodies were 
subjected to further testing.  As an initial test of antibody specificity, pre-absorption 
tests were carried out.  Antibodies 92 and 93 were incubated over-night at an 
appropriate experimental concentration with their corresponding antigenic peptide 
(EP072192 or EP072193, see table 5.4.A).  As a control, equal amounts of the 
antibodies were also incubated in the same way, but minus the peptide.  Two lanes of  
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Figure 5.4.B: All four of the novel NDE1 antibodies can detect a band of 
approximately the expected size of 38kDa when used to blot COS7 cell 
lysates containing V5-NDE1-SSSC.  Some antibodies also detect weaker 
minor bands, which may represent endogenous NDE1 isoforms. 
 
 
GST-NDE1-SSSC were run on a Western blot per antibody, and then the 92 and 93 
antibodies (both pre-absorbed and mock absorbed) were used to stain them.  Both 
antibodies detected a much stronger signal in the absence of the antigenic peptide 
(see figure 5.4.D).  This demonstrates that the antibodies are capable of being 
blocked by their antigenic peptides and therefore have immunoreactivity to them. 
 
5.4.4 The human NDE1 antibodies do not cross-react with NDEL1 
Previously produced NDE1 antibodies more often than not also detected NDEL1 (see 
section 5.3.2).  Based on the choice of antigenic peptide, these novel anti-NDE1 
antibodies should not detect NDEL1, but in order to be certain equal amounts of 
bacterially expressed GST-NDE1-SSSC and GST-NDEL1-PLSV were Western 
blotted and stained using the 92 and 93 antibodies.  Both antibodies detected the 
GST-NDE1, but not the GST-NDEL1, while an anti-GST antibody detected both 
(see figure 5.4.E).  It therefore appears that these antibodies are specific for NDE1, 
and do not cross-react with NDEL1. 
 
 
         



























Figure 5.4.C: The novel NDE1 antibodies all detect V5-NDE1-SSSC when it is over-expressed in COS7 cells. a) Antibody 92, 
b) Antibody 93, c) Antibody 94, d) Antibody 95. 154 
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Figure 5.4.D: a) The 92 antibody can detect GST-NDE1-SSSC in vitro (-) but 
this effect is considerably weaker when it has been incubated over-night with 
peptide EP072192 (+). This shows that the 92 antibody does indeed bind the 
peptide which it was originally raised against.  b) The peptide EP072193 can 




Figure 5.4.E: The 92 and 93 antibodies can both detect GST-NDE1-SSSC, 
but not GST-NDEL1-PLSV in vitro.  See figure 5.3.B for similar testing of 
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Table 5.4.B: Isoelectric points of different section of the NDE1-SSSC protein 
as determined by ExPASy ProtPatam tool (Gasteiger et al. 2005) 
demonstrate that the N-terminal region of NDE1 is considerably more acidic 
than the C-terminal region. 
 
 
5.4.5 Detection of multiple NDE1 isoforms in SH-SY5Y cells 
In chapter 3, the existence of transcripts encoding various NDE1 and NDEL1 splice 
variants in human brain cDNA was demonstrated.  In order to test if multiple 
isoforms of NDE1 also exist at the protein level, an SH-SY5Y cell lysate (prepared 
by Sheila Christie) was subjected to two-dimensional Western blotting.  SH-SY5Y 
cells are derived from a human neuroblastoma and therefore can serve as a crude 
model for human neuronal tissue.  By blotting in this manner, proteins can be 
separated from each other both by molecular mass (vertically) and by isoelectric 
point (horizontally).  The 93 antibody was then used to investigate NDE1 protein 
expression in the lysate.  Molecular weight and isoelectric points of the NDE1 
isoforms are described in table 3.1.B. 
 
Multiple NDE1 immunoreactive species are indeed detected (see figure 5.4.F.a).  
These include at least two distinct species of approximately the correct size and pI 
value to be NDE1-SSSC, NDE1-KMLL and/or NDE1-KRHS (see figures 5.4.F.b 
and 5.4.E.c).  Note that this technique regularly slightly over-estimated the molecular 
mass of proteins.  Several smaller and more acidic species are also visible.  If it is 
assumed that these also represent genuine NDE1, then given that the N-terminal 
domain of NDE1 is acidic, while the C-terminal end is basic (see table 5.4.B) it can  
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a) 
 
b)     c) 
 
 
Figure 5.4.F: a) 2-D Western blot of an SH-SY5Y cell lysate which has been 
stained using the 93 (NDE1) antibody.  b) Reduced exposure and 
enlargement of the most prominent signal, demonstrating that it includes at 
least two distinct species, shown by white arrows.  c) The theoretical relative 
positions of NDE1-SSSC, KRHS and KMLL on a 2-D Western blot.  These 
closely resemble the pattern of isoforms in part b, suggesting that at least two 
of these isoforms exist in SH-SY5Y cells. 
 
be hypothesised that these NDE1 species lack sections of the C-terminus, either due 
to alternative splicing, post-translational modification or protein degradation.  There 
is no sign of any signal corresponding to either the NDE1-S1a or S2 proteins and so 
it appears that these are not expressed to any significant degree in SH-SY5Y cells.  
The epitope to which this antibody was raised means that it would be unable to detect 










SSSC   
pI 5.10 
37.7kDa 
KRHS    
pI 5.15 
37.8kDa 
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5.5 The cellular localisation of NDE1 determined using specific 
antibodies 
 
5.5.1 Detection of NDE1 nuclear puncta in SH-SY5Y cells using the 93 
antibody 
Initially, the expression pattern of NDE1 was investigated in SH-SY5Y.  The cells 
were fixed using methanol and stained using the 93 antibody, as it was the most avid 
of the two human NDE1 antibodies produced.  A large proportion of cells displayed 
staining at the nucleus, as confirmed by colocalisation with the nuclear stain DAPI, 
an expression pattern not widely reported of NDEL1.  The exact nature of this 
nuclear staining varied.  Many cells displayed one or more large punctate structures 
within the nucleus, while some displayed a more diffuse pattern of smaller NDE1 
puncta.  Some staining was also seen in the cell body, although this tended to be 
diffuse and did not resemble a microtubule-like pattern. 
 
In an attempt to quantify these expression patterns, SH-SY5Y cells were grown on 
coverslips and stained using antibody 93.  Cells with intact nuclei were located and 
photographs taken of them on the microscope without first looking at the NDE1 
expression pattern in these cells.  Photos were taken from seven coverslips, with 10-
14 cells photographed per coverslip, for a total of n=86 cells.  Afterwards these 
images were analysed and every cell that was completely contained in any of the 
images was tallied based on the number of large nuclear puncta present and whether 
or not it contained diffuse background puncta.  Figure 5.5.A shows sample images 
and table 5.5.A shows the data.  87.2% of the cells contained at least one strong 
NDE1 nuclear puncta, with 33.7% having three or more.  In addition, 94.2% had a 
diffuse staining of smaller NDE1 puncta in the nucleus. 
 
In a similar way, n=70 SH-SY5Y cells were counted to determine if their 93 staining 
pattern was primarily nuclear, in the cell body or whether they were similarly 
expressed in both locations.  Figure 5.5.B shows sample images and table 5.5.B 
shows the data.  In 52.9% of cells, NDE1 was primarily in the nucleus, while in only 
15.7% was it seen to be primarily in the cell body. 
 







Figure 5.5.A: Examples of 93 (NDE1) antibody staining in SH-SY5Y cells. a) 
A cell with two strong nuclear puncta.  b) A cell with many strong nuclear 
puncta.  c) A cell (on left) with no strong nuclear puncta. 
 







Figure 5.5.B: Examples of 93 (NDE1) antibody staining in SH-SY5Y cells.  
The amount of diffuse staining in the nucleus (N) and cytoplasm (C) is 
compared.  a) Cells where N > C.  b) Cells where N = C.  c) Cells where N < 
C. 
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Large Puncta Number of cells Percentage of cells 
0 11 12.8 
1 24 27.9 
2 22 25.6 
 3-5 21 24.4 
 6+ 8 9.3 
Diffuse puncta Number of cells Percentage of cells 
Yes 81 94.2 
No 5 5.6 
 
Table 5.5.A:  The proportion of n=86 SH-SY5Y cells in which the NDE1 93 
antibody detected NDE1 puncta in the nucleus. 
 
NDE1 (93) localisation Number of cells Percentage of cells 
Primarily nucleus 37 52.9 
Primarily cell body 22 31.4 
Nucleus and cell body 11 15.7 
 
Table 5.5.B:  The proportion of n=70 SH-SY5Y cells in which the NDE1 93 
antibody detected staining primarily in the nucleus, in the cell body or 
comparably in both locations. 
 
 
As shown in section 5.3.1, when V5-NDE1 was over-expressed in SH-SY5Y cells a 
number of nuclear puncta were seen using an anti-V5 antibody.  These puncta are 
also detectable using the 93 antibody (see figure 5.5.C). 
 
5.5.1.1 The NDE1 93 nuclear structures do not appear to be centromeric 
nucleosomes 
The large NDE1 puncta within the nucleus resemble the expression pattern seen 
using markers of centromeric nucleosomes (Orthaus et al. 2008).  These are histone-
based structures found at the centres of each chromosome and which form the bases 
of kinetochores during mitosis.  The protein CENPA is a core element of this type of 
nucleosome, and antibodies raised against it can be used to identify the locations of 




         




















Figure 5.5.C: The anti-NDE1 93 antibody can detect the V5 punctate structures seen in the nucleus when V5-NDE1-SSSC is 
over-expressed in SH-SY5Y cells (see figure 5.3.A.c) 
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SH-SY5Y cells were examined by immunocytochemistry using the 93 antibody and 
an anti-CENPA antibody (see figure 5.5.D).  The CENPA antibody revealed a 
number of distinct nuclear puncta.  In some of the cells, one or two of the large 
NDE1 nuclear puncta colocalised with CENPA puncta, however, the majority of the 
puncta did not colocalise.  It can therefore be assumed that the NDE1 puncta do not 
simply represent centromeric nucleosomes. 
 
5.5.1.2 The small NDE1 93 nuclear structures are related to splicing speckles 
In addition to the large punctate structures, a more diffuse set of smaller structures 
were seen in the nucleus.  This staining bears some resemblance to that of nuclear 
speckles (Lamond and Spector 2003).  These structures contain machinery related to 
the splicing process and can be detected using antibodies against the Smith antigen, 
which consists of small nuclear riboprotein particles.  Such an antibody, Y12, was 
therefore used to investigate the localisation of splicing speckles in relation to NDE1.  
The staining pattern of antibody 93 showed considerable colocalisation with that of 
the Y12 antibody in SH-SY5Y cells (see 5.5.E).  This colocalisation occurs at 
numerous small semi-diffuse punctate structures throughout the nucleus, and appears 
to account for a large part of the “background” NDE1 nuclear staining.  This 
suggests that NDE1 may have a previously uncharacterised role either in splicing 
itself or in a related process.   
 
5.5.2 A putative NDE1 nuclear structure and the nucleus using the 94 
antibody 
The 94 antibody was raised against a peptide which is found in both human NDE1 
and mouse Nde1.  Its localisation was therefore tested in both human SH-SY5Y and 
mouse NIH-3T3 cells, using methanol to fix both.  In both cell lines, 94 showed a 
nuclear staining pattern (see figure 5.5.F), but interestingly this was distinct from the 
nuclear pattern seen using antibody 93 (as will be discussed in section 5.6.4).  Rather 
than showing an array of puncta in the nucleus, antibody 94 stained between one and 
three small cloud-like structures in each cell.  These bear some resemblance to 
nuclear stress bodies (Biamonti 2004) or potentially Oct1/PTF/transcription  (OPT)  
domains (Pombo et al. 1998). 
 
         




















Figure 5.5.D: NDE1 (93) colocalises with the centromeric nucleosome marker protein CENPA at individual punctate structures 




         




















Figure 5.5.E: The staining pattern of the anti-NDE1 93 antibody consistently overlaps with that of the anti-Smith antigen Y12 
antibody in the nuclei of SH-SY5Y cells, suggesting that NDE1 is present at splicing speckles. 
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Figure 5.5.F: a) Expression pattern of the mouse Nde1 94 antibody in SH-




5.5.3 NDE1 at the nucleus using the 95 antibody 
The mouse Nde1 95 antibody was used initially to stain NIH-3T3 cells.  Strikingly, 
the antibody showed Nde1 to be associated with the nuclear membrane, as well as 
potentially at structures within the nucleus (see 5.5.G.a).  This pattern may be 
specific to NIH-3T3 cells, or may be due to the fact that 95 was raised against an 
epitope found only in one specific splice variant (the mouse orthologue of NDE1-
KMLL).  This was, however, only visible following methanol fixation.  After 
paraformaldehyde fixation however, this nuclear membrane-like pattern was not seen  
 





























Figure 5.5.G: a) Expression pattern of the mouse Nde1 95 antibody in NIH-
3T3 cells following methanol fixation.  b) Expression pattern of the mouse 
Nde1 95 antibody in NIH-3T3 cells following paraformaldehyde fixation. 
 
and instead Nde1 was seen to be primarily cytoplasmic, with some nuclear puncta 
(see figure 5.5.G.b).  Methanol can be more effective at revealing epitopes than 
paraformaldehyde fixation, providing a potential explanation for this effect, although 
whether of not either expression pattern can be replicated in an independent mouse 
cell line should be determined. 
 
When used on SH-SY5Y cells, only a very faint, primarily cytoplasmic stain was 
seen.  This signal is probably non-specific, as the 95 antigenic peptide bears limited 
sequence similarity to the corresponding section of human NDE1. 
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Figure 5.5.H: Expression pattern of the anti-NDE1 92 antibody in SH-SY5Y 
cells. 
 
 Colocalisation Centrosome but No detectable 
   no colocalisation  centrosome 
Number of cells 22 41 50 
Percentage of cells 
with centrosomes 
34.9 65.1 0 
Percentage of total 
cells 
19.5 36.3 44.2 
 
Table 5.5.C: Number of SH-SY5Y cells in which NDE1 (93) colocalised with 
γ-tubulin.  When no colocalisation was seen, cells were counted based on 
whether a centrosome-like γ-tubulin puncta was visible. 
 
 
5.5.4 The 92 antibody does not obviously detect endogenous NDE1 
When antibody 92 was used to stain SH-SY5Y cells, only a faint punctate pattern in 
the cytoplasm was seen with no obvious sign of signal within the nucleus.  The 
pattern of expression does not resemble the published expression patterns of NDEL1 
or over-expressed NDE1 (see figure 5.5.H).  Given the high concentration of this 
antibody required to detect recombinant NDE1 (see table 2.4), which was detected 
considerably more easily by antibody 93, it is possible that the signal seen here does 
not represent endogenous NDE1, and may instead be non-specific staining.  
Similarly, it has not proved possible to detect endogenous NDE1 by Western blotting 
using this antibody.  Due to this uncertainty, the 93 antibody will be used instead for 
the remainder of the thesis. 
 
  170    
 
5.5.5 Endogenous NDE1 associates with the centrosome 
It has been widely reported that NDEL1 is a centrosomal protein and over-expressed 
NDE1 is also known to localise there (see section 1.3.3.1).  To confirm that 
endogenous NDE1 also shows this localisation, SH-SY5Y cells were co-stained with 
the NDE1 93 antibody and an antibody against γ-tubulin, a commonly used marker 
of the centrosome.  In some cells NDE1 was indeed seen to colocalise with γ-tubulin 
(see figure 5.5.I).  Centrosomes were not visible in all cells, however.  Of n=63 cells 
with visible centrosomes, 34.9% had NDE1 present at them (see table 5.5.C). It 
therefore appears that endogenous NDE1 is indeed found at the centrosome, but not 
in all cells. 
 
Colocalisation between NDE1 and γ-tubulin was also seen in some mouse NIH-3T3 
cells using the Nde1 95 antibody (see figure 5.5.J.a), but could not obviously be seen 
using the Nde1 94 antibody (see figure 5.5.J.b). 
 
5.5.6 NDE1 colocalisation with γ-tubulin confirmed using confocal 
microscopy 
In order to further confirm the localisation of endogenous NDE1 to the centrosome in 
SH-SY5Y cells, confocal microscopy was used.  This technique allows the user to 
generate a “stack” of two-dimensional immunofluorescence images from each cell, 
each taken at a different depth.  Therefore it can be determined whether two proteins 
colocalise within the cell’s three-dimensional shape.  It is also possible using the 
Zeiss LSM510 system to gather quantitative values for the intensity of the 
immunofluorescence at a given point on the image.  SH-SY5Y cells were therefore 
once again stained with the NDE1 93 and anti-γ-tubulin antibodies.  These were then 
viewed by confocal microscopy with the assistance of Becky Carlyle.  Again, 
colocalisation of the two proteins was visible at the centrosome (see figure 5.5.K) 





         



















Figure 5.5.I: NDE1 (93) is seen to co-localise with γ-tubulin in a subset of SH-SY5Y cells at peri-nuclear punctate structure 
(white arrow), suggesting that endogenous NDE1 is found at the centrosome.  
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Figure 5.5.J: a) Nde1 95 stains the centrosome (white arrow, as defined by γ-tubulin) in some but not all NIH-3T3 cells.  b) 
Nde1 94 does not stain the centrosome, as defined by γ-tubulin of NIH-3T3 cells.  172 
 




Figure 5.5.K:  Confocal microscopy analysis of NDE1 93 (green) and γ-tubulin 
(red) in an SH-SY5Y cell.  Image shows a slice of the cell.  Graph shows the 
intensity of each antibody along the one-dimensional white line from the 
above image.  The two staining patterns colocalise, indicating NDE1 is at the 





5.6.1 The subcellular localisation of endogenous NDE1 
In this chapter, four novel anti-NDE1 antibodies were used to investigate the 
expression pattern of endogenous NDE1 protein within the cell.  While the expression 
patterns shown by the antibodies varied, there were two recurring themes: Expression 
of NDE1 at the nucleus (although the type of nuclear expression pattern seen did vary 
between antibodies) and expression at the centrosome.  These will now be discussed 
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5.6.2 NDE1 at the nucleus 
There are two published reports in which a faint nuclear NDE1/NDEL1 expression 
pattern was reported (Yan et al. 2003; Suzuki et al. 2007).  Both of these were seen 
using antibodies that detected both endogenous NDE1 and NDEL1.  It was therefore 
unclear whether the expression pattern represented NDE1, NDEL1 or specific 
isoforms of one of them.  The new 93 antibody described here, which does not detect 
NDEL1, demonstrates that this signal is due, at least in part, to NDE1.  This is 
consistent with the identification of potential NLS in two NDE1 isoforms (see section 
4.5), although such puncta have been seen using over-expressed NDE1-SSSC which 
does not have such a sequence. 
 
Within the nucleus, two distinct expression patterns of NDE1 are seen - a large 
number of small puncta throughout the nucleus, and a smaller number of discreet 
larger puncta.  In any given cell, one such large puncta is likely to represent the 
centrosome, while the nature of the remaining ones remains a mystery.   These 
structures are not centromeric nucleosomes, but may represent other nuclear bodies 
such as paraspeckles (Fox et al. 2002).  A promising possibility, however, comes from 
the recent identification of a subpopulation of DISC1 which resides at promyelocytic 
leukaemia bodies (Kamiya et al. 2008), raising the possibility that NDE1 may also be 
present here.  Promyelocytic leukaemia bodies are nuclear structures with diverse 
functions, including involvement in the phosphorylation and acetylation of proteins, 
transcriptional regulation and heterochromatin formation (Bernardi and Pandolfi 
2007).  These large puncta are also seen in some SH-SY5Y cells that had been 
transfected with over-expressed NDE1 and, based on this work, Fumiaki Ogawa has 
gone on to observe similar structures when NDE1 was over-expressed in mouse 
hippocampal neurons (Bradshaw et al. 2008). 
 
The smaller, more dispersed, NDE1 structures in the nucleus, meanwhile, overlap 
with the signal detected using the Y12 antibody.  This antibody was raised against the 
Smith antigen, a collection of small nuclear riboprotein particles, and marks splicing 
speckles within the nucleus.  These structures contain splicing factors, kinases and 
phosphatases and have therefore been suggested to be involved in the regulation of 
mRNA splicing (Lamond and Spector 2003).  The presence of one or more NDE1 
isoforms at this location, therefore, suggests that NDE1 may play a, previously 
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unknown, role in this or a related process.  Further work is required in order to better 
understand this. 
 
5.6.3 NDE1 at the centrosome 
That NDE1 is seen at the centrosome is not surprising, given that NDEL1 is well 
known to localise here (see section 1.3.3.1).  What is more surprising is that 
colocalisation of NDE1 with γ-tubulin was only seen in a relatively small fraction of 
the cells, with mouse Ndel1 having been reported to be found “predominantly” at the 
centrosome (Sasaki et al. 2000).  A more direct comparison is required, but this may 
suggest that NDE1 plays a role at the centrosomes of a lower proportion of cells than 
does NDEL1.   
 
Using confocal microscopy, NDE1 was seen to be predominantly on one side of the 
centrosome (as defined by γ-tubulin staining).  This may imply that NDE1 binds 
predominantly or exclusively to one of the two centrioles, and fits in well with a 
previously published observation that NDEL1 binds only to the mother centriole of 
COS7 cells (Guo et al. 2006). 
 
5.6.4 Differing staining patterns of the NDE1 antibodies 
The variations in the staining patterns of the different NDE1 antibodies may be 
indicative of different NDE1 isoforms adopting differing cellular localisations.  For 
example, the novel nuclear structure detected using isoform 94 may be due to the 
NDE1-S1b isoform, which would not be detectable by any of the other antibodies.  
Similarly, the 95 antibody can detect only the NDE1-KMLL isoform or its mouse 
orthologue, and so its prominent nuclear localisation pattern must be due to this 
isoform.  Finally, the 93 antibody is the only one which can theoretically detect 
NDE1-S2, although this was not observable by two-dimensional Western blotting, 
and so its prominent nuclear staining pattern could theoretically be in part due to this 
NDE1 variant.  The two-dimensional Western blot also suggests the existence of other 
NDE1 isoforms besides the ones described in chapter 3.  These may be due to 
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A more pragmatic possibility, however, would be that one or more of the antibodies 
cross-reacts with proteins other than NDE1, and that these may be responsible for one 
or more of the localisation patterns seen.  Specifically, the unique nuclear localisation 
patterns of the 94 and 95 antibodies must be viewed with a degree of suspicion at the 
present time, as they do not represent anything seen either with over-expressed protein 
or with other antibodies.   
 
In order to test whether these patterns are specific or not, constructs could be 
generated encoding the suspected NDE1 nuclear isoforms, and their cellular 
localisations viewed.  Another approach would be to make use of RNAi to 
specifically knock-down expression of NDE1.  If the antibodies are indeed specific to 
NDE1, then such a treatment should dramatically decrease the signal seen by both 
immunofluoresence and Western blotting using the antibodies.  Isoform-specific 
RNAi constructs could even be used to determine if the varying expression patterns of 
the antibodies are a direct result of NDE1 alternate-splicing or not.  Antigen recovery 
techniques could also be used.  Finally, the antibodies should be tested in a larger 
variety of cell lines and also in primary cultures, in order to confirm that the 
expression patterns seen are consistent and not cell line-specific.  In particular, the 
mouse 94 and 95 antibodies have so far been tested in only one mouse cell line, NIH-
3T3, and could be tested in mouse primary neuron cultures.  Until analyses such as 
those described above have been performed, the data presented in this chapter should 
be regarded as preliminary.   
 
Nevertheless, the best demonstration that a protein exhibits a specific localisation 
pattern is through replication with independently produced antibodies, raised against 
non-overlapping regions of the protein.  Therefore, while the data described here 
cannot be taken as definitive, it does provide a benchmark for future investigation. 
 
5.6.5 The problem of antibody cross-reactivity 
As has been demonstrated, all three commercially available NDE1 antibodies (at time 
of writing) are unable to distinguish between NDE1 and NDEL1.  Interestingly, a 
recent paper also investigated one of these antibodies (10233-1-AP) and concluded 
that it was largely NDE1-specific (Vergnolle and Taylor 2007).  They did this through 
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Antibody Target Original paper Cross-reactivity? 
mNudE Mouse NDE1 (Feng et al. 2000) (Not stated) 
210 + 211 NDEL1 (Niethammer et al. 2000) (Not stated) 
C-6 NDEL1 (Sasaki et al. 2000) (Not stated) 
Nudel NDEL1 (Yan et al. 2003) Yes 
4-9C Rat NDEL1 (Yamaguchi et al. 2004) No 
NOAB Rat NDEL1 (Hayashi et al. 2005) (Not stated) 
NudE Mouse NDE1 (Soukoulis et al. 2005) (Not stated) 
P-NDEL1 Phospho-NDEL1 (Toyo-Oka et al. 2005) (Not stated) 
Nudel NDEL1 (Guo et al. 2006) (Not stated) 
NDEL1 NDEL1 (Kamiya et al. 2006) No (Burdick et al. 2008) 
NudE NDE1 (Liang et al. 2007) (Not stated) 
Nudel NDEL1 (Liang et al. 2007) (Not stated) 
α-P-251 Phospho-NDEL1 (Mori et al. 2007) (Not stated) 
mNudE Mouse NDE1 (Stehman et al. 2007) Yes 
NDE1 NDE1 (Burdick et al. 2008) No 
 
Table 5.6:  A list of non-commercial NDE1 and NDEL1 antibodies published in 
the literature.  Only five have, to date, been reported to have been tested for 
cross-reactivity between NDE1 and NDEL1. 
 
 
use of NDE1 RNAi, which greatly reduced the signal detected by the antibody.  Some 
NDE1 signal did remain however, implying that the antibody may also detect NDEL1 
to some degree, in agreement with the results reported here.  The difference in the 
degree to which the antibody appears NDE1-specific in the two studies is likely due to 
a combination of the different methods used (knocking down of endogenous NDE1 
expression as opposed to direct detection of NDE1 and NDEL1 in vitro) and the fact 
the relationship between the strength of signal on a Western blot, used in both studies, 
and the amount of a protein present is not linear, especially once the signal becomes 
saturated. 
 
Given the high level of amino acid similarity between the NDE1 and NDEL1 
proteins, it is likely that other NDE1/NDEL1 antibodies would also cross-react in a 
similar way to the commercial antibodies described above.  Table 5.6 shows a list of 
novel NDE1 and NDEL1 antibodies described in the literature to date.  As can be 
seen, only a fraction of these are reported as having been tested in order to determine 
whether they are specific to NDE1 or NDEL1.   Based on these results, it appears 
reasonable to assume that a substantial proportion of these antibodies will cross-react, 
making it difficult to fully interpret results gained whilst using them. 
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Chapter 6 - Protein binding partners of NDE1 
include DISC1 and members of its pathway 
 
6.1 Introduction 
NDEL1 is known to have at least two distinct protein-protein interaction sites.  These 
correspond to a short predicted C-terminal helix, where proteins including DISC1 and 
dynein bind (Sasaki et al. 2000; Millar et al. 2003; Brandon et al. 2004), and parts of 
a longer N-terminal coiled-coil where LIS1 binds and self-association occurs (Sasaki 
et al. 2000; Yan et al. 2003).  These putative structures appear to be conserved in 
NDE1 as well as NDEL1 (see chapter 4).  NDEL1 can form multimers (Sasaki et al. 
2000; Derewenda et al. 2007) and NDE1 has been seen to do the same.  Such 
multimers therefore have the potential to bind to several proteins simultaneously.  
This suggests that NDE1 and NDEL1 may be able to act as interaction hubs, binding 
simultaneously to more than one protein, possibly as part of a larger protein complex.  
The most studied protein interaction partners of NDEL1 to date are LIS1 and DISC1, 
however study of these proteins as potential NDE1 interactors has been very limited. 
 
DISC1 is implicated in binding to over 100 separate proteins; mostly as a result of 
yeast-two-hybrid screening (see section 1.2.2.4). One DISC1 interactor of particular 
interest is phosphodiesterase 4B (PDE4B), which was found to be disrupted by a 
chromosomal translocation in a proband with schizophrenia (Millar et al. 2005b), and 
which has since been associated with schizophrenia in several populations (Pickard et 
al. 2007; Fatemi et al. 2008; Numata et al. 2008b) and with major depression 
(Numata et al. 2008a). 
 
Multiple protein interaction sites within DISC1 have been mapped and occur along 
the length of DISC1 suggesting that DISC1 is also likely to be a hub protein.  For 
example, the sites known to be involved in PDE4B binding are primarily in the N-
terminal quarter of DISC1 (Millar et al. 2005b; Murdoch et al. 2007), while the 
NDEL1 binding site is near the C-terminus (see figure 1.3.B).  This therefore raises 
the interesting possibility that PDE4B, encoded by a gene with known links to 
psychiatric illness, may bind to DISC1 at the same time as NDE1 and/or NDEL1. 
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6.2 Confirmation that endogenous NDE1 interacts with LIS1 
 
6.2.1 Endogenous LIS1 and NDE1 co-immunoprecipitate 
Mammalian NDE1 was originally characterised after it was found to bind to LIS1 in a 
series of yeast-two-hybrid screens (Feng et al. 2000; Kitagawa et al. 2000; Sasaki et 
al. 2000).  The authors then went on to demonstrate that, in rodents, these proteins 
were also capable of co-immunoprecipitating each other when over-expressed in cell 
lines.  To date, however, complexing of endogenous NDE1 and LIS1 has not been 
demonstrated. 
 
The 93 antibody, generated in chapter 5, was therefore used to immunoprecipitate 
NDE1 from a COS7 cell lysate.  Using a commercial antibody, LIS1 was seen to be 
co-immunoprecipitated (see figure 6.2.A).  It therefore appears that endogenous 
NDE1 and LIS1 can complex together in the mammalian cell. 
 
6.2.2 Endogenous LIS1 and NDE1 colocalise in some cells at a 
centrosome-like structure 
In order to further confirm the LIS1-NDE1 interaction, their expression patterns were 
compared.  Immunocytochemistry was therefore used to visualise endogenous LIS1 
and NDE1 (antibody 93) within SH-SY5Y cells.  The expression patterns of the two 
proteins differed considerably, with LIS1 being found primarily in the cell body, 
while NDE1 was primarily nuclear (see figure 6.2.B).  Colocalisation was seen, 
however, in a subset of cells (less than one quarter).  This was seen usually at a bright 
puncta either at or adjacent to the nucleus.  Given that LIS1 is known to be at the 
centrosome (Feng et al. 2000; Niethammer et al. 2000) and endogenous NDE1 has 
now been seen there also (see section 5.5.5), it can reasonably be assumed that NDE1 
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Figure 6.2.A: LIS1 was co-immunoprecipitated from a COS7 lysate using the 



















Figure 6.2.B: NDE1 and LIS1 
colocalise principally at a single 
centrosome-like puncta in SH-


























Figure 6.2.C:  Sample confocal microscopy image of LIS1 (red) and NDE1 93 
(green) in COS7 cells.  Graph shows intensities of the two antibodies along 
the white arrow in the image above.  At the large perinuclear puncta, 
colocalisation of the two proteins is clearly seen. 
 
 
6.2.3 LIS1 and NDE1 colocalisation by confocal microscopy 
In order to confirm the colocalisation of LIS1 and NDE1 to this centrosome-like 
puncta, confocal microscopy was utilised with assistance from Becky Carlyle.  The 
NDE1 93 and LIS1 antibodies were this time used to stain COS7 cells.  
Colocalisation was again repeatably seen to occur at a single centrosome-like puncta 





















Figure 6.3.A: a) V5-NDE1-SSSC and GFP-NDE1-SSSC were over-
expressed in COS7 cells and immunoprecipitated using an anti-V5 antibody.  
GFP-NDE1 was co-immunoprecipitated.  b) In vitro transcribed and 
translated GFP-NDE1-SSSC can be co-immunoprecipitated by an anti-V5 
antibody in the presence of V5-NDE1-SSSC, but not in its absence. 
 
 
6.3 NDE1 and NDEL1 complexes 
 
6.3.1 NDE1 forms homodimers 
NDEL1 molecules have been previously been shown to form homodimers (Efimov 
and Morris 2000; Sasaki et al. 2000; Maiolica et al. 2007).  In order to investigate 
whether NDE1 does the same, V5-NDE1-SSSC and GFP-NDE1-SSSC were over-
expressed in COS7 cells.  By using an anti-V5 antibody it was possible to co-
immunoprecipitate the GFP-tagged NDE1 (see figure 6.3.A.a), suggesting that the 
two NDE1 proteins formed a complex together within the cell.  This is in agreement 
with a similar experiment performed elsewhere (Feng and Walsh 2004).  The use of 
such protein tags for immunoprecipitation experiments is well established and so it 
seems highly unlikely that the interaction is due to V5-GFP interactions, nevertheless 
this possibility cannot be formally discounted without an additional negative control. 
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However, this result alone merely shows that two or more NDE1 monomers can co-
exist in the same complex, not necessarily that they bind directly to each other.  If 
both bound simultaneously to a third protein, for example a LIS1 dimer, then they 
would still be able to co-immunoprecipitate each other from cell lysates.  Therefore, 
in order to demonstrate direct binding, an alternative to a cell lysate is required.  An 
in vitro transcription and translation system was therefore used to produce V5-
NDE1-SSSC and GFP-NDE1-SSSC in a cell free environment.  These two pools of 
protein were mixed and immunoprecipitation was performed using an anti-V5 
antibody.  As a negative control, GFP-NDE1-SSSC alone was used.  GFP-NDE1-
SSSC could indeed be co-immunoprecipitated using this system, but only in the 
presence of V5-NDE1-SSSC (see figure 6.3.A.b).  Given the lack of other proteins 
present compared to in a cell lysate, it can be concluded that NDE1 self-association 
probably occur through direct interaction of NDE1 monomers.  Based on a published 
structural analysis of NDEL1 (Derewenda et al. 2007), in which X-ray defraction 
was used in order to study the N-terminal coiled-coil segment of NDEL1 and 
NDEL1 multimers, it appears likely that this interaction occurs principally in the 
form of a dimer. 
 
6.3.2 NDE1 exists in a complex with NDEL1 
Both NDE1 and NDEL1 have been shown to form dimers and the self-association 
domain of NDEL1 (Sasaki et al. 2000) is well conserved in NDE1 (75.2% identity, 
96.2% similarity from NDEL1 amino acids 57-189).  It is therefore reasonable to 
predict that NDE1 and NDEL1 proteins may also be able to bind to each other.  GFP-
NDEL1-PLSV and V5-NDE1-SSSC were therefore over-expressed in COS7 cells.  
NDE1 was immunoprecipitated using an anti-V5 antibody, and GFP-NDEL1 was 
seen to be co-immunoprecipitated with it (see figure 6.3.B.a), implying that NDE1 
and NDEL1 can co-exist in the same protein complex. 
 
To see if endogenous protein behaves in the same way, the 93 antibody was used to 
immunoprecipitate NDE1 from an SH-SY5Y lysate.  By using the 231 antibody,  
 
 


































Figure 6.3.B: a) V5-NDE1-SSSC can co-immunoprecipitate GFP-NDEL1-
PLSV using an anti-V5 antibody when both are over-expressed in COS7.  b) 
Endogenous NDEL1 (antibody 231) can be co-immunoprecipitated from an 
SH-SY5Y lysate using an endogenous anti-NDE1 antibody (93).  c) V5-
NDEL1-PLSV is not seen to co-immunoprecipitate by GFP-NDE1-SSSC 
using an anti-GFP antibody when the two proteins are transcribed and 
translated in vitro.  The immunoprecipitation of GFP-NDE1-SSSC is 
confirmed to have worked. 
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NDEL1 was seen to have been co-immunoprecipitated (see figure 6.3.B.b), showing 
that endogenous NDE1 and NDEL1 complex together.  A similar result has since 
been published elsewhere using independent antibodies (Burdick et al. 2008).  
Surprisingly, it appeared to be considerably easier to co-immunoprecipitate NDE1 
and NDEL1 using endogenous protein than it was using the tagged over-expressed 
protein.  While co-immunoprecipitation experiments using different antibodies are 
not directly comparable, this nevertheless presented the possibility that an additional 
cellular factor is required for them to complex, a factor which is limiting when over-
expressed NDE1 and NDEL1 form a complex. 
 
To further investigate this phenomenon, V5-NDEL1-PLSV and GFP-NDE1-SSSC 
were produced using the in vitro transcription and translation system.  
Immunoprecipitating using an anti-GFP antibody, only GFP-NDE1-SSSC, and not 
V5-NDEL1-PLSV, was precipitated (see figure 6.3.B.c).  This experiment was 
repeated three times, each with the same negative result.  It therefore appears that it 
is not possible for NDE1-NDEL1 interactions to occur under these conditions, 
despite NDE1 self association interactions being detected using the same system (see 
figure 6.3.A.b).  This suggests that NDE1-NDEL1 complexes are of a different form 
to NDE1-NDE1 or NDEL1-NDEL1 complexes, as will be discussed in section 6.7.1. 
 
6.3.3 Comparison of NDE1 and NDEL1 localisations 
When over-expressed in HEK293T cells, V5 and GFP tagged NDE1-SSSC and 
NDEL1-KMLL are found to colocalise, principally at a perinuclear structure which 
resembles the centrosome (see figure 6.3.C.a).  This pattern was not dependent on 
which protein was labelled with which tag.  It cannot be presumed that these 
localisations are reflective of endogenous protein, however. 
 
As NDE1 antibody 93 and NDEL1 antibody 231, were raised in rabbits, a direct 
comparison of the staining patterns of the two is not possible.  A small amount of the 
NDE1 93 antibody was therefore conjugated directly to a green fluorescent tag.  This 
conjugated antibody, 93-488, produces a similar expression pattern to 93 but shows  
 
         




























Figure 6.3.C: a) GFP-NDE1-SSSC and V5-NDEL1-PLSV colocalise in HEK293T cells.  b) The 93-488 (NDE1) and 231 
(NDEL1) antibodies colocalise extensively but not completely in SH-SHY5Y cell bodies. 
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nuclear NDE1 in a diffuse, rather than punctate, pattern.  When the 93-488 and 231 
antibodies were compared in SH-SY5Y cells (see figure 6.3.C.b), wide-spread 
NDE1-NDEL1 colocalisation was seen.  Specifically, the two proteins were seen 
together in the cell body and at the centrosome.  Without γ-tubulin staining, it was 
not possible to determine whether this localisation was across the whole centrosome 
or just at a single centriole.  NDE1 expression at the nucleus appeared to be greater 
than that of NDEL1, relative to their expression elsewhere in the cell.  
 
6.3.4 Partial colocalisation of NDE1 and NDEL1 by confocal microscopy 
In order to further investigate the expression patterns of the 93-488 and 231 
antibodies, the cells were viewed by confocal microscopy, with assistance from 
Becky Carlyle.  Looking at SH-SY5Y cells, the NDE1 and NDEL1 antibodies were 
repeatably seen to colocalise at a large perinuclear structure which can be presumed 
to be the centrosome (see figure 6.3.D.a). 
 
Interestingly, when the intensities of the antibody fluorescence were measured along 
a line crossing the nucleus (see figure 6.3.D.b), it was seen that the 93-488 antibody 
shows a stronger staining pattern than 231 within this organelle.  In comparison, 231 
showed the stronger signal at the nuclear periphery.  Both proteins appear to be 
present at the nucleus, however. 
 
6.4 The NDE1-DISC1 interaction 
 
6.4.1 Confirmation that NDE1 binds directly to DISC1 
As a first step towards confirming that DISC1 and NDE1 interact, as had been shown 
through yeast-two-hybrid screening (Millar et al. 2003; Brandon et al. 2004), FLAG-
tagged DISC1 and V5-tagged NDE1-SSSC were over-expressed in COS7 cells.  The 
V5-NDE1 could be co-immunoprecipitated with the FLAG-DISC1 using an anti-
FLAG antibody (figure 6.4.A.a), implying that the two over-expressed proteins were 
able to complex with each other, in agreement with results that have since been 
published elsewhere (Burdick et al. 2008). 
 
 



























Figure 6.3.D:  Confocal microscopy of NDE1 93-488 (green) and NDEL1 231 
(red) in SH-SY5Y cells.  Graphs show intensities of each antibody along the 
red line marker on the corresponding image.  Estimates of the positions of 






















Figure 6.4.A: a) V5-NDE1-SSSC was co-immunoprecipitated by FLAG-
DISC1 using an anti-FLAG antibody when both were over-expressed in 
COS7 cells. b) V5-DISC1 was co-immunoprecipitated with GFP-NDE1-SSSC 
using an anti-GFP antibody and in vitro transcribed and translated protein. 
 
 
In order to determine if this is a direct interaction (rather than simultaneous binding 
of DISC1 and NDE1 to a third protein), in vitro transcribed and translated V5-DISC1 
and GFP-NDE1-SSSC were mixed together.  V5-DISC1 could be co-
immunoprecipitated using an anti-GFP antibody in the presence of GFP-NDE1-
SSSC, but not in its absence (figure 6.4.A.b).  This strongly implies that DISC1 and 
NDE1 bind directly to each other as suggested by the yeast-two-hybrid results. 
 
6.4.2 NDE1 binds multiple isoforms of endogenous DISC1 
The DISC1 protein is known to exist as a number of different species of varying 
sizes (James et al. 2004).  In order to determine which endogenous DISC1 isoforms 
NDE1 interacts with, the 93 antibody was used to immunoprecipitate NDE1 from an 
SH-SY5Y cell lysate.  The αDISC1 antibody is raised against a C-terminal region of 
DISC1 and has been characterised previously (Ogawa et al. 2005), detecting multiple 
DISC1 species of the same size as those detected using other established antibodies 
(James et al. 2004).  The α-DISC1 antibody was able to detect numerous species of  
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Figure 6.4.B: Multiple DISC1 isoforms co-immunoprecipitated using an anti-
NDE1 antibody (93) from an SH-SY5Y lysate. 
 
DISC1 which had co-immunoprecipitated with NDE1 (see figure 6.4.B).  These 
included the full length (~100kDa) form, as well as species of sizes of 70-80kDa.  It 
therefore appears that NDE1 can bind to multiple isoforms of DISC1 within the  
human cell.  The nature of the species remains to be determined but could be 
analysed by, for example, mass spectroscopy. 
 
6.4.3 NDE1 and DISC1 colocalise at a centrosome-like structure 
DISC1 has been previously shown at the centrosome (Morris et al. 2003; James et al. 
2004), where it colocalises with over-expressed NDEL1 (Kamiya et al. 2006).  In 
order to determine if DISC1 and NDE1 also colocalised at this location, FLAG-
DISC1 and V5-NDE1-SSSC were over-expressed in HEK293T cells.  Colocalisation  
of V5 and FLAG antibodies in the cells was restricted, but was seen most clearly at a 
large puncta on the edge of the nucleus (see figure 6.4.C) which closely resembles 
the centrosome.   
 
6.5 NDE1 exists in a complex with ATF4 
 
6.5.1 NDE1 complexes with ATF4 
Activating Transcription Factor 4 (ATF4) is a DISC1-interacting protein (Millar et 
al. 2003; Morris et al. 2003; Sawamura et al. 2008) which has been suggested to be 
associated with schizophrenia (Kakiuchi et al. 2007; Qu et al. 2008).  In order to 
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Figure 6.5.A: V5-NDE1-SSSC can co-immunoprecipitate GFP-ATF4 using an 
anti-V5 antibody when both are over-expressed in COS7 cells. 
 
investigate whether NDE1 and ATF4 may bind to DISC1 simultaneously, COS7 
cells were co-transfected with V5-tagged NDE1-SSSC and GFP-tagged ATF4.  By  
using an anti-V5 antibody, it was possible to co-immunoprecipitate ATF4 with 
NDE1 (figure 6.5.A).  It therefore appears that NDE1 and ATF4 can exist in the 
same complex. 
 
6.5.2 NDE1 and ATF4 show some colocalisation 
Staining SH-SY5Y cells with antibody 93 and an anti-ATF4 antibody, it could be 
seen that endogenous NDE1 and ATF4 colocalise in some cells (figure 6.5.B).  
Typically the two colocalised at one, or occasionally two, punctate structures in the 
nucleus.  It would be interesting to know whether this was the same type of nuclear 
structure as that at which NDE1 and CENPA were seen to colocalise in section 
5.5.1.1, a question which could be addressed using three-colour 
immunofluorescence. 
 
6.6 NDE1 exists in a complex with PDE4B1 
 
6.6.1 Over-expressed NDE1 can complex with PDE4B1 
In order to test if NDE1 and PDE4B1 can exist in the same protein complex, for 
example by simultaneous binding to DISC1, PDE4B1 and V5-tagged NDE1-SSSC 
were over-expressed in COS7 cells.  PDE4B could be immunoprecipitated using an 
anti-V5 antibody (figure 6.6.A), indicating that the two over-expressed proteins were 
indeed forming a complex together. 
 
 
         
         






















Figure 6.5.B: NDE1 (green) and ATF4 (red) colocalise at a nuclear punctate structure in some, but not all, SH-SY5Y cells.  
White arrows indicate points of colocalisation 
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Figure 6.6.A: PDE4B1 (detected using a pan-PDE4B antibody) is seen to be 
co-immunoprecipitated with V5-NDE1-SSSC using an anti-V5 antibody when 
both are over-expressed in COS7 cells. 
 
Figure 6.6.B: Endogenous PDE4B had previously been immunoprecipitated 
from an SH-SY5Y lysate by Sheila Christie and Kirsty Millar using a pan-
PDE4B antibody.  They showed DISC1 and NDEL1 to be co-
immunoprecipitated.  The membrane was now also probed using the NDE1 
93 antibody and a commercial LIS1 antibody.  Both proteins were seen to 
have been co-immunoprecipitated with PDE4B. 
 
 
6.6.2 Endogenous PDE4B can complex with NDE1 and LIS1 
Previously, Kirsty Millar and Sheila Christie performed an immunoprecipitation 
experiment from an SH-SY5Y lysate using an anti-PDE4B antibody, and showed 
that NDEL1 (231) is co-immunoprecipitated (Bradshaw et al. 2008).  This suggests 
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Figure 6.6.C: a) V5-NDE1-SSSC was not seen to co-immunoprecipitate with 
PDE4A10 when over-expressed in COS7 cells.  b) V5-NDE1-SSSC and 
PDE4C2 were over-expressed in COS7 cells.  A PDE4C protein co-
immunoprecipitated with V5-NDE1.  c) V5-NDE1-SSSC and PDE4D5 were 
over-expressed in COS7 cells.  A PDE4D protein co-immunoprecipitated with 
V5-NDE1.  All co-immunoprecipitations were done using an anti-V5 antibody. 
 
 
This lysate and immunoprecipitate were once again Western blotted and this time 
stained using the 93 antibody.  NDE1 is indeed clearly seen to be co-
immunoprecipitated (see figure 6.6.B).  It therefore appears that the complexing of 
NDE1 and PDE4B shown using over-expressed protein also occurs with endogenous 
protein.  Additionally, LIS1 was co-immunoprecipitated, indicating that it also exists 
in a complex with PDE4B. 
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6.6.3 Over-expressed NDE1 can complex with a range of PDE4 proteins 
There are four separate genes encoding PDE4 proteins in humans named PDE4A-D 
(Houslay and Adams 2003).  Each of these then has a number of splice variants, for 
example PDE4B has five, termed PDE4B1-5 (Houslay and Adams 2003; Cheung et 
al. 2007).  These isoforms can be divided into three broad categories based on a 
conserved configuration of functional domains.  These categories are long, short and 
super-short.  Given that NDE1 has been seen to complex with one long PDE4 
isoform, PDE4B1, it is reasonable to hypothesise that it may be able to also complex 
with other long PDE4 isoforms. 
 
Four sets of COS7 cells were co-transfected with V5-NDE1-SSSC and a 
representative long PDE4 isoform from one of PDE4A-D.  Using an anti-V5 
antibody, it was possible to co-immunoprecipitate PDE4B1, PDE4C2 and PDE4D5 
with V5-NDE1 (see figure 6.6.C).  In three attempts, however, PDE4A10 was not 
definitively co-immunoprecipitated.  It remains unclear whether this is due to lack of 
a biological interaction, or simply due to technical problems.  It therefore appears as 
if NDE1 is capable of forming a complex with a range of PDE4 long isoforms, but 
not necessarily with all of them.  Results of a similar experiment, using NDEL1 
rather than NDE1, have recently been published (Collins et al. 2008).  They showed 
co-immunoprecipitation of over-expressed NDEL1 with PDE4A5, PDE4B1, 




6.7.1 The nature and localisation of the NDE1-NDEL1 complex 
In this chapter, NDE1 and NDEL1 have been demonstrated to co-exist in complexes 
by means of co-immunoprecipitation.  An implication of this finding is it that the two 
proteins are capable of working cooperatively within the cell.  It therefore follows 
that NDE1 and NDEL1 are likely to share some of the same cellular functions.  It 
also adds further complexity to the issue of using antibodies to detect NDE1 and 
NDEL1 within the cell.  Not only must it be clarified if the antibody detects NDE1, 
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NDEL1 or both, but is possible that any signal detected may be from a complex 
containing both proteins anyway. 
 
Given that both NDE1 and NDEL1 form homo-dimers, and their close amino acid 
similarity, the existence of a NDE1-NDEL1 heterodimer can be predicted.  However, 
while the NDE1-NDEL1 interaction appeared very strong using endogenous protein, 
it was relatively weak using over-expressed protein and was not visible at all in vitro.  
Given that robust NDE1-NDE1 self-association could be consistently shown using 
all three of these systems, it must be concluded that the NDE1-NDEL1 interaction is 
fundamentally different in nature to NDE1-NDE1 or NDEL1-NDEL1 self 
association.  The simplest explanation for this would be that the two proteins do not 
interact directly, but instead simultaneously bind to a third protein such as LIS1 or 
DISC1.  An alternative conclusion can be drawn by comparing their amino acid 
sequences and noting that the NDEL1 tetramerisation domain (Derewenda et al. 
2007) is almost perfectly conserved in NDE1 (81% identity, 99% similarity), while 
the dimerisation domains differ to a greater extent (56% identity, 92% similarity).  
Thus NDE1 and NDEL1 may only be able to interact when homodimers of each 
protein bind to form a heterotetramer.  In this case, the lack of binding in vitro would 
be explained by the lack of a cellular factor required to aid in the binding of the 
proteins, or if such a tetramer was a thermodynamically unfavourable configuration 
at the low protein concentrations present in such an experiment, compared to the 
much higher total protein content of a cell. 
 
Some NDEL1 signal was detected in the nucleus using the NDEL1 231 antibody.  
This may represent NDE1 cross-reactivity, however it is also possible that NDEL1 
could genuinely be present in this location.  This could happen in two ways.  Firstly, 
it is possible that there exists an additional, but not yet described, NDEL1 isoform 
which has an NLS sequence.  Secondly, NDE1 and NDEL1 have been shown to 
complex together.  It is therefore possible that a complex (such as a heterotetramer) 
containing NDE1-KMLL could be targeted to the nucleus, taking any NDEL1 
proteins in the complex with it. 
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A caveat to co-immunoprecipitation analysis using over-expressed protein is that the 
possibility that protein tags (in this case V5 and GFP) interact with each other cannot 
be formally excluded without the use of an additional negative control in which the 
tags alone are expressed and immunoprecipitation performed.  Similarly, the fact that 
the 93 antibody is successful in co-immunoprecipitating a variety of proteins raises 
the possibility that the co-immunoprecipitation may be an artefact of using the 
antibody.  Again this could be discounted by the addition of an additional negative 
control, in this case demonstrating that 93 cannot co-immunoprecipitate some other 
protein.  Nevertheless, the fact that the work with both the endogenous and over-
expressed protein yields the same results (NDE1-NDEL1 interaction) implies that the 
interaction is genuine and not a false positive.  The same is also true of other NDE1 
interactions described in the chapter. 
 
6.7.2 DISC1 interaction with NDE1 and NDEL1 
The interaction of DISC1 with NDEL1 is very well established; however this is the 
first work to demonstrate a DISC1-NDE1 interaction using endogenous protein.  
Interestingly, NDE1 is seen to co-immunoprecipitate with several different DISC1 
species, including the full length 100kDa species as well as the 75kDa and 71kDa 
species which may be localised to the mitochondria (Ozeki et al. 2003; James et al. 
2004).  This implies that NDE1 is likely to associate with DISC1 in multiple parts of 
the cell. 
 
6.7.3 NDE1 as part of a DISC1 mega-complex 
DISC1 is known to interact with NDE1 and NDEL1, each of which also show 
evidence of being associated with schizophrenia.  However DISC1 interacts with 
other proteins, notably PDE4B, that have also been associated with major mental 
illness.  It is highly implausible that DISC1 would be involved in multiple 
independent schizophrenia-related pathways.  The alternative, however, would be 
that they are in fact not two distinct pathways, but part of the same one.  It is 
therefore gratifying to learn that NDE1 and NDEL1 exist in a complex with PDE4B 
in the cell, possibly by binding simultaneously to DISC1.  That LIS1 also co-
immunoprecipitated with PDE4B implies that much of the NDE1-NDEL1-LIS1-
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dynein complex may co-exist with PDE4B in vivo as part of a DISC1 “mega-
complex”. 
 
It can be hypothesised that such a complex would consist of a central DISC1 
multimer, with PDE4B and NDE1/NDEL1 attached to it.  LIS1 is known to be able 
to bind directly to DISC1 (Camargo et al. 2007), but could also bind NDE1 or 
NDEL1 molecules in the complex. 
 
Other proteins which are known to bind both DISC1 and at least one of NDE1 and 
NDEL1 are 14-3-3ε (Toyo-Oka et al. 2003; Camargo et al. 2007; Taya et al. 2007), 
pericentrin-B (Miyoshi et al. 2005; Guo et al. 2006), DBZ/Su48 (Hirohashi et al. 
2006b; Camargo et al. 2007; Hattori et al. 2007) and PCM1 (Guo et al. 2006; 
Kamiya et al. 2008).  It is therefore possible that any one of these could exist in a 
DISC1-NDE1/NDEL1 complex.  There is however no evidence as yet to suggest that 
they might bind at the same time as PDE4B.  A schematic of these, as well as other 
some other proteins which bind DISC1 and NDE1/NDEL1, is shown in figure 6.7. 
 
A crucial next step is to determine the roles of the various proteins in such a mega-
complex: Which serve regulatory functions and which have active roles in the cell?  
How do these functions interact with each other?  One aspect of this will be 
addressed in the next chapter. 
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Figure 6.7: Known protein-protein interactions (black lines) involving DISC1 
and at least one of NDE1 and NDEL1, as determined by a literature search. 
Data taken from the following papers: (Efimov and Morris 2000; Faulkner et 
al. 2000; Feng et al. 2000; Kitagawa et al. 2000; Niethammer et al. 2000; 
Sasaki et al. 2000; Sweeney et al. 2001; Millar et al. 2003; Morris et al. 2003; 
Ozeki et al. 2003; Toyo-Oka et al. 2003; Brandon et al. 2004; Kamiya et al. 
2005; Miyoshi et al. 2005; Soukoulis et al. 2005; Guo et al. 2006; Hirohashi et 
al. 2006b; Kamiya et al. 2006; Ma et al. 2006; Sayer et al. 2006; Camargo et 
al. 2007; Hattori et al. 2007; Liang et al. 2007; Stehman et al. 2007; Taya et 
al. 2007; Vergnolle and Taylor 2007; Yamada et al. 2008) 
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Chapter 7 - NDE1 as a substrate of Protein 
Kinase A 
 
7.1 NDE1 is phosphorylated by PKA 
 
7.1.1 NDE1 phosphorylation is detectable with an anti-PKA substrate 
antibody 
Bioinformatics analysis predicts that NDE1 is phosphorylatable by a number of 
different kinases (see table 4.4.B).  One of these kinases, PKA, is of particular 
interest as it is cAMP-dependent and therefore influenced by cAMP 
phosphodiesterases such as PDE4B (see figure 1.2.D).  As a result, it would be 
interesting to know whether NDE1 is indeed a substrate of PKA. 
 
As an initial test, V5-NDE1-SSSC was over-expressed in COS7 cells and the cells 
were treated with the drugs IBMX and forskolin.  Forskolin is known to increase 
cAMP production within cells through the activation of adenylyl cyclase, while 
IBMX is a phosphodiesterase inhibitor and thus reduces the rate of cAMP 
degradation.  In combination, these drugs should raise the cellular levels of cAMP, 
increasing the activity of PKA.  These cells were then lysed and immunoprecipitation 
performed using an anti-V5 antibody.   
 
The immunoprecipitate was Western blotted and stained using an antibody raised 
against the phosphorylated peptide RRXp(S/T).  This motif is known to be a 
canonical substrate site for PKA phosphorylation (Shabb 2001).  Therefore this 
antibody should in theory show immunoreactivity to proteins which PKA has 
phosphorylated.  NDE1 has one RRXS motif at amino acids 303-306, however it also 
has a highly similar KRXT motif at amino acids 128-131.  The manufacturers of the 
PKA substrate antibody say that is should also be able to detect this phosphorylated 
motif.  The antibody did indeed a band of the correct size to be NDE1 using the PKA 
substrate antibody, and an identical band when the gel re-stained using an anti-V5 
antibody (see figure 7.1.A) suggesting that this band could be phosphorylated NDE1.   
 
  202    
 
 
Figure 7.1.A: V5-NDE1-SSSC was over-expressed in COS7 cells.  Cells 
were treated with IBMX and forskolin to increase PKA activity and lysates 
were immunoprecipitated using an anti-V5 antibody.  Identical size bands 
were seen in both the lysate and immunoprecipitate using V5 and a 
phosphorylated PKA substrate antibody, suggesting the NDE1 to be 
phosphorylated.  The smaller band may represent a form of NDE1 lacking a 
post-translational modification (such as additional non-PKA phosphorylation) 
or translated using the alternate start codon at methionine-23.  That both 
antibodies are capable of detecting it suggests that it is unlikely to be non-
specific binding of the antibodies to a non-NDE1 protein. 
 
 
Figure 7.1.B: COS7 cells were transfected with V5-NDE1-SSSC and ensuing 
lysates were immunoprecipitated using an anti-V5 antibody.  Cells treated 
with IBMX and forskolin to raise their cAMP levels showed considerably 
higher levels of phosphorylated V5, as visualised using a PKA substrate 
antibody.  This effect was largely abolished in cells which were also treated 
with the PKA inhibitor H89.  The V5 staining shows that this effect was not 
due to differing V5-NDE1 expression. 
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This is consistent with the idea of V5-NDE1 being phosphorylated at a location 
matching a PKA substrate motif, although further work is needed to confirm this. 
 
7.1.2 NDE1 phosphorylation is cAMP and H89 sensitive 
In order to confirm that the apparent phosphorylation seen on NDE1 was due to the 
action of PKA, and not by another kinase that uses a similar substrate motif, the 
above experiment was repeated using three parallel sets of COS7 cells.  The first of 
these was mock treated, the second was treated with IBMX and forskolin while the 
third was treated with IBMX, forskolin and H89, an inhibitor of PKA activity. 
 
A NDE1-sized band was again seen using the PKA substrate antibody following 
treatment with IBMX and forskolin (see figure 7.1.B).  This band was greatly 
reduced or absent in cells that were mock treated or treated with H89 in addition to 
IBMX and forskolin.  The levels of total V5-NDE1-SSSC, as determined using an 
anti-V5 antibody did not significantly vary.  It therefore appears that this 
phosphorylation of NDE1 is sensitive to the levels of cAMP in the cell and can be 
inhibited by H89.  Together this implies that NDE1 is being phosphorylated in a 
PKA-dependent manner.  An alternative approach would have been the use of RNAi 
to block PKA expression in the cells, and thus PKA-dependant phosphorylation. 
 
7.1.3 NDE1 can be phosphorylated by PKA in vitro 
The tests performed so far have demonstrated that phosphorylation of NDE1 is PKA-
dependent, but not necessarily that PKA is the kinase which phosphorylates NDE1.  
It is also possible that a kinase down-stream of PKA may instead perform the 
phosphorylation.  Therefore, in order to determine whether PKA can phosphorylate 
NDE1 directly, GST and GST-tagged NDE1-SSSC were bacterially expressed and 
purified from pGEX-6P1 and pGEX-6P1-NDE1-SSSC plasmid vectors respectively 
(see section 5.2.).  These were then treated with recombinant PKA and analysed by 
Western blotting using the PKA substrate antibody.  GST-NDE1 clearly showed a 
phosphorylation signal, while a larger quantity of GST did not (see figure 7.1.C).  
This indicates that the site or sites of phosphorylation are found entirely within the  
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Figure 7.1.C: GST and GST-NDE1-SSSC were purified from transformed 
bacteria and treated with recombinant PKA.  GST-NDE1 (~70kDa) is seen to 
be phosphorylated using the PKA substrate antibody, while a larger amount 
of GST (~28kDa) is not.  This signal is dependent on PKA treatment.  The 
additional products seen in the GST-NDE1 lanes may represent the results of 
premature translation termination, as the fact that they were successfully 
purified indicate that the GST tag is intact.  These additional products do not 
appear to be phosphorylated, implying a C-terminal phosphorylation site. 
 
amino acids derived from NDE1, rather than those from the GST tag.  Neither PKA 
alone nor untreated GST-NDE1 produced a similar phosphorylation signal.   
 
Together this indicates that PKA is capable of phosphorylating NDE1 directly in 
vitro, strongly suggesting that it is also responsible for the cAMP/H89-sensitive 
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7.2 Determining the PKA phosphorylated residues of NDE1 
 
7.2.1 Site-directed mutagenesis of potential PKA phosphorylation sites 
Plasmid constructs were created encoding mutant forms of NDE1 which lack 
potential PKA phosphorylation sites.  A pDEST-40-NDE1-T131A construct was 
created by using the QuikChange II kit and the T131A F & R primers (see table 
2.5.A) to perform a PCR reaction on the pDEST-40-NDE1-SSSC plasmid.  These 
primers theoretically replaced threonine-131 of the NDE1 gene with an alanine, as 
well as removing a BssHII restriction enzyme target site from the plasmid.  Thus, 
digesting samples of different clones with BssHII and running them on an agarose 
gel allowed the clones to be screened for the T131A mutation.  One of the colonies 
bearing the mutation (as confirmed by sequencing) was then grown and used to 
produce the mutant plasmid. 
 
In a similar manner, a pDEST-40-NDE1-S306A construct was generated using the 
S306A F & R primers (see table 2.5.A), which mutated serine-306 to an alanine, 
while also removing an AleI site.  Finally, the S306A primers were applied to the 
pDEST-40-NDE1-T131A plasmid in order to create a double-knockout pDEST-40-
NDE1-T131A-S306A plasmid. 
 
7.2.2 NDE1 is phosphorylated by PKA at serine-306 
V5-tagged NDE1-S306A and wild type NDE1 constructs were transfected into 
parallel sets of COS7 cells.  These were treated with IBMX/forskolin and an anti-V5 
antibody was used to immunoprecipitate the over-expressed NDE1.  Using the PKA 
substrate antibody, a marked decrease in phosphorylation of the S306A mutant was 
seen when compared to the wild-type construct (see figure 7.2.A.a). 
 
Three further independent repeats of the experiment were performed (two of which 
were performed in part by Sheila Christie).  The resulting blots were then scanned 
into a computer and densitometry was used to quantify the ratio of the PKA substrate 
and V5 antibody signals visible in the immunoprecipitate of each experiment.  Using 
a one-tailed paired t-test, the difference in phosphorylation level between wild type  
 
















































Figure 7.2.A: COS7 cells were transfected with V5-NDE1-SSSC constructs 
and the ensuing lysates immunoprecipitated using an anti-V5 antibody.  a) 
Less phosphorylated NDE1 is detectable using the S306A mutant compared 
to wild-type NDE1, suggesting that serine-306 is a site of phosphorylation.  b) 
Densitometry was performed in order to quantify four such experiments.  The 
ratio of PKA substrate to V5 signal in the immunoprecipitate of each 
experiment was quantified and the difference between wild-type and S306A 
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and mutant NDE1 was found to be significant (p=0.023, see figure 7.2.A.b).  
Densitometry was performed with Kirsty Millar. 
 
This finding suggests that serine-306 is a major site of PKA phosphorylation on 
NDE1.  That the S306A mutation does not abolish phosphorylation altogether, 
however, indicates that other sites of PKA phosphorylation also exist. 
 
7.2.3 Potential phosphorylation of NDE1 by PKA at theroinine-131 
The NDE1-T131A and wild type NDE1 constructs were then transfected into parallel 
sets of COS7 cells.  IBMX/forskolin was applied and an anti-V5 antibody was used 
to immunoprecipitate the proteins.  Using the PKA substrate antibody, a slight 
difference in V5-NDE1 phosphorylation was seen between the wild-type and mutant 
NDE1.  Over four independent experiments this was not seen to be significant 
however (see figures 7.2.B.a and 7.2.B.c, two of the repeats performed in part by 
Sheila Christie).  This would suggest that threonine-131 is unlikely to be a major site 
of PKA phosphorylation on NDE1. 
 
The test was then repeated in order to compare the phosphorylation levels of NDE1-
S306A single mutant and of the NDE1-T131A-S306A double mutant.  This 
experiment was performed three times (the latter two with assistance from Sheila 
Christie) and the results were again analysed by densitometry.  Consistently, the 
double mutant showed evidence of reduced phosphorylation when compared to the 
single mutant (see figure 7.2.B.b).  The difference between the S306A and T131A-
S306A mutants does not reach the boundary of statistical significance (p=0.091, see 
figure 7.2.B.c), although the difference between the double mutant and wild-type 
NDE1 (p=0.003) was a lot more significant than that between wild type and S306A 
(p=0.023).  It therefore appears that threonine-131 may be an additional site of PKA 
phosphorylation on NDE1.  Furthermore, that this was only clearly visible on the 
background of an S306A mutant presents the possibility that the phosphorylation 
status of one site may influence the phosphorylation potential of the other.  
Alternatively, this may be due to differences in the ability of the antibody to detect 
each site (see section 7.4.1).  Densitometry was performed by Kirsty Millar. 
 




















Figure 7.2.B: a) V5-NDE1-T131A shows a small change in level of 
phosphorylation compared to wild-type V5-NDE1 in COS7 cells following 
IBMX-forskolin treatment.  b) This change is more obvious on the 
background of an S306A mutation in NDE1.  c) Densitometry analysis of four 
independent experiments. 
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7.2.4 Predictions of other potential PKA sites on NDE1 
That mutation of both serine-306 and threonine-131 did not completely abolish 
phosphorylation of V5-tagged NDE1 implies that one or more additional sites of 
PKA phosphorylation must exist.  Therefore an alternative online phosphorylation 
site prediction program, NetPhosK 1.0 (Blom et al. 2004), was used to search for 
other, more weakly predicted, potential PKA phosphorylation sites in NDE1-SSSC.   
 
In total, five other such sites were predicted (see table 7.2), although none of these 
conform precisely to the conventional RRX(S/T) PKA substrate motif (Shabb 2001) 
and it is therefore unclear which, if any, of these sites the PKA substrate antibody 
may be able to detect.  No potential PKA phosphorylation sites are predicted to exist 
in the V5-tag. 
 
7.3 Investigating the effects of PKA phosphorylation of NDE1 
 
7.3.1 Predicting the effects of PKA phosphorylation on cellular NDE1 
Threonine-131 is located in the N-terminal coiled-coil of NDE1, in domains that are 
known in NDEL1 to be involved in LIS1 binding and tetramerisation (Yan et al. 
2003; Derewenda et al. 2007).  Looking at the published structure of NDEL1 
tetramers (Derewenda et al. 2007) it can be seen that the four threonine-131 residues 
are within very close proximity of each other and all point into the centre of the 
coiled-coil (see figure 7.3.A.a and 7.3.A.b).  This suggests that phosphorylation of 
this residue would be highly unlikely to occur subsequent to multimerisation, and 
indeed it may prevent multimerisation all together.  The threonine-131 residues of 
the NDEL1 dimer are approximately 10Å apart, while in a tetramer, they can come 
within 3Å of their counterparts running in the opposite direction.  Given that a 
phosphate group has a diameter of 5.8Å, tetramerisation following threonine-131 
phosphorylation would seem to be highly unlikely.  Disruption of multimerisation in 
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Site Motif NetPhosK Detectable  Location in NDE1 
    score by Scansite?   
S94 RXXS 0.57 No Coiled-coil (dimerisation site) 
T131 KRXT 0.72 Yes Coiled-coil (tetramerisation site) 
S223 RXXS 0.77 No Unstructured central region 
S252 XRXS 0.78 No Protein-binding α-helix 
S273 KXXS 0.53 No Protein-binding α-helix 
S306 RRXS 0.85 Yes Unstructured C-terminal tail 
S307 RXXS 0.70 No Unstructured C-terminal tail 
 
Table 7.2: Sites of NDE1-SSSC predicted to be PKA phosphorylated using 
the program NetPhosK 1.0 (Blom et al. 2004).  Score is a rating from 0 to 1 of 
the likelihood that the site is phosphorylated in vitro.  The default cut-off value 
of 0.50 is used.  Two of the sites are also detectable by Scansite 2.0 using its 
default stringency setting of “Medium” (see table 4.4.B) 
 
 
than monomers of NDEL1 (Tarricone et al. 2004).  Threonine-131 is also conserved 
in NDEL1. 
 
Serine-306 is located near the C-terminus of the protein, immediately after the short 
predicted coil domain.  It is possible that it is close enough to this coil to affect the 
binding of NDE1 to DISC1, dynein, dynactin and/or pericentrin-B, all of which are 
known to interact with NDE1 and/or NDEL1 in this region (Sasaki et al. 2000; 
Brandon et al. 2004; Liang et al. 2004; Guo et al. 2006).  Additionally serine-306 
lies within the NLS which was predicted to be found in NDE1-KMLL (figure 
7.3.A.c).  It is therefore possible that it could alter the cellular localisation of this 
isoform.  This residue is not conserved in NDEL1. 
 
7.3.2 Generation of a phospho-mimic NDE1 construct 
The residues aspartic acid and glutamic acid are chemically similar to 
phosphorylated serine and threonine residues respectively in terms of their size and 
charge.  It is therefore possible to use mutant proteins, bearing either a serine to 
aspartic acid mutation or a threonine to glutamic acid one, as a model for a 
constitutively phosphorylated wild type protein.  Therefore a construct encoding V5-
NDE1 with a T131E mutation was generated in order to mimic PKA phosphorylated  
 

























Figure 7.3.A: a) The structure N-terminal coiled-coil regions of four NDEL1 
molecules in a tetramer (Derewenda et al. 2007).  All threonine residues are 
indicated in blue, with threonine-133 residues are indicated by a white box.  
b) Focus on the four threonine-133 residues.  Distances between the oxygen 
atoms (to which the phosphate group would bind) are indicated.  Structures 
viewed using Deep View/Swiss-Pdb View 3.7.  c) The amino acid sequence 
of NDE1-KMLL around serine-306 (blue), with the basic residues of the 
putative NLS (red) and residues which are part of the unique C-terminal tail 
of NDE1-KMLL (underlined). 
 




Figure 7.3.B: COS7 cells were transfected with V5-NDE1-SSSC (either wild-
type or mutant) plus GFP-NDEL1-PLSV.  Cells were IBMX/forskolin or mock 
treated and were immunoprecipitated using an anti-V5 antibody.  GFP-
NDEL1 is preferentially co-immunoprecipitated by the NDE1-T131E mutant 
compared to wild-type NDE1 and the T131A mutant.  In contrast, 
endogenous LIS1 is preferentially co-immunoprecipitated by wild-type NDE1 
and T131A compared to the T131E mutant.  The overall level of V5-NDE1 is 
approximately consistent over the four samples.  This blot is representative of 
two experiments.  The 50kDa band visible in the LIS1 blot is IgG. 
 
 
NDE1.  The mutation was generated as in section 7.2.1, using the T131E F & R 
primers (see table 2.5.A). 
 
7.3.3 Mock phosphorylation of NDE1 threonine-131 affects its 
interactions with LIS1 and NDEL1 
In section 6.7.1, it was theorised that while NDE1 could form homodimers with 
itself, NDE1-NDEL1 interactions could only occur through tetramerisation.  
Therefore, in order to test the effect of threonine-131 phosphorylation on NDE1 
tetramerisation, the NDE1-NDEL1 interaction was investigated. 
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COS7 cells were co-transfected with constructs encoding GFP-NDEL1-PLSV and 
V5-NDE1-SSSC, with the NDE1 being either wild-type or carrying one of the 
T131A or T131E mutations.  Cells were IBMX/forskolin treated and an anti-V5 
antibody used to immunoprecipitate the NDE1.  In two independent experiments, 
NDEL1 was seen to co-immunoprecipitate more strongly with NDE1-T131E than it 
did with wild type NDE1 or NDE1-T131A (figure 7.3.B).  The amount of NDE1 
immunoprecipitated meanwhile remained largely unchanged.  This suggests that the 
interaction of NDE1 with NDEL1 may be PKA sensitive. 
 
The same immunoprecipitates were then also stained using an anti-LIS1 antibody.  
Strikingly, the amount of LIS1 co-immunoprecipitated by the NDE1-T131E mutant 
was considerably less than by wild-type NDE1 or NDE1-T131A (figure 7.3.B).  
While these findings are still preliminary, and further repeats are needed to be 
certain, this suggests that the phosphorylation status of threonine-131 may play a key 





7.4.1 The mechanism of PKA-phosphorylation of NDE1 
NDE1 has been demonstrated to be phosphorylated at PKA substrate-consensus sites.  
That this phosphorylation is sensitive to cAMP levels and to an inhibitor of PKA, 
combined with the fact that recombinant PKA can phosphorylate NDE1 in vitro, 
strongly implies that the kinase responsible is PKA. 
 
NDE1 phosphorylation by PKA occurs at multiple sites, the most prominent of these 
being serine-306, at the C-terminal unstructured tail of NDE1 and proximal to the 
helical region implicated in DISC1, dynein, dynactin and pericentrin-interaction 
(Sasaki et al. 2000; Brandon et al. 2004; Liang et al. 2004; Guo et al. 2006).  
Threonine-131, found in coiled-coil region implicated in tetramerisation an LIS1-
interaction (Yan et al. 2003; Derewenda et al. 2007), also appears to be a 
phosphorylation site, although this result did not meet statistical significance.  That 
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mutation of both these sites did not completely abolish PKA-phosphorylation implies 
that other lesser-used sites of phosphorylation also exist.  Potential locations for the 
remaining PKA phosphorylation site(s) are at serines-94, 223, 252, 273 and 307. 
 
Interestingly, the potential phosphorylation of NDE1 at threonine-131 was only 
visible when an S306A mutation was also introduced.  Assuming that threonine-131 
is a genuine site of phosphorylation, there are several potential explanations for this.  
Firstly, phosphorylation of serine-306 may cause a configurational shift in the 
structure of NDE1, altering the feasibility of the threonine-131 being phosphorylated. 
A more likely explanation, however, would be that serine-306 is phosphorylated at a 
considerably higher frequency than threonine-131 and thus the signal from serine-
306 phosphorylation masks any alteration of the phosphorylation status at the other 
site.  This is very plausible as the position of threonine-131 within the coiled-coil is 
likely to prevent the residue from being accessible to PKA after it has formed a 
dimer.  Additionally, the fact that the PKA substrate antibody was raised against the 
RRXp(S/T) motif means that it may well detect phosphorylation at serine-306 
(RRXpS) more strongly than phosphorylation at threonine-131 (KRXpT), potentially 
preventing alterations in the threonine-131 site from being easily detectable. 
 
Given that the primary site of PKA-phosphorylation on NDE1, serine-306, is not 
conserved in NDEL1, it appears unlikely that NDEL1 is also PKA phosphorylated to 
a similar degree as NDE1.  Phosphorylation of NDEL1 at a site equivalent to 
threonine-131 remains a possibility and has been suggested to occur in a recent study 
(Collins et al. 2008). 
 
7.4.2 Threonine-131 of NDE1 as a potential protein-interaction “switch” 
In the previous chapter, phosphodiesterase 4 molecules were shown to exist in 
complex with NDE1, implying the existence of DISC1 complexes in vivo containing 
both PDE4B and NDE1/NDEL1.  PDE4s are involved in regulation levels of cAMP 
within the cell and may therefore influence the activity of cAMP-dependent kinases 
such as PKA.  The discovery that NDE1 is phosphorylated by PKA therefore 
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suggests for the first time a functional link between PDE4s and DISC1’s centrosomal 
protein interactors. 
 
NDE1 is PKA phosphorylated on serine-306.  The effect of this phosphorylation on 
NDE1 is not yet known, but may influence the protein-protein interactions which 
occur at its C-terminal helix.  In NDE1-KMLL, this site is also within a predicted 
nuclear-localisation signal and therefore may influence cellular localisation of the 
protein.  Determining the exact effect of this phosphorylation should therefore by a 
major goal of future work. 
 
Threonine-131 also appears to be a PKA phosphorylation site for NDE1, although 
additional work is required in order to be certain of this.  Based on the published 
model for NDEL1 (Derewenda et al. 2007) this site is likely to be buried within a 
coiled-coil and therefore inaccessible to PKA after dimerisation has occurred.  It is 
possible, however, that phosphorylation could still occur while NDE1 was a 
monomer.  This theory is consistent with the fact that threonine-131 phosphorylation 
was seemingly less common than serine-306 phosphorylation.   
 
Through use of a mock-phosphorylated NDE1 mutant (a T131E mutation), it was 
suggested that threonine-131 is important for determining the protein-interaction 
partners of NDE1.  Mock-phosphorylation led to NDE1 preferentially binding to 
NDEL1 and is therefore likely to also affect NDE1 tetramerisation, although the 
ability of NDE1 to form dimers makes this difficult to study using this technique.  
The mock-phosphorylation also led to reduced LIS1 binding.  It is interesting to note 
that phosphorylation of T131 appears to increase NDE1/NDEL1 interaction, whereas 
it had been previously predicted to block the interaction (see section 7.3.1).  This 
effect would presumably be caused by the phosphorylation altering the coiled-coil, 
either forcing it to be looser or else breaking the α-helix around it, altering the overall 
configuration of the coil and favouring the interaction of NDEL1 over LIS1.  While 
these results are still preliminary and in need of further replication, a model for the 
mechanism of this phosphorylation can be proposed.  NDE1 monomers would be 
phosphorylated or dephosphorylated depending on the local cAMP concentration.  
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Once dimerisation occurred, the phosphorylation status of the component monomers 
would “set” the binding affinities of the resulting dimer for LIS1, NDEL1 and 
potentially other protein interactors. 
 
It is also interesting to note that in a recent publication, mutation of alanine-131 of 
NDEL1 to an aspartic acid dramatically increased the strength of NDEL1-NDEL1 
interactions on a peptide array (Collins et al. 2008).  This residue is immediately 
adjacent to threonine-132, the NDEL1 equivalent of threonine-131 on NDE1.  Given 
the similarity between aspartic acid and the glutamic acid which was mutated into 
NDE1-T131E, it is perhaps unsurprising that the two mutations have similar effects.  
This further reinforces the theory that this region of NDE1/NDEL1 plays a 
significant role in determining their propensity to form either homotetramers or 
heterotetramers with each other. 
 
It has previously been reported that DISC1 binds preferentially to the inactive form 
of PDE4B and that, for certain isoforms, binding of DISC1 to PDE4 is PKA-
dependent (Millar et al. 2005b; Murdoch et al. 2007).  Combined with the potential 
for PKA-dependent NDE1-LIS1 and NDE1-NDEL1 interactions, this suggests that 
regulation of the DISC1 complex, which includes PDE4B and NDE1, is likely to be 
highly complex (figure 7.4) and further study is needed in order to understand this 
better. 
 
Determining whether this “mock-phosphorylation” truly resembles the role of PKA 
phosphorylation at threonine-131 in vivo remains a priority for future work.  Should 
this mechanism be seen to truly represent NDE1 within the cell, further analysis of 
how these NDEL1/LIS1 binding switches works remain an important steps in future 
study of NDE1.  Regardless, the ability of the T131E mutant to alter protein 
interactions of NDE1 will make it a useful tool for future analysis of the protein. 
 




















Figure 7.4: A crude schematic of the effect of local cAMP levels on the 
DISC1 complex.  At low cAMP levels DISC1 (specifically the 71kDa form) 
binds to inactive PDE4B as well as NDE1.  NDE1 meanwhile binds to LIS1, 
while NDE1-NDEL1 interactions are relatively weak.  At high cAMP 
concentrations, PDE4B and NDE1 can become phosphorylated by PKA, as 
indicated by orange stars.  This leads to PDE4B becoming active and 
disassociating from DISC1 (Millar et al. 2005b; Murdoch et al. 2007).  Newly 
dimerised NDE1, meanwhile, now preferentially binds to NDEL1 over LIS1.  
Note: This diagram does not take into account the fact that both LIS1 and 
NDEL1 can also bind to DISC1 directly (Millar et al. 2003; Morris et al. 2003; 
Ozeki et al. 2003; Brandon et al. 2004; Camargo et al. 2007).  The effect of 
cAMP on these interactions is yet to be determined. 
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Chapter 8 - Concluding Remarks 
 
8.1 Studying NDE1 
In this thesis the Nuclear Distribution Factor E (Aspergillus nidulans) homologue 1 
(NDE1) protein has been studied.  This protein is of considerable interest in the study 
of psychiatric illness due to its known neurodevelopmental function, its relationship 
with Disrupted-In-Schizophrenia 1 (DISC1) and evidence that genetic variation in 
NDE1 may be associated with schizophrenia pathology. 
 
In the opening chapter, three main goals were set out: to determine a basic biology of 
NDE1, to better understand its relationship with NDEL1 and to investigate the role 
of NDE1 in the DISC1 pathway, focusing specifically on its relationship with 
DISC1-interacting phosphodiesterases.  Each of these points will be addressed in 
turn. 
 
8.2 Establishing a basic biology of NDE1 
Using bioinformatics analysis, I have predicted that the NDE1 dimer, like NDEL1, 
contains a major coil, but that in addition, both proteins have an a C-terminal protein-
binding α-helix.  The coil and the helix are predicted to be separated by a flexible 
disordered region which may allow for the binding of different combinations of 
protein interactors.  Additionally, I have demonstrated experimentally that multiple 
splice forms of NDE1 (as well as at least two of NDEL1) are expressed in the brain.  
Most of the isoforms encoded by these splice forms are predicted to be full-length, 
differing only at the extreme C-terminus.  This region may function as an isoform-
specific regulatory domain, allowing for complex regulation of pools of NDE1 
within the cell. 
 
I have now established that endogenous NDE1 is found at the centrosome and can 
interact with LIS1, consistent with findings gained using over-expressed protein 
(Feng et al. 2000; Kitagawa et al. 2000).  More surprising, however, was the novel 
identification of NDE1 in the nucleus using both over-expressed and endogenous 
NDE1.  This is potentially an isoform-specific localisation as only two NDE1 
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isoforms are predicted to have nuclear localisation signals (for example the 95 
antibody, which is specific for mouse Nde1-KMLL, detects a unique nuclear 
envelope expression pattern)  and implies previously unknown functions for NDE1 
within the cell. 
 
8.3 The relationship between NDE1 and NDEL1 
Structurally, NDE1 and NDEL1 are predicted to be highly similar, sharing both a 
highly conserved coiled-coil and α-helix.  Similarly, they have been shown to share a 
number of “core” features including centrosomal localisation and the ability to 
interact with LIS1 and DISC1.  Interestingly, their localisation patterns may not be 
identical, with NDE1 being potentially more highly expressed in the nucleus.  
Another potential difference between the two proteins is that both are predicted to 
have differing patterns of phosphorylation, and one such NDE1-specific 
phosphorylation site has been demonstrated experimentally, suggesting that post-
translational regulation of the two proteins is likely to vary. 
 
I have now shown that NDE1 and NDEL1 can form complexes in the cell.  Such a 
complex is unlikely to be a simple heterodimer, but may take the form of a 
heterotetramer.  That they interact at all, however, implies a previously unknown 
cooperative role for the proteins within the cell.  For example, it is possible that the 
NLS motifs predicted on certain NDE1 isoforms could be used to localise NDE1-
NDEL1 complexes to the nucleus.  That the two proteins appear to show similar but 
not totally identical expression patterns within cultured cells indicates that NDE1-
NDEL1 complexes do occur, but that they are also likely to function independently. 
 
8.4 NDE1 within the DISC1 pathway 
NDEL1 is a robustly established DISC1-interacting protein, and I have now 
demonstrated a similar relationship between NDE1 and DISC1.  Intriguingly, NDE1 
was seen to exist in a complex with other DISC1-interacting proteins including 
ATF4 and PDE4B1.  That three schizophrenia-related proteins (DISC1, NDE1 and 
PDE4B1) co-complex suggests that this protein complex is functionally important 
for our understanding of major mental illness.  Interestingly LIS1 was also seen to 
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form a complex with PDE4B.  Should this prove to be the same complex that 
contains DISC1 and NDE1 also, then it would strongly suggest that the DISC1-
NDE1-PDE4B exists at the centrosome. 
 
PDE4 proteins are involved in the degradation of cAMP in a negative feedback 
mechanism involving cAMP-sensitive PKA (see figure 1.2.D).  The discovery that 
PKA in turn can phosphorylate NDE1 provides, for the first time, a functional link 
between phosphodiesterases and the DISC1 pathway.  Furthermore, the initial 
evidence suggesting that PKA phosphorylation affects the binding affinity of NDE1 
for NDEL1 and LIS1 suggests that this process is likely to be of significant 
biological importance.  That DISC1-PDE4B binding is also known to be cAMP-
dependent (Millar et al. 2005b) suggests that regulation of the DISC1 complex, 
including both PDE4B and NDE1, by cAMP is likely to be highly regulated. 
 
8.5 Future work 
This thesis has answered a range of questions regarding NDE1, its role in the cell and 
relationship with the DISC1 pathway.  However, other questions still remain and 
indeed several new ones have been generated.  Issues which should be addressed in 
future work include the following: 
 
1. Transcripts of several NDE1 and NDEL1 splice variants have been shown to 
exist in the brain.  A logical next step would be to prepare plasmid constructs 
encoding each of these different isoforms.  These could then be used to 
investigate differences between the isoforms in terms of cellular localisation, 
post-translational regulation and protein-protein interaction capabilities.  A 
more long term approach would then be to generate custom antibodies against 
each isoform in order to study them in their endogenous state. 
2. It has been predicted that both NDE1 and NDEL1 possess, in addition to their 
N-terminal coiled-coil region, a smaller α-helix near the C-terminus and an 
unstructured region linking the two.  It would therefore be interesting to 
attempt to confirm these predictions through biophysical methods. 
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3. NDE1 and NDEL1 are predicted to be differentially regulated by 
phosphorylation.  Phosphorylation of NDE1 by PKA at threonine-131 has 
been demonstrated, but it would also be useful to investigate the other 
potential phosphorylation events experimentally. 
4. In chapter 5, NDE1-specific antibodies were used to investigate NDE1 
localisation and it was seen to exist in the nucleus.  This localisation ideally 
needs to be confirmed using independent antibodies.  Use of isoform specific 
antibodies, such as those mentioned in point 1, would also be useful to test 
the prediction that this localisation is due to the potential nuclear localisation 
signals of two NDE1 isoforms. 
5. The NDE1 antibodies described in this thesis have so far been used only in 
cell lines.  It would be informative to make further use of them on tissue 
samples, and in particular in the brain. 
6. A variety of DISC1-interacting proteins, including NDE1, NDEL1, LIS1 and 
PDE4B, have been demonstrated to exist in complex with each other, 
although it remains to be demonstrated whether all of these exist in a single 
“mega-complex” or not.  This could be investigated, for example, through use 
of affinity chromatography followed by mass spectroscopy. 
7. While threonine-131 appears to be a PKA phosphorylation site on NDE1, 
comparison of its phosphorylation status with that of wild-type NDE1 or 
NDE1-S306A (using a PKA substrate antibody) did not yield a significant p-
value.  It therefore must still be confirmed that this is a genuine 
phosphorylation site.  Possible future steps include the use of a C-terminally 
truncated NDE1 construct containing only the coiled-coil regions, in order to 
decrease the signal caused by other PKA substrate sites on the protein.  
Alternatively, an N-terminally truncated mutant, which would lack the 
dimerisation domain and force NDE1 to exist as a monomer, may increase 
the amount of phosphorylation at threonine-131.  Finally mouse Nde1, in 
which threonine-131, but not serine-306 is conserved, could be used to 
further investigate this. 
8. NDEL1 has a threonine residue equivalent to threonine-131 of NDE1.  It 
should therefore be determined whether NDEL1 is also a substrate of PKA. 
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9. Use of a NDE1-T131E mutant appeared to affect the binding affinity of 
NDE1 for NDEL1 and LIS1 in two independent tests.  This result needs 
repeating further in order to confirm the functional consequences.  Use of 
NDE1 deletion constructs such as those described in point 5 may help in this 
analysis. 
10. If phosphorylation of threonine-131 of NDE1 does affect its ability to bind to 
LIS1 then it is likely to have dramatic effects on its cellular role, for example 
whether it is found at the microtubules.  Further investigation of the T131E 
mutant, its cellular localisation and whether it forms complexes with proteins 
like dynein and possibly even DISC1, would be of great interest. 
11. The PDE4 protein family are involved in cAMP degradation and therefore 
have an affect of cAMP-dependent PKA.  It would therefore be interesting to 
know whether PDE4B or PDE4D activity had a direct effect on the level of 
NDE1 phosphorylation. 
12. Serine-306 is known to be PKA phosphorylated on NDE1 and a 
corresponding site does not exist on NDEL1.  Work is needed, however, to 
determine in what way this phosphorylation regulates the biology of NDE1 in 
the cell. 
13. Finally, mutation of both threonine-131 and serine-306 did not completely 
abolish PKA phosphorylation of NDE1.  It therefore still remains to be 
determined how many other PKA phosphorylation sites there are on NDE1 
and where they are located. 
 
8.6 Final comments 
DISC1 is considered to be one of the most promising candidate genes for 
schizophrenia currently under investigation.  As the DISC1 protein appears to 
function in vivo as a scaffold protein, understanding of its role within the cell can be 
gained through the study of its protein interaction partners.  NDE1, like NDEL1 and 
PDE4B appears to be a promising DISC1-interaction protein, due to its known role 
in neurodevelopment and evidence associating it with schizophrenia.  This thesis has 
attempted to close the gap in our understanding of NDE1 compared to these other 
DISC1-interactors and has furthermore shed light on mechanisms by which NDE1 
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interacts with both NDEL1 and PDE4B.  That multiple schizophrenia-related 
proteins interact within the cell strongly suggests that the complex is likely to play a 
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Appendix – Relevant publications 
 
At the time of writing, three journal articles have been published relevant to this 
thesis.  Details of these articles and my contribution to each of them are described 
below.  Full versions of the articles and their supplementary online material follow. 
 
The first article was published by Nature Publishing group, who grant permission to 
“reproduce the Contribution in whole or in part in any printed volume (book or 
thesis) of which they are the author(s).” The latter two articles were published by 
Elsevier, who grant “the right to include the journal article, in full or in part, in a 
thesis or dissertation”. 
 
Publication 1 
“The DISC locus in psychiatric illness”  
Jennifer E. Chubb, Nicholas J. Bradshaw, Dinesh C. Soares, David J. Porteous & J. 
Kirsty Millar  
Molecular Psychiatry (2008) 13 (1) 36-64 
My part of this review article was written alongside chapter 1 of this thesis.  My 




“NDE1 and NDEL1: Multimerisation, alternate splicing and DISC1 
interaction”  
Nicholas J. Bradshaw, Sheila Christie, Dinesh C. Soares, Becky C. Carlyle, David J. 
Porteous and J. Kirsty Millar 
Neuroscience Letters (2009) 449 (3) 228-233 
 
This article contains work found in chapters 3-6 of this thesis.  I performed all 
experiments described in the paper with the following exceptions: Both the V5 and 
GFP-tagged NDE1 and NDEL1 constructs were generated by Kirsty Millar and 
Sheila Christie, the NDE1-KMLL nuclear localisation signal was identified by 
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Dinesh Soares and confocal microscopy was performed with considerably assistance 
by Becky Carlyle.  The manuscript was co-written by Kirsty Millar and me, with 




“DISC1, PDE4B and NDE1 at the centrosome and synapse”  
Nicholas J. Bradshaw*, Fumiaki Ogawa*, Beatriz Antolin-Fontes, Jennifer E. 
Chubb, Becky C. Carlyle, Sheila Christie, Antoine Claessens, David J. Porteous and 
J. Kirsty Millar 
Biochemical and Biophysical Research Communications (2008) 377 (4) 1091-1096 
 
This article contains work found in chapters 4, 6 and 7 of this thesis.  The 
endogenous co-immunoprecipitation of PDE4B was performed by Sheila Christie 
and Kirsty Millar, with additional probings by Antoine Claessens and me.  I 
performed all of the co-immunoprecipitation experiments involving over-expressed 
NDE1.  Some of the colocalisation experiments within cell lines were performed by 
me and the remainder by Sheila Christie, with confocal microscopy being performed 
by Becky Carlyle.  I performed all of the experiments relating to PKA 
phosphorylation of NDE1, with the exception of some repetitions of the 
phosphorylation mutant experiments, which were performed in part by Sheila 
Christie and the densitometry, which was performed with Kirsty Millar.  I performed 
all of the bioinformatics analysis.  The paper was co-written by myself, Kirsty Millar 
and Fumiaki Ogawa, with input by David Porteous, Christoph Grunewald and Shaun 
Mackie.  Graphics were prepared by Kirsty Millar, Fumiaki Ogawa and Sarah West.  
*Fumiaki Ogawa and I are joint first authors. 
 
